EurekaMag Full Text Articles Chapter 67,457

Kalita, O.; Vaverka, M.; Hrabalek, L.; Zlevorova, M.; Cechakova, E.; Trojanec, R.; Kneblova, M.; Mgr., ; Tuckova, L.; Muzik, J. 2014: P17.44 * the effect of a Surgery Rationale on Life Expectancy within Primary Glioblastoma Multiforme Patients: Resection Compare to Sole Biopsy. Six and Half Year Regular Follow-Up Experiences of one Onco-Centredatabase of Intracranial Tumours (Doit) of Czech Republic. Neuro-Oncology 16(Suppl 2): ii 97

Kaloshi, G.; Cakani, B.; Diamandi, P.; Brace, G.; Rroji, A.; Petrela, M. 2014: P17.45 * Carboplatin Alone And In Combination With Bevacizumab In A 5Mg/Kg Every-3-Week Schedule, In Patients With Recurrent Glioblastomas: A Single Center Experience. Neuro-Oncology 16(Suppl 2): ii 97

Kamer, S.; Akagunduz, O.; Ertan, Y.; Akal n, T.; Ozgiray, E.; Oner, K.; Eraslan, C.; Call , C.; Oktar, N.; Anacak, Y. 2014: P17.46 * Late Pseudoprogression in Glioblastoma Patients: Comparable Analysis with Real Tumor Progression. Neuro-Oncology 16(Suppl 2): ii 98

Kaufman, K.L.; Ly, L.; McKay, M.; Mallawaaratchy, D.M.; Mactier, S.; Crossett, B.; Molloy, M.; Buckland, M.E.; McDonald, K.L.; Christopherson, R.I. 2014: P17.47 * Comprehensive Proteomic Profiling of Bevacizumab-Resistant Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 2): ii 98

Kim, C.; Kim, Y.; Han, J.; Kim, Y.; Kim, I.; Yun, C.; Kim, T.; Joo, J. 2014: P17.48 * Survival Benefit of Levetiracetam in Glioblastoma: A Prospective Single-Center Study. Neuro-Oncology 16(Suppl 2): ii 98

Kim, C.; Kim, Y.; Park, C.; Lee, S.; Kim, Y.; Kim, I.; Kim, I.; Joo, J.; Park, M.; Lee, M. 2014: P17.49 * Treatment Strategy for Who Grade Iii Gliomas: The Lessons Learned from the Retrospective Multicenter Analysis of 243 Patients. Neuro-Oncology 16(Suppl 2): ii 98-ii 99

Kumthekar, P.; Grimm, S.A.; Marymont, M.; Mehta, M.; Chandler, J.; Muro, K.; Jovanovic, B.; Helenowski, I.; McCarthy, K.; Raizer, J. 2014: P17.50 * Phase Ii Study of Arsenic Trioxide and Temozolomide in Combination with Radiation Therapy in Patients with Malignant Gliomas. Neuro-Oncology 16(Suppl 2): ii 99

Roessler, K.; Sommer, B.; Wimmer, C.; Hamer, H.M.; Blumcke, I.; Buchfelder, M. 2014: O5.07 * the Impact of Neuronavigation and Intraoperative High-Field Mri on Surgery of Gangliogliomas in Patients with Drug Resistant Epilepsy. Neuro-Oncology 16(Suppl 2): ii 11

Lloyd, R.E.; Keatley, K.; Littlewood, D.J.; Holt, W.V.; Higgins, S.C.; An, Q.; Fillmore, H.L.; Pilkington, G.J.; McGeehan, J.E. 2014: P17.51 * Functional Prediction of Mitochondrial DNA Mutations in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 2): ii 99

Zaruma, C.L.; Arregui, E.; Cano, J.M.; Gonzalez, J.; Amo-Salas, M.; Lopez, C.; Moreno, J.M.B. 2014: P17.52 * Analysis of Risk and Prognosis Factors in Glioblastoma - Our Experience in 104 Patients. Neuro-Oncology 16(Suppl 2): ii 99

Lombardi, G.; Puppa, A.D.; Zustovich, F.; Pambuku, A.; Farina, P.; Zagonel, V. 2014: P17.53 * the Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: Our Experience. Neuro-Oncology 16(Suppl 2): ii 99-ii 100

Mallawaaratchy, D.M.; McDonald, K.L.; Sykes, E.K.; Buckland, M.E.; Christopherson, R.I.; Kaufman, K.L. 2014: P17.54 * Novel Proteins Associated with Invadopodia Structures in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 2): ii 100

Mathew, R.; Goacher, E.; Bhargava, D.; Chakrabarty, A.; Roberts, P.; Goodden, J.; Loughrey, C.; Chumas, P. 2014: P17.55 * Unravelling Grade 3 Gliomas. Neuro-Oncology 16(Suppl 2): ii 100

Megyesi, J.F.; Costello, P.; McDonald, W.; Macdonald, D.; Easaw, J. 2014: P17.56 * a 3-Dimensional Matrix Assay to Help Predict Treatment Response to Temozolomide in Patients with Gliobastoma: Update of Results and Subgroup Analysis of Patients Undergoing Mgmt Testing. Neuro-Oncology 16(Suppl 2): ii 100

Minniti, G.; Scaringi, C.; Falco, T.; Lanzetta, G.; DeSanctis, V.; Enrici, R.M. 2014: P17.57 * Combined Chemoradiation in Elderly Patients with Glioblastoma: Comparison of two Radiation Schedules. Neuro-Oncology 16(Suppl 2): ii 100

Gasparre, G.; Vidone, M.; Cricca, M.; Savini, C.; Trevisan, E.; Soffietti, R.; Faccani, G.; Leone, M.; Morra, I. 2014: P17.58 * Detection of Human Papilloma Virus DNA in a Subset of Glioblastoma Samples. Neuro-Oncology 16(Suppl 2): ii 101

Mrugala, M.M.; Adair, J.E.; Beard, B.C.; Silbergeld, D.L.; Halasz, L.; Rockhill, J.K.; Kiem, H. 2014: P17.59 * Transplanted Mgmtp140K Gene-Modified Cd34+ Cells In Patients With Newly Diagnosed Glioblastoma Chemo-Protect Bone Marrow And Lead To Prolonged Survival. Neuro-Oncology 16(Suppl 2): ii 101

Mrugala, M.M.; Graham, C.A.; Rockhill, J.K.; Silbergeld, D.L. 2014: P17.60 * Novo-Ttf 100A System Used Successfully In A Patient With A Ventriculo-Peritoneal Shunt. Neuro-Oncology 16(Suppl 2): ii 101

Carrabba, G.; Bertani, G.; Cogiamanian, F.; Ardolino, G.; DiCristofori, A.; Zarino, B.; Locatelli, M.; Barbieri, S.; Caroli, M.; Rampini, P. 2014: O5.08 * Intra-Operative Neurophysiological Monitoring and small Craniotomies: Results in a Consecutive Series of 85 Patients with Brain Tumors. Neuro-Oncology 16(Suppl 2): ii 11

Nakabayashi, H.; Fushitani, R. 2014: P17.61 * Anti-Tumor effects of S14161 in Glioblastoma cells. Neuro-Oncology 16(Suppl 2): ii 101

Neuwelt, E.A.; Muldoon, L.L.; Gahramanov, S. 2014: P17.62 * the Importance of Delayed Pseudoprogression and the Problem with Rano in Gbm. Neuro-Oncology 16(Suppl 2): ii 101-ii 102

Ochiai, Y.; Sano, E.; Yamamuro, S.; Ogino, A.; Fukushima, T.; Tsumoto, K.; Ueda, T.; Yutaka, O.; Yoshino, A.; Yoichi, K. 2014: P17.63 * Combination Therapy with Temozolomide, Interferon-Beta, and Ribavirin in Glioma cell Lines. Neuro-Oncology 16(Suppl 2): ii 102

Pace, A.; Antenucci, A.; Mandoj, C.; Villani, V.; Carapella, C.M.; Fabi, A.; Conti, L. 2014: P17.64 * Angiogenic and Procoagulant Factors in Plasma of Brain Tumour Patients Treated with Bevacizumab. Neuro-Oncology 16(Suppl 2): ii 102

Pasqualetti, F.; Ferrazza, P.; Cocuzza, P.; Delishaj, D.; Morganti, R.; Pasqualetti, G.; Fatigante, L.; Fabrini, M.; Monzani, F. 2014: P17.65 * Radio-Chemotherapy with Temozolomide in Elderly Patients with Glioblastoma. A Mono-Institutional Experience. Neuro-Oncology 16(Suppl 2): ii 102

Perez, J.; Fernandez, J.; Ribas, T.; Barrio, P.; Mostaza, A. 2014: P17.67 * Subcutaneous Metastases from a Glioblastoma Multiforme: Case Report and Review of Literature. Neuro-Oncology 16(Suppl 2): ii 103

Petinou, V.; Perry, C.J.; Nicholl, I.D.; Singh, J.; Lea, R.W.; Welsby, P.J. 2014: P17.68 * Characterisation of a Novel Aspirin Analogue in Malignant Glioma. Neuro-Oncology 16(Suppl 2): ii 103

Petruzzi, A.; Finocchiaro, C.Y.; Simonetti, G.; Gaviani, P.; Casali, C.; Silvani, A.; Lamperti, E. 2014: P17.69 * Fotemustine Tratment: What about Glioblastoma Patients' Quality of Life?. Neuro-Oncology 16(Suppl 2): ii 103

Pineda, E.; Valduvieco, I.; Pujol, T.; Oleaga, L.; Ribalta, T.; Caral, L.; Gonzalez, J.; Boget, T.; Graus, F.; Verger, E. 2014: P17.70 * can Elderly Patients with Glioblastoma Benefit from Conventional Chemo-Radiotherapy Treatment?. Neuro-Oncology 16(Suppl 2): ii 103-ii 104

Pollo, B.; Mazzetti, S.; Patane, M.; Calatozzolo, C.; Cacciatore, F.; Silvani, A.; DiMeco, F.; Nunziata, R. 2014: O1.04 * Role of Aquaporin4 in Human Brain Metastases: Study of 60 Cases. Neuro-Oncology 16(Suppl 2): ii 1-ii 2

Oppido, P.A.; Cattani, F.; Carapella, C.M.; Villani, V. 2014: O5.09 * Ventricular high Grade Glioma: Neuroendoscopy and Adjuvant Therapy. Neuro-Oncology 16(Suppl 2): ii 11

Patane, M.; Calatozzolo, C.; Mazzetti, S.; Nunziata, R.; Spinello, S.; Farinotti, M.; Finocchiaro, G.; Pollo, B. 2014: P17.71 * Role of Atrx and Tert Expression as Diagnostic and Prognostic Factors on Anaplastic Gliomas. Neuro-Oncology 16(Suppl 2): ii 104

Prevost, C.; Ferrandi, D.; Corsetti, M.T.; Mascolo, M.; Depaoli, L.; Salvi, F.; Bottaro, R.; Melato, M.; Palermo, M.; Ruiz, L. 2014: P17.72 * Acute Lymphoblastic Leukemia after Temozolomide Treatment for Oligodendroglioma: Case Report. Neuro-Oncology 16(Suppl 2): ii 104

Rizzo, A.; Girgenti, V.; Vasco, C.; Zucchetti, F.; Calatozzolo, C.; Salmaggi, A.; Blandino, G.; Donzelli, S.; Maschio, M.; Ciusani, E. 2014: P17.73 * in Vitro Analysis of Cytotoxic effects of Brivaracetam and Lacosamide on Human Glioblastoma cells. Neuro-Oncology 16(Suppl 2): ii 104

Romeo, F.; Maddalena, G.; Conserva, V.; Fumai, V.; Fiorentino, L.; Alloro, E.; Toscano, S.; D'Agostino, A. 2014: P17.74 * Monofocal Lesion of Demyelinating Disease and Differential Diagnosis with high Grade Glioma - Case Report. Neuro-Oncology 16(Suppl 2): ii 105

Rozumenko, A.V.; Rozumenko, V.D. 2014: P17.75 * Utility Of 3D Surgical Planning For Resection Of High-Grade Gliomas. Neuro-Oncology 16(Suppl 2): ii 105

Kickingereder, P.; Hamisch, C.; Suchorska, B.; Galldiks, N.; Visser-Vandewalle, V.; Goldbrunner, R.; Kocher, M.; Treuer, H.; Voges, J.; Ruge, M.I. 2014: P17.76 * Low-Dose Rate Stereotactic Iodine-125 Brachytherapy for the Treatment of Inoperable Primary and Recurrent Glioblastoma: Single-Center Experience with 201 Cases. Neuro-Oncology 16(Suppl 2): ii 105

Senft, C.; Zappi, J.; Gessler, F.; Mittelbronn, M.; Franz, K.; Seifert, V. 2014: P17.78 * Secondary Glioblastoma - Outcome and Prognostic Factors. Neuro-Oncology 16(Suppl 2): ii 105-ii 106

Servida, M.; Sciacca, F.; Paterra, R.; Finocchiaro, G. 2014: P17.79 * A Melanoma-Astrocytoma Syndrome Associated To A Constitutive Microduplication On 5P15.33, Containing The Tert Gene. Neuro-Oncology 16(Suppl 2): ii 106

Simonetti, G.; Gaviani, P.; Innocenti, A.; Botturi, A.; Lamperti, E.; Silvani, A. 2014: P17.80 * Anaplastic Glioma: An Update on Treatment Strategies. Neuro-Oncology 16(Suppl 2): ii 106

Smrdel, U. 2014: P17.81 * Treatment and Survival of Elderly Glioblastoma Patients in Slovenia 1999 - 2013. Neuro-Oncology 16(Suppl 2): ii 106

Stanzani, E.; Martinez-Soler, F.; Gimenez-Bonafe, P.; Vidal, N.; Tortosa, A. 2014: P17.82 * Itga6 is Involved in Radioresistance of Glioblastoma Stem cells. Neuro-Oncology 16(Suppl 2): ii 106-ii 107

Stevens, G.H.J.; Sakruti, S.; Griffin, S.; Peereboom, D.; Ahluwalia, M.S. 2014: P17.83 * Outcomes of Recurrent Glioblastoma Patients Treated with Bevacizumab at a Tertiary Care Center. Neuro-Oncology 16(Suppl 2): ii 107

Souchelnytskyi, S.; Stragliotto, G. 2014: P17.84 * Cancer Proteomics and Systems Biology for Personalized Medicine. Neuro-Oncology 16(Suppl 2): ii 107

Stragliotto, G.; Rahbar, A.; Bartek, J.; Soderberg-Naucler, C. 2014: P17.85 * low Levels of Human Cytomegalovirus Infection in Glioblastoma Multiforme Associates with Patient Survival; a Prospective Study. Neuro-Oncology 16(Suppl 2): ii 107

Synowitz, M.; Szulkowski, F.; Holtmann, I.R.; Boddeke, H.W.; Kettenmann, H.; Pelz, A.; Wolf, S.A. 2014: P17.86 * Identification of Regulated Genes in Glioma-Associated Microglia/Macrophages using Microarray. Neuro-Oncology 16(Suppl 2): ii 107-ii 108

Person, O.K.-; Eran, A.; Darawshe, F.; Tzuk-Shina, T. 2014: P17.88 * the Clinical Significance of Ependymal Enhancement at Presentation in Patients with Malignant Glioma: Single Center Experience. Neuro-Oncology 16(Suppl 2): ii 108

Sefranek, D.; Wendl, C.; Hutterer, M.; Hau, P.; Uhl, M. 2014: P17.89 * effects of Glioblastoma First-Line Trials on Time Delay to Initiation of Treatment, Signs of Early Tumor Progression and Progression-Free Survival. Neuro-Oncology 16(Suppl 2): ii 108

Ungureanu, G.; Iancu, I.; Chitu, A.; Berce, C.; Florian, I.S. 2014: P17.90 * Estrogen Receptor Expression in Glioblastoma Influences Pfs and Life Expectancy of Patients. Neuro-Oncology 16(Suppl 2): ii 108-ii 109

Heimberger, A.; Wei, J.; Nduom, E.; Kong, L.; Ivan, C.; Fuller, G.N.; Gilbert, M.R.; Conrad, C.A.; Calin, G.A. 2014: O6.01 * Targeting the Immune Checkpoint Network with Mir-138 Exerts Therapeutic Efficacy in Murine Models of Glioma. Neuro-Oncology 16(Suppl 2): ii 12

Urup, T.; Grunnet, K.; Christensen, I.J.; Michaelsen, S.R.; Broholm, H.; Stockhausen, M.T.; Lassen, U.; Poulsen, H.S. 2014: P17.91 * Clinical Variables Serve as Predictive Factors in a Model for Clinical Response to Bevacizumab in Recurrent Glioblastoma Multiforme: An Observational Study of a Cohort of Consecutive Non-Selected Patients from a Single Institution. Neuro-Oncology 16(Suppl 2): ii 109

Vaz, M.; Munoz del Toro, J.; Gutierrez, J.; Ley Urzaiz, L.; Carrrato, A.; Madariaga, A.; Pian, H.; del Alamo, M. 2014: P17.92 * Glioblastoma in Elderly Patients: Survival Outcome. Neuro-Oncology 16(Suppl 2): ii 109

Villani, V.; Fabi, A.; Terrenato, I.; Telera, S.; Marucci, L.; Carosi, M.; Vidiri, A.; Carapella, C.M.; Pace, A. 2014: P17.93 * Third Line Chemotherapy in high Grade Gliomas: There is a Benefit?. Neuro-Oncology 16(Suppl 2): ii 109

Wibom, C.; Spaeth, F.; Dahlin, A.; Langseth, H.; Hovig, E.; Rajaraman, P.; Andersson, U.; Melin, B. 2014: P17.94 * Glioma Gwas Hits - Markers for Risk or for Prognosis?. Neuro-Oncology 16(Suppl 2): ii 109-ii 110

Wong, E.T.; Engelhard, H.H.; Tran, D.D.; Kew, Y.; Mrugala, M.M.; Cavaliere, R.; Villano, J.L.; Rudnick, J.; Sumrall, A.L.; Zhu, J. 2014: P17.95 * Novottf-100A Alternating Electric Fields Therapy For Recurrent Glioblastoma: An Analysis Of Patient Registry Data. Neuro-Oncology 16(Suppl 2): ii 110

Eisele, G.; Roelcke, U.; Conen, K.; Huber, F.; Weiss, T.; Hofer, S.; Heese, O.; Westphal, M.; Weller, M. 2014: P18.01 * Complementary Therapy Use in a Cohort of Swiss Glioma Patients. Neuro-Oncology 16(Suppl 2): ii 110

Young, H.E.; Im, S. 2014: P18.02 * a Comparison of the effects of Attention Deficit on Rehabilitation Functional Outcomes in Brain Tumor Patients and Subacute Stroke Patients. Neuro-Oncology 16(Suppl 2): ii 110

Hansen, P.; Meldgaard, A. 2014: P18.03 * Patient Feedback Interviews for Development of Discharge Procedures. Neuro-Oncology 16(Suppl 2): ii 110-ii 111

Jakes, A.D.; Boyer, M.; Hatfield, P. 2014: P18.04 * Clinical Progress and Survival of Patients with Glioblastoma after Hypo-Fractionated Radiotherapy. Neuro-Oncology 16(Suppl 2): ii 111

Rosenberg, S.; Meirrovitz, A.; Leker, R.; Mordechai, A.; Linetzky, E.; Cohen, J.; Peretz, T.; Lossos, A. 2014: P18.05 * Treatment of Acute Ischemic Stroke in Cancer Patients. Neuro-Oncology 16(Suppl 2): ii 111

Berghoff, A.S.; Kiesel, B.; Widhalm, G.; Wohrer, A.; Dieckmann, K.; Filipits, M.; Marosi, C.; Hainfellner, J.A.; Preusser, M.; Wick, W. 2014: O6.02 * Analysis of Pd1 and Pd-L1 Expression in Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 12

Maschio, M.; Dispenza, S.; Dinapoli, L.; Giannarelli, D.; Fabi, A.; Pompili, A.; Carapella, C.M.; Vidiri, A.; Pace, A.; Cantelmi, T. 2014: P18.06 * Zonisamide as Add-On Antiepileptic Drug in Patients with Brain Tumor-Related Epilepsy: Preliminary Data of a Pilot Study. Neuro-Oncology 16(Suppl 2): ii 111

Pace, A.; Villani, V.; Benincasa, D.; DiPasquale, A.; Carapella, C.M.; Pompili, A. 2014: P18.07 * Palliative Sedation for Brain Tumor Patients at the End of Life. Neuro-Oncology 16(Suppl 2): ii 1-ii 112

Pardo-Moreno, J.; Sepulveda, J.; Conde-Moreno, A.; Baron, M.; Reynes, G.; Belenguer, A. 2014: P18.08 * a Multicentric, Observational, non Interventional Study of Efficacy and Safety of Lacosamide for the Treatment of Epileptic Seizures in Patients with Brain Tumors. Neuro-Oncology 16(Suppl 2): ii 112

Sherwood, P.R.; Weimer, J.; Price, T.; Ren, D.; Lieberman, F.; Donovan, H. 2014: P18.09 * Stress induced Immune Dysfunction in Neuro-Oncology Caregivers. Neuro-Oncology 16(Suppl 2): ii 112

Thier, K.; Calabek, B.; Tinchon, A.; Grisold, W.; Oberndorfer, S. 2014: P18.10 * Assessment of Clinical Signs and Symptoms as Well as Treatment in the End of Life of Glioblastoma Patients. Neuro-Oncology 16(Suppl 2): ii 112

Grauer, O.M.; Wolfer, J.; Hasselblatt, M.; Dubinski, D.; Bogdahn, U.; Stummer, W.; Wiendl, H. 2014: O6.04 * Granulocytic Myeloid-Derived cells Obtained from Blood Mainly Suppress T-Cell Proliferation in Patients with Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 13

Burger, M.C.; Zhang, C.; Jennewein, L.; Schonfeld, K.; Genssler, S.; Grez, M.; Tonn, T.; Mittelbronn, M.; Steinbach, J.P.; Wels, W.S. 2014: O6.05 * Erbb2/Her2-Specific Natural Killer cells for Adoptive Immunotherapy of Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 13

Herold-Mende, C.C.; Mossemann, J.; Jungk, C.; Ahmadi, R.; Unterberg, A.; Capper, D.; vonDeimling, A.; Beckhove, P. 2014: O6.06 * Peripheral T cell Responses in Glioblastoma Patients Are Associated with an Improved Survival. Neuro-Oncology 16(Suppl 2): ii 13

Labussiere, M.; Boisselier, B.; Mokhtari, K.; DiStefano, A.; Rahimian, A.; Saulnier, O.; Paterra, R.; Finocchiaro, G.; Marie, Y.; Sanson, M. 2014: O6.08 * Combined Analysis of Tert, Egfr and Idh Status Define Distinct Prognostic Classes of Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 14

DuFour, S.; Maenhout, S.K.; Niclou, S.P.; Thielemans, K.; Neyns, B.; Aerts, J.L. 2014: O1.05 * Axitinib, a Selective Vegfr-1,-2,-3 Tyrosine Kinase Inhibitor, Inhibits Tumor Growth and Increases Infiltration of Immune cells in an Intracranial Melanoma Mouse Model. Neuro-Oncology 16(Suppl 2): ii 2

Ochs, K.; Ott, M.; Rauschenbach, K.J.; Sahm, F.; Opitz, C.A.; von Deimling, A.; Wick, W.; Platten, M. 2014: O6.09 * Prostaglandin e Receptor-4 Activation Regulates Tryptophan Metabolism in Human Malignant Gliomas. Neuro-Oncology 16(Suppl 2): ii 14

Weiler, M.; Kessler, T.; Sahm, F.; Blaes, J.; Osswald, M.; Milford, D.; Urban, S.; Ruiz de Almodovar, C.; Heiland, S.; Wick, W. 2014: O6.10 * Glioma cell Vegfr-2 Expression Impairs Chemotherapeutic and Antiangiogenic Treatments in Pten-Deficient Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 14

Wen, P.Y.; Lee, E.Q.; Van Den Bent, M.; Soffieti, R.; Bendszus, M.; Mehta, M.; Baumert, B.; Vogelbaum, M.; Chang, S.M.; Lin, N.U. 2014: O7.01 * Response Assessment in Neuro-Oncology (Rano) Criteria for Brain Metastases. Neuro-Oncology 16(Suppl 2): ii 15

Scoccianti, S.; Greto, D.; Bordi, L.; Bono, P.; Pecchioli, G.; Casati, M.; Vanzi, E.; Compagnucci, A.; Gadda, D.; Livi, L. 2014: O7.02 * Radiosurgery and Brain Metastases: Adequate Sequence of Brain Mri can Significantly Change the Intracranial Disease Staging. Neuro-Oncology 16(Suppl 2): ii 15

Price, S.J.; Boonzaier, N.R.; Lupson, V.; Larkin, T. 2014: O7.03 * Idh-1 Mutated Glioblastomas Have a less Invasive Phenotype than Idh-1 Wild type Glioblastomas: A Diffusion Tensor Imaging Study. Neuro-Oncology 16(Suppl 2): ii 15

Nowosielski, M.; Kremser, C.; Schocke, M.; Gizewski, E.; Iglseder, S.; Muigg, A.; Freyschlag, C.; Stockhammer, G.; Hutterer, M. 2014: O7.04 * Dce-Mri Discriminates between Responder and Non-Responder in Recurrent High-Grade Glioma Patients Undergoing Anti-Angiogenic Treatment. Neuro-Oncology 16(Suppl 2): ii 15-ii 16

Galldiks, N.; Ruge, M.I.; Hamisch, C.; Stoffels, G.; Ceccon, G.; Rapp, M.; Sabel, M.; Langen, K. 2014: O7.05 * Differentiation Of Local Recurrent Brain Metastasis From Radiation-Induced Changes Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Pet. Neuro-Oncology 16(Suppl 2): ii 16

Shevtsov, M.; Nikolaev, B.; Yakovleva, L.; Marchenko, Y.; Dobrodumov, A.; Margulis, B.; Ischenko, A.; Khachatryan, W.; Guzhova, I. 2014: O7.06 * Magnetic Nanoparticles Conjugated to a Recombinant Heat Shock Protein Hsp70 for Targeting Experimental Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 16

Chang, J.H.; Kim, E.; Kang, S.; Kim, S.; Yun, M. 2014: O7.07 * Pet Imaging of Brain Gliomas with C-11 Acetate: Comparison with F-18 Fdg Pet. Neuro-Oncology 16(Suppl 2): ii 16

Henriksen, O.M.; Larsen, V.A.; Muhic, A.; Hansen, A.E.; Larsson, H.B.W.; Poulsen, H.S.; Law, I. 2014: O7.08 * One-Stop Shopping In Brain Tumor Imaging: Initial Experience With Pet/Mr For Simultaneous Evaluation Of Tumor Metabolism, Structure And Blood Volume Using [18F]-Fluor-Ethyl-Thyrosine Pet And Dsc-Mri. Neuro-Oncology 16(Suppl 2): ii 16-ii 17

Mazzetti, S.; Calatozzolo, C.; Patane, M.; Farinotti, M.; Nunziata, R.; Lodrini, S.; Bianca, P. 2014: O1.06 * Novel Markers of Meningioma Aggressiveness - a Study of Meningioma versus Peritumoral Nervous Tissue. Neuro-Oncology 16(Suppl 2): ii 2

Rachinger, W.; Stocklein, V.; Haug, A.R.; Schuller, U.; Schichor, C.; Thon, N.; Tonn, J.C. 2014: O7.09 * [68Ga]-Dotatate-Pet Imaging Predicts Somatostatin Receptor Ii Expression In Meningiomas. Neuro-Oncology 16(Suppl 2): ii 17

Coope, D.J.; Karabatsou, K.; Green, S.; Wall, G.; Bambrough, J. 2014: O7.10 * Correlation of Pre-Operative Language Fmri with Intra-Operative Direct Cortical Stimulation Findings in Glioma Surgery Identifies Potential False Positive Fmri Activations with Conventional Analysis. Neuro-Oncology 16(Suppl 2): ii 17

Bertero, L.; Ruda, R.; Castellano, A.; Trevisan, E.; Magistrello, M.; Pellerino, A.; Riva, M.; Falini, A.; Bello, L.; Soffietti, R. 2014: O8.01 * Pre-Operative Chemotherapy as a New Strategy in Treating low Grade Gliomas in Eloquent Areas. Neuro-Oncology 16(Suppl 2): ii 17-ii 18

Cahill, D.P.; Loebel, F.; Bogner, W.; Marjanska, M.; Gerstner, E.; Batchelor, T.; Rosen, B.R.; Chi, A.; Andronesi, O.C. 2014: O8.02 * Monitoring Of Treatment Response In Idh-Mutant Gliomas With In-Vivo 3D Magnetic Resonance Spectroscopy. Neuro-Oncology 16(Suppl 2): ii 18

Izquierdo, C.; Majos, C.; Simo, M.; Lucas, A.; Macia, M.; Plans, G.; Gil, M.; Velasco, R.; Bruna, J. 2014: O8.03 * low Grade Diffuse Astrocytoma - Prognostic Factors to Anaplastic Transformation. Neuro-Oncology 16(Suppl 2): ii 18

Reyes-Botero, G.; Laigle-Donadey, F.; Mokhtari, K.; Martin-Duverneuil, N.; Delattre, J.Y. 2014: O8.04 * Temozolomide After Radiotherapy In Recurrent "Low-Grade" Diffuse Brainstem Glioma In Adults. Neuro-Oncology 16(Suppl 2): ii 18

Riva, M.; Lopci, E.; Raneri, F.; Alfiero, T.; Pessina, F.; Castellano, A.; Falini, A.; Chiti, A.; Bello, L. 2014: O8.05 * Structural Characterization of low Grade Gliomas by Integration of Mr, Ultrasound and Pet Imaging. Neuro-Oncology 16(Suppl 2): ii 18-ii 19

Calatozzolo, C.; Patane, M.; Mazzetti, S.; Eoli, M.; Farinotti, M.; Nunziata, R.; Finocchiaro, G.; Pollo, B. 2014: O8.06 * Atrx and Tert Expression in Relapsing low Grade Glioma. Neuro-Oncology 16(Suppl 2): ii 19

Gleize, V.; Alentorn, A.; Connen de Kerillis, L.; Labussiere, M.; Mangesius, S.; Ducray, F.; Mokhtari, K.; Villa, C.; Sanson, M. 2014: O8.08 * Cic Mutation Is A Poor Prognosis Factor In 1P19Q Codeleted Gliomas, Associated To An Up-Regulation Of Proliferation Pathways. Neuro-Oncology 16(Suppl 2): ii 19

Kraemer, D.; Orie, S.I.; Ketter, R.; Oertel, J.; Urbschat, S. 2014: O1.07 * Intracranial Hemangiopericytomas Lack Typical Cytogenetic and Epigenetic Features of Meningiomas: A Comprehensive Molecular Genetic Study. Neuro-Oncology 16(Suppl 2): ii 2-ii 3

Mathew, R.; Spink, S.; O'Hara, D.; Loughrey, C.; Wright, E.; Chakrabarty, A.; Patankar, T.; MacMullen-Price, J.; Goodden, J.; Chumas, P. 2014: O8.09 * the Leeds low Grade Glioma Service 2010-13. Neuro-Oncology 16(Suppl 2): ii 19-ii 20

Armstrong, T.S.; Aldape, K.; Gajjar, A.; Haynes, C.; Hirakawa, D.; Gilbertson, R.; Gilbert, M.R. 2014: O8.10 * a Model for Research Initiatives for Rare Cancers: The Collaborative Ependymoma Research Network (Cern). Neuro-Oncology 16(Suppl 2): ii 20

Mathew, R.; Alli, S.; Hayes, J.; Parslow, R.; Goodden, J.; Chumas, P. 2014: O9.01 * the Role of Gender in Cns Tumour Incidence and Survival. Neuro-Oncology 16(Suppl 2): ii 20

Boele, F.W.; Klein, M.; Armstrong, T.S.; Reijneveld, J.C.; Postma, T.J.; Taphoorn, M.J.B.; Aaronson, N.K.; Heimans, J.J.; Sherwood, P.R. 2014: O9.02 * Needs of Informal Caregivers of Primary Malignant Brain Tumor Patients in the United States and the Netherlands: An International Comparison. Neuro-Oncology 16(Suppl 2): ii 20

Petruzzi, A.; Finocchiaro, C.Y.; Vistalli, G.; Botturi, A.; Milanesi, I.; Silvani, A.; Lamperti, E. 2014: O9.04 * high Grade Gliomas and Caregivers' Psychological Burden. Neuro-Oncology 16(Suppl 2): ii 21

Habets, E.J.J.; Dirven, L.; Wiggenraad, R.; Zwinkels, H.; Lycklamaa Nijeholt, G.J.; Taphoorn, M.J.B. 2014: O9.05 * Cognitive Functioning, Health-Related Quality of Life and Survival after Stereotactic Radiotherapy in Patients with Brain Metastases. Neuro-Oncology 16(Suppl 2): ii 21

Berendsen, S.; Kroonen, J.; Seute, T.; Snijders, T.; Broekman, M.L.D.; Spliet, W.G.M.; Willems, M.; Artesi, M.; Bours, V.; Robe, P.A. 2014: O9.06 * Prognostic Relevance and Oncogenic Correlates of Epilepsy in Glioblastoma Patients. Neuro-Oncology 16(Suppl 2): ii 21

Meskal, I.; Gehring, K.; van der Linden, S.; Rutten, G.-J.; Sitskoorn, M. 2014: O9.07 * Cognitive Improvement after Meningioma Surgery. Neuro-Oncology 16(Suppl 2): ii 21-ii 22

Koekkoek, J.A.F.; Dirven, L.; Reijneveld, J.C.; Pasman, H.R.W.; McNamara, S.; Grisold, W.; Stockhammer, G.; Marosi, C.; Taphoorn, M.J.B.; Heimans, J.J. 2014: O9.08 * End of Life Care in High-Grade Glioma Patients in three European Countries: A Comparative Study. Neuro-Oncology 16(Suppl 2): ii 22

Back, M.; Bailey, D.; Schembri, G.; Kastelan, M.; Bailey, E.; Wheeler, H. 2014: O2.01 * Radiation Therapy Dose Painting Utilizing Fet and Fdg Pet in the Management of high Grade Glioma. Neuro-Oncology 16(Suppl 2): ii 3

Pellerino, A.; Bertero, L.; Trevisan, E.; Magistrello, M.; Soffietti, R.; Ruda, R. 2014: O9.09 * Efficacy and Tolerability of Lacosamide in Patients with Glioma: A Prospective Study. Neuro-Oncology 16(Suppl 2): ii 22

Knudsen-Baas, K.M.; Johannesen, T.B.; Engeland, A.; Engelsen, B.A.; Storstein, A.M.; Owe, J.F. 2014: O9.10 * Anti-Epileptic Treatment in Glioma, a Norwegian Population-Based Study. Neuro-Oncology 16(Suppl 2): ii 22-ii 23

Wick, W.; Capper, D.; Sill, M.; Hovestadt, V.; Pfister, S.M.; Platten, M.; Reifenberger, G.; von Deimling, A.; Weller, M.; Wiestler, B. 2014: O10.01 * Prognostic and Predictive Biomarker-Based Subgroups in the Noa-04 Trial. Neuro-Oncology 16(Suppl 2): ii 23

Figarella-Branger, D.; Mokhtari, K.; Dehais, C.; Jouvet, A.; Uro-Coste, E.; Colin, C.; Carpentier, C.; Ducray, F.; Idbaih, A.; Network, F.P. 2014: O10.02 * Mitotic Index, Microvascular Proliferation And Necrosis Define Three Groups Of 1P/19Q Co-Deleted Anaplastic Oligodendrogliomas Associated With Different Genomic Alterations. Neuro-Oncology 16(Suppl 2): ii 23

Fack, F.; Espedal, H.; Keunen, O.; Golebiewska, A.; Obad, N.; Zheng, L.; Gotlieb, E.; Harter, P.; Niclou, S.; Bjerkvig, R. 2014: O10.03 * Physiological and Biological Responses of Human Glioblastomas to Bevacizumab Treatment Assessed by Metabolomic Flux Analysis. Neuro-Oncology 16(Suppl 2): ii 23

Herrlinger, U.; Schafer, N.; Steinbach, J.P.; Weyerbrock, A.; Hau, P.; Goldbrunner, R.; Leutgeb, B.; Urbach, H.; Stummer, W.; Glas, M. 2014: O10.04 * the Randomized, Multicenter Glarius Trial Investigating Bevacizumab/Irinotecan Vs Standard Temozolomide in Newly Diagnosed, Mgmt-Non-Methylated Glioblastoma Patients: Final Survival Results and Quality of Life. Neuro-Oncology 16(Suppl 2): ii 23-ii 24

Taal, W.; Oosterkamp, H.M.; Walenkamp, A.M.E.; Dubbink, H.J.; Beerepoot, L.V.; Hanse, M.; Buter, J.; Honkoop, A.; Boerman, D.; Vos, F.Y.F.; Dinjens, W.N.M.; Enting, R.H.; Taphoorn, M.J.B.; van den Berkmortel, F.W.P.J.; Jansen, R. 2014: O10.05 * Final Analysis of the Belob Trial (A Randomized Phase Ii Study on Bevacizumab versus Bevacizumab plus Lomustine versus Lomustine Single Agent in Recurrent Glioblastoma) and First Radiology Review Results. Neuro-Oncology 16(Suppl 2): ii 24

Trevisan, E.; Bertero, L.; Cassoni, P.; Morra, I.; Pasqualetti, F.; Lolli, I.; Castiglione, A.; Ciccone, G.; Ruda, R.; Soffietti, R. 2014: O10.06 * a Phase Ii Study of Aino (Italian Association of Neuro-Oncology) on Bevacizumab and Fotemustine for Recurrent Glioblastoma: Outcome, Patterns of Relapse and Salvage Treatments. Neuro-Oncology 16(Suppl 2): ii 24

Duerinck, J.; DuFour, S.; Bouttens, F.; Verschaeve, V.; Everaert, H.; DeRaedt, S.; Van Binst, A.; Neyns, B. 2014: O10.07 * Randomized Phase Ii Study of Axitinib Vs. Standard of Care in Patients with Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 24-ii 25

Xu, T.; Wang, H.; Yan, Y.; Qin, R.; Jiang, Y.; Lu, Y.; Li, W.; Xia, C.; Chen, J. 2014: O10.08 * high G-Protein-Coupled Receptors 65 (Gpr65) Expression Predicts a Poorer Surgical Outcome of Glioblastoma Patients. Neuro-Oncology 16(Suppl 2): ii 25

Navarria, P.; Pessina, F.; Tomatis, S.; Mancosu, P.; Ascolese, A.; Lopci, E.; Bizzi, A.; Clerici, E.; Bello, L.; Scorsetti, M. 2014: O2.02 * Role of an Integrated Imaging for Target Volume Definition and Radiotherapy Planning in Patients with Diagnosed high Grade Glioma. Neuro-Oncology 16(Suppl 2): ii 3

Mason, M.T.; McNamara, M.G.; Tieu, M.T.; Lwin, Z.; Millar, B.A.; Menard, C.; Laperriere, N.; Milosevic, M.; Mason, W.P.; Chung, C. 2014: O10.09 * Reduction in Neutrophil-Lymphocyte Ratio during Initial Concurrent Chemoradiotherapy is Prognostic for Survival of Glioblastoma Patients. Neuro-Oncology 16(Suppl 2): ii 25

Massimino, M.; Biassoni, V.; Miceli, R.; Schiavello, E.; Warmuth-Metz, M.; Modena, P.; Giangaspero, F.; Spreafico, F.; Bach, F.; Gandola, L. 2014: O10.10 * Results of Nimotuzumab and Vinorelbine, Radiation and Re-Irradiation for Diffuse Pontine Glioma in Childhood. Neuro-Oncology 16(Suppl 2): ii 25

Jung, S.; Pei, J.; Ryu, H.H.; Park, I.H.; Wen, M.; Jang, W.Y.; Jung, T.Y.; Moon, K.S.; Kim, I.Y. 2014: S1.02 * Sublethal Irradiation Enhances Invasiveness of Malignant Glioma Cells; Implications for Radiotherapy of Human Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 25-ii 26

Itakura, H.; Achrol, A.; Loya, J.; Mitchell, L.; Azad, T.; Echegaray, S.; Yeom, K.; Napel, S.; Harsh, G.; Gevaert, O. 2014: S1.03 * Glioblastoma Subtypes Defined by Quantitative Imaging Map to different Canonical Signaling Pathways. Neuro-Oncology 16(Suppl 2): ii 26

Balaziova, E.; Busek, P.; Hilser, M.; Vomelova, I.; Sromova, L.; Krepela, E.; Sedo, A. 2014: P01.01 * Expression of Fibroblast Activation Protein Alpha in Human High-Grade Gliomas. Neuro-Oncology 16(Suppl 2): ii 26

Lotsch, D.; Englinger, B.; Pichler, J.; Hainfellner, J.; Marosi, C.; Czech, T.; Knosp, E.; Buchroithner, J.; Spiegl-Kreinecker, S.; Berger, W. 2014: P01.02 * Fibroblast Growth Factor 4 Contributes to 3-Dimensional Growth of Human Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 26-ii 27

Biedermann, J.; El-Ardat, K.A.; Conde, M.; Wiedemuth, R.; Peitzsch, M.; Eisenhofer, G.; Kunz-Schughart, L.; Temme, A.; Schrock, E.; Klink, B. 2014: P01.03 * Functional Characterisation Of The Isocitrate Dehydrogenase 1 (Idh 1) R132H Mutation In Gliomas. Neuro-Oncology 16(Suppl 2): ii 27

Brend, T.; Kelly, Z.; Ajaz, M.; Morgan, R.; Pandha, H.; Short, S.C. 2014: P01.04 * Therapeutic Potential of Targeting Hox Protein Function in Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 27

Fedele, V.; Dai, F.; Marinescu, V.; Kim, H.; Weyerbrock, A.; Prinz, M.; Bredel, M.; Carro, M. 2014: P01.05 * Zbtb18 Methylation Promotes Mesenchymal Transformation in Glioblastoma. Neuro-Oncology 16(Suppl 2): ii 27

Vinas, D.; Serrano-Heras, G.; Perona-Morata, A.B.; DeAndres, P.; Fortes, J.; Segura, T.; DeCampos, J.M. 2014: P01.06 * Hif-1 and Hif-2 as Posible New Targets in the Treatment of von Hippel-Lindau Disease Hemangioblastomas. Neuro-Oncology 16(Suppl 2): ii 27-ii 28

Verhaak, R.G.W.; Kim, H.; Zheng, S.; Amini, S.S.; Virk, S.M.; Mikkelsen, T.; Brat, D.J.; Grimsby, J.; Sougnez, C.; Muller, F.; Hu, J.; Sloan, A.E.; Cohen, M.L.; Van Meir, E.G.; Scarpace, L. 2014: The P53 Pathway and Ancestral Progenitors Are Associated with Tumor Recurrence in Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 3

Brat, D.J. 2014: Integrative Genomic Characterization of Lower Grade Gliomas. Neuro-Oncology 16(Suppl 3): iii 3

Eberhart, C.; Raabe, E.; Hanaford, A.; Pomeroy, S. 2014: Modelling high Myc Medulloblastoma and other Brain Tumors using Human Neural Stem cells. Neuro-Oncology 16(Suppl 3): iii 4

Wick, W.; Wiestler, B.; Capper, D.; Sill, M.; Hovestadt, V.; Schliesser, M.G.; Weiss, E.; Jones, D.T.W.; Roth, P.; Pfister, S.M.; Korshunov, A.; Platten, M.; Reifenberger, G.; von Deimling, A.; Weller, M. 2014: Prognostic and Predictive Biomarker-Based Subgroups in the Noa-04 Trial. Neuro-Oncology 16(Suppl 3): iii 4

McDonald, K.L.; Ha, W.; Sevim, H. 2014: Mif-Cd74 Guided Therapeutic Strategy for the Upfront Treatment of Gbm Patients with an Unmethylated Mgmt Promoter. Neuro-Oncology 16(Suppl 3): iii 4-iii 5

Singh, S.K.; Manoranjan, B.; Venugopal, C.; Vora, P.; McFarlane, N.; Garg, N.; Singh, M.; Mann, A.; Bakhshinyan, D.; Mahendran, S.; Dunn, S. 2014: Sox2 Identifies the Treatment-Refractory Stem cell Population in Group 2 Medulloblastoma. Neuro-Oncology 16(Suppl 3): iii 5

Aldape, K.; Zadeh, G.; Sulman, E. 2014: Molecular-Based Grading in Idh-Mutant Lower Grade Gliomas. Neuro-Oncology 16(Suppl 3): iii 5

Yan, H.; Killela, P.J.; Reitman, Z.J.; Jiao, Y.; Bettegowda, C.; Agrawal, N.; Diaz, L.A.; Friedman, A.H.; Friedman, H.; Gallia, G.L.; Giovanella, B.C.; Grollman, A.P.; He, T.C.; He, Y.; Hruban, R.H. 2014: Tert Promoter Mutations Occur Frequently in Gliomas and a Subset of Tumors Derived from cells with low Rates of Self-Renewal. Neuro-Oncology 16(Suppl 3): iii 5-iii 6

Lamszus, K.; Kathagen, A.; Holz, M.; Schulte, A.; Westphal, M. 2014: "Go Or Grow" - Links Between Cellular Function, Glucose Metabolism And Glioma Microenvironment. Neuro-Oncology 16(Suppl 3): iii 6

Claus, E.B.; Calvocoressi, L.; Greenhalgh, S.; Walsh, K.; Schildkraut, J.; Bondy, M.; Wiemels, J.; Wrensch, M.; Al-Mefty, O.; Townsend, J. 2014: Genetic Changes in Radiation-Associated Meningioma. Neuro-Oncology 16(Suppl 3): iii 1

Colman, H.; Cohen, A.; Aldape, K.; Sato, M.; Mason, C.; Diefes, K.; Heathcock, L.; Abegglen, L.; Shrieve, D.; Couldwell, W.; Schiffman, J. 2014: Distinct Copy Number Alterations and Incidence of Chromothripsis Associated with Grade and Prognosis in Idh Mutant and Wild-Type Gliomas. Neuro-Oncology 16(Suppl 3): iii 6

Horbinski, C.; Liu, Y.; Gilbert, M.R.; Kyprianou, N. 2014: Mutant Idh1 Suppresses Apoptosis Regulator Par-4 in Gliomas. Neuro-Oncology 16(Suppl 3): iii 6

Perry, A.; Reis, G.F.; Pekmezci, M.; Hansen, H.M.; Marshall, R.E.; Rice, T.; Wiencke, J.F.; Wrensch, M.R.; Walsh, K.M.; Perry, A. 2014: Cdkn2A Loss Is Associated With Shortened Survival In Infiltrating Astrocytomas But Not Oligodendrogliomas Or Mixed Oligoastrocytomas. Neuro-Oncology 16(Suppl 3): iii 1-iii 22

Watts, C.; Piccirillo, S.; Spiteri, I.; Sottoriva, A.; Touloumis, A.; Marioni, J.; Curtis, C.; Tavare, S. 2014: Complex Evolutionary Dynamics Generates Genetic Diversity and Intra-Tumor Heterogeneity in Individual Patients with Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 7

Bettegowda, C.; Sausen, M.; Leary, R.; Kinde, I.; Agrawal, N.; Bartlett, B.; Wang, H.; Luber, B.; Kinzler, K.; Vogelstein, B.; Papadopoulos, N. 2014: Detection of Circulating Tumor DNA in Early and Late Stage Human Malignancies. Neuro-Oncology 16(Suppl 3): iii 7

Brandner, S.; Benedykcinska, A.; Li, N.; Henriquez, N. 2014: Novel Approach to Model Brain Tumours by Inducing Locally Restricted and Stem cell Selective Gene Targeting. Neuro-Oncology 16(Suppl 3): iii 7

Hegi, M.E.; Kurscheid, S.; Sciuscio, D.; Samarzija, I.; Stupp, R.; Delorenzi, M. 2014: Genetic and Epigenetic Deregulation Are Associated with the Aberrant Expression of a Stem cell Related Hox Gene Signature in Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 8

Chiocca, E.A.; Price, R.L.; Hollon, T.; Alvarez-Breackenridge, C.; Fernandez, S.; Oglesbee, M.; Cook, C.; Lawler, S.; Kwon, C.-H. 2014: Cytomegalovirus Contributes to Glioblastoma in the Context of Tumor Suppressor Mutations. Neuro-Oncology 16(Suppl 3): iii 8

Sulman, E.P.; Wang, Q.; Ezhilarasan, R.; Goodman, L.D.; Gumen, J.; Sun, P.; Aldape, K.; Alfred Yung, W.; Heffernan, T.; Draetta, G.F.; Lang, F.F. 2014: The Treatment-Resistant Mesenchymal Signature in Glioblastoma Derives from Tumor cells Independent of Stroma. Neuro-Oncology 16(Suppl 3): iii 8

French, P.; Erdem-Eraslan, L.; Kros, J.M.; Oosterkamp, H.M.; Walenkamp, A.M.E.; Beerepoot, L.; Hanse, M.; Buter, J.; Honkoop, A.; van der Holt, B.; Vernhout, R.M.; Sillevis Smitt, P.A.E.; Taal, W.; van den Bent, M.J. 2014: Identification of Patients with Recurrent Gbm that Benefit from Bevacizumab. Neuro-Oncology 16(Suppl 3): iii 8-iii 9

Jenkins, R.B.; Decker, P.; Kosel, M.; Eckel-Passow, J.; Walsh, K.M.; Smirnov, I.V.; Caron, A.; Kollmeyer, T.; Rice, T.; Hansen, H.M.; Molinaro, A.M.; McCoy, L.S.; Bracci, P.M.; Cabriga, B.S.; Marshall, R. 2014: Mutation-Based Molecular Glioma Classification: Prevalence and Association with Germline Risk Snps. Neuro-Oncology 16(Suppl 3): iii 1

Hirose, Y.; Sasaki, H. 2014: Astrocytic Tumors With Gain On 7Q And Those With Gain Of Whole Chromosome 7 Belong To Distinct Subgroups Characterized By Various Genetic Factors Including Idh1 And Tp53. Neuro-Oncology 16(Suppl 3): iii 9

Guo, D.; Geng, F.; Aggarwal, R.; Liu, J.; Yoo, J.Y.; Guo, Q.; Guo, J.Y.; Hurwitz, B.; Ru, P.; Cheng, C.; Joshi, K.; Ichiro, N.; Kaur, B.; Chakravarti, A. 2014: Interplay of Lipid Droplets and Autophagy Regulates Glioblastoma Survival. Neuro-Oncology 16(Suppl 3): iii 9

Lonser, R.R.; Frerich, J.; Huntoon, K.; Yang, C.; Merrill, M.; Abdullaev, Z.; Pack, S.; Shively, S.; Stamp, G.; Zhuang, Z. 2014: Vasculogenesis in von Hippel-Lindau Disease Associated Tumors. Neuro-Oncology 16(Suppl 3): iii 9

Mukasa, A.; Aihara, K.; Gotoh, K.; Saito, K.; Nagae, G.; Tsuji, S.; Tatuno, K.; Yamamoto, S.; Takayanagi, S.; Narita, Y.; Shibui, S.; Aburatani, H.; Saito, N. 2014: Frequent H3F3A K27M Mutations In Thalamic Gliomas From Young Adult Patients. Neuro-Oncology 16(Suppl 3): iii 9-iii 10

Canoll, P.; Sims, P.; Gil, B.; Pisapia, D.; Malone, H.; Goldstein, H.; Lei, L.; Sonabend, A.; Yun, J.; Samanamud, J.; Sims, J.; Teich, A.; Sheth, S.; McKhann, G.; Sisti, M. 2014: Image Guided Rna-Seq Reveals Subtype-Specific Patterns at the Infiltrative Margins of Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 10

Ichikawa, T.; Onishi, M.; Kurozumi, K.; Maruo, T.; Inoue, S.; Michiue, H.; Yoshida, K.; Fuji, K.; Ishida, J.; Shimazu, Y.; Oka, T.; Chiocca, E.A.; Date, I. 2014: Annexin A2 Regulates Angiogenesis and Invasion Phenotypes of Malignant Glioma. Neuro-Oncology 16(Suppl 3): iii 10

DiMeco, F.; Prada, F.U.; Perin, A.; Aiani, L.; Martegani, A.; Solbiati, L.; Lamperti, M.; Casali, C.; Legnani, F.; Mattei, L.; Saladino, A.; Saini, M. 2014: Intraoperative Contrast Enhanced Ultrasound in Brain Tumor Surgery. Neuro-Oncology 16(Suppl 3): iii 10

Kuo, J.S.; Weichert, J.P.; Clark, P.A.; Kandela, I.K.; Vacaro, A.; Clark, W.; Longino, M.; Pinchuk, A.; Farhoud, M.; Swanson, K.I.; Floberg, J.; Traynor, A.; Hall, L.T.; Pazoles, C. 2014: Novel Alkylphosphocholine Analogs for Broad Spectrum Cancer Imaging and Therapy. Neuro-Oncology 16(Suppl 3): iii 10-iii 11

Muragaki, Y.; Iseki, H.; Maruyama, T.; Suzuki, T.; Yoshimitsu, K.; Chernov, M.; Ikuta, S.; Tamura, M.; Okamoto, J.; Hayashi, M.; Okada, Y. 2014: Information-Guided Surgery using Intraoperative Mri and Functional Mapping for Gliomas. Neuro-Oncology 16(Suppl 3): iii 11

Niclou, S.P.; Fack, F.; Hochart, G.; Oudin, A.; Leenders, W.; Gottlieb, E.; Bjerkvig, R.; Stauber, J. 2014: In Situ Metabolic Profiling Sheds Light on Oxidative Stress Pathways in Idh1 Mutant Oligodendroglioma. Neuro-Oncology 16(Suppl 3): iii 11

Walsh, K.M.; Walsh, K.M.; Codd, V.; Smirnov, I.V.; Rice, T.; Decker, P.A.; Hansen, H.M.; Kollmeyer, T.; Kosel, M.L.; Molinaro, A.M.; McCoy, L.S.; Bracci, P.M.; Cabriga, B.S.; Pekmezci, M.; Zheng, S. 2014: Telomere Length Variants Are Associated with High-Grade Glioma Risk: Identification of a Novel Glioma Risk Locus by Genome-Wide Association Study. Neuro-Oncology 16(Suppl 3): iii 2

Reardon, D.A.; Gokhale, P.; Ligon, K.; Liao, X.; Rodig, S.; Zhou, J.; Win, L.; Hodi, F.S.; Kohl, N.E.; Freeman, G. 2014: Immune Checkpoint Blockade for Glioblastoma: Preclinical Activity of Single Agent and Combinatorial Therapy. Neuro-Oncology 16(Suppl 3): iii 11-iii 12

Ronen, S.M.; Izquierdo-Garcia, J.L.; Chaumeil, M.M.; Cai, L.M.; Phillips, J.J.; Pieper, R.O. 2014: Metabolic Imaging Biomarkers for Mutant Idh1 Gliomas. Neuro-Oncology 16(Suppl 3): iii 12

Batchelor, T.T.; Gerstner, E.R.; Emblem, K.E.; Duda, D.G.; Kalpathy-Cramer, J.; Snuderl, M.; Ancukiewicz, M.; Polaskova, P.; Pinho, M.C.; Jennings, D.; Plotkin, S.R.; Chi, A.S.; Eichler, A.F.; Dietrich, J.; Hochberg, F.H. 2014: Increased Perfusion Due to Vascular Normalization Improves Oxygenation and Survival in Glioblastoma Patients Treated with Cediranib with or without Chemoradiation. Neuro-Oncology 16(Suppl 3): iii 12

Chang, S.M.; Elkhaled, A.; Jalbert, L.; Phillips, J.J.; Cha, S.; Molinaro, A.; Nelson, S.J. 2014: Imaging Biomarkers of Malignant Progression of Diffuse Low-Grade Gloma (Lgg). Neuro-Oncology 16(Suppl 3): iii 1-iii 22

Nelson, S.J.; Elkhaled, A.; Jalbert, L.; Wen, Q.; Phillips, J.J.; Molinaro, A.; Berger, M.; Chang, S.M. 2014: Ex Vivo Metabolic Signatures of Gliomas Based upon Tumor Grade, Imaging Characteristics and Treatment History. Neuro-Oncology 16(Suppl 3): iii 12-iii 13

Tonn, J.C.; Suchorska, B.; Jansen, N.L.; Linn, J.; Kretzschmar, H.; Janssen, H.; Eigenbrod, S.; Simon, M.; Popperl, G.; Kreth, F.W.; la Fougere, C.; Weller, M. 2014: Prognostic Value Of O-(2-[18F]Fluorethyl)-L-Tyrosine Positron Emission Tomography (18Fet-Pet) Within The Clinical Course In Newly Diagnosed Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 13

Butowski, N.; Bankiewicz, K.; Kells, A.; Martin, A.; Berger, M.; Aghi, M.; Prados, M.; Chang, S.; Clarke, J. 2014: A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan using Real-Time Imaging with Gadolinium in Patients with Recurrent high Grade Glioma. Neuro-Oncology 16(Suppl 3): iii 13

Jensen, R.; Salzman, K.; Schabel, M. 2014: Preoperative Dynamic Contrast-Enhanced Mri Correlates with Molecular Markers of Hypoxia and Vascularity in Specific Areas of Intratumoral Microenvironment and is Predictive of Patient Outcome. Neuro-Oncology 16(Suppl 3): iii 13

Prabhu, S.; Vabulas, M.; Kumar, V.A.; Hamilton, J.D.; Martinez, J.J.; Rao, G.; Sawaya, R. 2014: Real-Time Atlas-Based Stereotactic Neuronavigation. Neuro-Oncology 16(Suppl 3): iii 14

Wakabayashi, T.; Fujii, M.; Natsume, A.; Motomura, K.; Hayashi, Y.; Mori, K. 2014: Brain Tumor Surgery Navigation System Based on Updating Preoperative Images using Positional Information of Surgical Tools. Neuro-Oncology 16(Suppl 3): iii 14

Molinaro, A.M.; Olshen, A.; Strawderman, R. 2014: Tree Derived Survival Risk Groups in Differentiating Risk for Glioma Patients. Neuro-Oncology 16(Suppl 3): iii 2

Bao, S.; Cheng, L.; Huang, Z.; Zhou, W.; Wu, Q.; Rich, J.N. 2014: Glioblastoma Stem Cell-Derived Pericytes and Tumor Angiogenesis. Neuro-Oncology 16(Suppl 3): iii 14

Dirks, P.B.; Meyer, M.; Reimand, J.; Lan, X.; Head, R.; Zhu, X.; Kushida, M.; Bayani, J.; Pressey, J.C.; Lionel, A.; Clarke, I.D.; Cusimano, M.; Squire, J.; Scherer, S.; Bernstein, M. 2014: Single cell Derived Clonal Analysis of Human Glioblastoma Links Functional and Genomic Heterogeneity. Neuro-Oncology 16(Suppl 3): iii 14

Furnari, F.; Gomez, G.; Volinia, S.; Croce, C.; Zanca, C.; Li, M.; Gutmann, D.; Brennan, C.; Cavenee, W. 2014: Mutant Egfr Suppression of Microrna-9 Induces Foxp1 to Enhance Glioblastoma Tumorigenicity. Neuro-Oncology 16(Suppl 3): iii 14-iii 15

Gomez-Manzano, C.; Gabrusiewicz, K.; Cortes-Santiago, N.; Hossain, M.B.; Conrad, C.; Fuller, G.; Aldape, K.; Lang, F.; Gilbert, M.; Alfred Yung, W.K.; Fueyo, J. 2014: Presence of a Distinctive Myeloid Population is Associated with the Invasive Tumor Phenotype Observed after Anti-Angiogenesis Therapies. Neuro-Oncology 16(Suppl 3): iii 15

Laterra, J.; Lopez-Bertoni, H.; Lal, B.; Li, A.; Caplan, M.; Guerrero-Cazares, H.; Eberhart, C.G.; Quinones-Hinojosa, A.; Li, Y. 2014: Epigenetic Regulation of Gbm cell Stemness and Tumor Propagating Capacity by Oct4 and Sox2. Neuro-Oncology 16(Suppl 3): iii 15

Plate, K.H.; Scholz, A.; Mittelbronn, M.; Harter, P.; Dumont, D.; van Slyke, P.; Reiss, Y. 2014: Moving beyond Vegf: Inhibing Glioma Angiogenesis by Targeting the Tie2/Angiopoietin Signaling Pathway. Neuro-Oncology 16(Suppl 3): iii 15

Rich, J.N. 2014: Target Identification in Glioma Initiating cells. Neuro-Oncology 16(Suppl 3): iii 15-iii 16

Taylor, M.D.; Mack, S.; Witt, H.; Dirks, P.; Pfister, S.; Korshunov, A. 2014: Epigenome Alterations Define Lethal Cimp Positive Ependymomas of Infancy. Neuro-Oncology 16(Suppl 3): iii 16

Bergers, G.; Lu, K.; Rivera, L. 2014: Understanding and Tackling the Tumor-Immune cell Dialogue during Progression and Therapeutic Resistance. Neuro-Oncology 16(Suppl 3): iii 16

Cheng, S.; Feng, H.; Lopez, G.Y.; Kim, C.K.; Duncan, C.G.; Alvarez, A.; Nishikawa, R.; Nagane, M.; Su, A.-J.; Auron, P.E.; Hedberg, M.L.; Wang, L.; Grandis, J.R.; McLendon, R.E.; Bigner, D.D. 2014: Egfr Phosphorylation of Dcbld2 Recruits Traf6 and Stimulates Akt-Promoted Tumorigenesis. Neuro-Oncology 16(Suppl 3): iii 16-iii 17

Kesari, S.; Tsigelny, I.F.; Mukthavaram, R.; Kouznetsova, V.L.; Chao, Y.; Pastorino, S.; Jiang, P.; Pingle, S.C.; Wrasidlo, W.; Makale, M. 2014: Development of Novel small Molecules that Target Glioblastoma Stem cells. Neuro-Oncology 16(Suppl 3): iii 17

Lathia, J.D.; Hale, J.S.; Sloan, A.E.; Gladson, C.L.; Hazen, S.L.; Horbinski, C.; Rich, J.N.; Brown, J.M. 2014: Integration of Cancer Stem cell Maintenance and Lipid Metabolism by Scavenger Receptors. Neuro-Oncology 16(Suppl 3): iii 17

Lim, D.A.; Hwang, W.W.; Salinas, R.D.; Siu, J.J.; Kelley, K.W.; Delgado, R.N.; Paredes, M.F.; Alvarez-Buylla, A.; Oldham, M.C.; Lim, D.A. 2014: Distinct and Separable Roles for Histone Methyltransferase Ezh2 in Neurogenic Astrocytes. Neuro-Oncology 16(Suppl 3): iii 17

Marino, S.; Ricci, B.; Greco, A.; Acquati, S. 2014: A Novel Polycomb Feed Forward Loop in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 3): iii 17

Phillips, J.J.; Wade, A.; Tran, V.M.; McKinney, A. 2014: Extracellular Regulators of Glioblastoma Signaling. Neuro-Oncology 16(Suppl 3): iii 18

Rosenfeld, S.S.; Venere, M.; Lammerding, J.; Ivkovic, S.; Amendolara, B.; Crish, J.; Picariello, H.; Rich, J.; Canoll, P. 2014: Molecular Motors as Novel Targets to Block Glioma Dispersion and Proliferation. Neuro-Oncology 16(Suppl 3): iii 18

Rubin, J.B.; Sun, T.; Warrington, N.M.; Luo, J.; Brooks, M.; Dahiya, S.; Sengupta, R. 2014: Cell Intrinsic Sexual Dimorphism in the Rb and P21 Pathways Underlies Male Predominance in Gbm. Neuro-Oncology 16(Suppl 3): iii 18-iii 19

Sampetrean, O.; Saya, H. 2014: Integrated Analysis Identifies different Metabolic Signatures within Both Tumor-Initiating cells and Stem cells in a Murine Glioblastoma Model. Neuro-Oncology 16(Suppl 3): iii 19

Wrensch, M.; Walsh, K.M.; Smirnov, I.V.; Rice, T.; Hansen, H.M.; Molinaro, A.M.; McCoy, L.S.; Bracci, P.M.; Cabriga, B.S.; Perry, A.; Marshall, R.; Pekmezci, M.; Zheng, S.; Wiemels, J.L.; Tihan, T. 2014: Single Nucleotide Polymorphisms (Snps) Associated with Glioma Survival. Neuro-Oncology 16(Suppl 3): iii 2

Van Meir, E.G.; Lee, S.-H.; Khwaja, F.W.; Zerrouqi, A.; Zhang, Z.; Olson, J.J.; Kaluzova, M.; Hadjipanayis, C.G.; Devi, N.S. 2014: A Novel P53 Bystander effect Induces Glioblastoma cell Death through a Glycosylation-Dependent Mechanism. Neuro-Oncology 16(Suppl 3): iii 19

Bredel, M.; Ferrarese, R.; Harsh, G.R.; Yadav, A.K.; Bug, E.; Maticzka, D.; Reichardt, W.; Masilamani, A.P.; Dai, F.; Kim, H.; Hadler, M.; Scholtens, D.M.; Yu, I.L.Y.; Beck, J.; Srinivasasainagendra, V. 2014: Aberrant Splicing of a Brain-Enriched Alternative Exon Eliminates Tumor Suppressor Function and Promotes Oncogene Function during Brain Tumorigenesis. Neuro-Oncology 16(Suppl 3): iii 19-iii 20

Kaplan, D.; Grinshtein, N.; Rioseco, C.; Luchman, A.; Datti, A.; Aman, A.; Uehling, D.; Prakesch, M.; Wrana, J.; Cairncross, G.; Shen, Y.; Jones, S.; Marra, M.; Senger, D.; Robbins, S. 2014: Combined Drug Screening and Phosphoproteomics Identifies Candidate Brain Tumor Therapeutics and Novel Targets in Primary Human Brain Tumor-Initiating cells. Neuro-Oncology 16(Suppl 3): iii 20

Lu, Z. 2014: The Warburg effect and beyond. Neuro-Oncology 16(Suppl 3): iii 20

Nabors, L.B.; Filippova, N.; Yang, X. 2014: Hur Dependent Regulation of Centrosomes. Neuro-Oncology 16(Suppl 3): iii 20

Nister, M.; He, X.; Karimi, M.; Hedren, A.; Ekstrom, T.J. 2014: Epigenetically Disturbed Neural Stem/Progenitor cells in the Pre-Neoplastic Stage of Pdgf-Induced Mouse Glioma. Neuro-Oncology 16(Suppl 3): iii 20-iii 21

Petritsch, C.; Lerner, R.; Lewis, K.; Andor, N.; Ozawa, T.; Yoshida, Y.; McMahon, M.; Nicolaides, T.; David James, C. 2014: Stem- and Progenitor-Like cell Contribution to Malignant Astrocytoma Heterogeneity. Neuro-Oncology 16(Suppl 3): iii 21

Rak, J.; Magnusa, N.; Garniera, D.; Meehana, B.; McGrawa, S.; Leea, T.H.; Caronb, M.; Bourqueb, G.; Milsomc, C.; Jabadoa, N.; Traslera, J. 2014: Procoagulant Tissue Factor Expression is linked to Distinct Subtypes in Glioblastoma and Plays a Role in Tumor Dormancy. Neuro-Oncology 16(Suppl 3): iii 1-iii 22

Saya, H. 2014: Mechanisms of Adaptive Radioprotection in Glioma Stem cells. Neuro-Oncology 16(Suppl 3): iii 21

Tabatabai, G.; Wirsching, H.-G.; Krishnan, S.; Florea, A.-M.; Frei, K.; Krayenbuhl, N.; Hasenbach, K.; Reifenberger, G.; Weller, M. 2014: Inhibiting Invasion and Stemness in Glioblastoma by Thymosin Beta 4 Gene Silencing: A Potential Therapeutic Target?. Neuro-Oncology 16(Suppl 3): iii 21-iii 22

Fujimaki, T.; Fukuoka, K.; Shirahata, M.; Suzuki, T.; Adachi, J..; Yanagisawa, T.; Mishima, K.; Wakiya, K.; Matsutani, M.; Nishikawa, R. 2014: Initial Symptoms of Pineal Region Tumors - Comparison to Historical Control of Pre-Ct Era -. Neuro-Oncology 16(Suppl 3): iii 3

Takeshima, H.; Yokogami, K.; Mizuguchi, A.; Yamasaki, K.; Kawasoe, T.; Morishita, K. 2014: Function of Ecotropic Viral Integration Site 1 (Evi1) Gene in Mouse Neural Precursor cells and Human Glioma Initiating cells. Neuro-Oncology 16(Suppl 3): iii 22

Goldman, S.; Fangusaro, J.; Lulla, R.; Chi, S.; Manley, P.; Robison, N.; Kroon, H.-A.; Kieran, M. 2014: Phase I Individual Dose Titration Trial of the Human Corticotropin-Releasing Factor (Hcrf), Corticorelin Acetate Injection (Xerecept) in Pediatric Patients with Peritumoral Edema of the Brain. Neuro-Oncology 16(Suppl 3): iii 23

Eisenstat, D.D.; Zagozewski, J.; Ziegler, K.; Japoni, S.; Jiang, Q.; Underhill, D.A. 2014: Transcriptional Regulation of Oligodendroglial cell Fate by Dlx Homeobox Genes: Potential Relevance to Histone H3.3 Mutations in Pediatric high Grade Glioma. Neuro-Oncology 16(Suppl 3): iii 25

Erdreich-Epstein, A.; Xu, J.; Ren, X. 2014: Pid1 is a Novel Sensitizer of Brain Tumor cells to Chemotherapy. Neuro-Oncology 16(Suppl 3): iii 26

Finlay, J.L.; Liu, Y.; Haley, K.; Erdreich-Epstein, A.; Rushing, T.; Grimm, J.; Wong, K.E.; Kiehna, E.; Krieger, M.D.; Gilles, F.; Badie, B.; D'Apuzzo, M.; Dhall, G. 2014: Preliminary Results Of A Prospective Feasibility Pilot Study Of "Gempox" (Gemcitabine, Oxaliplatin, And Paclitaxel) In Pediatric And Adult Patients With Refractory Or Recurrent Central Nervous System (Cns) Germ Cell Tumors (Gct): The International Cns Gct Consortium Trial, Cns Gct-4. Neuro-Oncology 16(Suppl 3): iii 26

Gupta, N.; Hashizume, R.; Andor, N.; Zhang, Z.; Petritsch, C.; Mueller, S.; James, C.D. 2014: Biologically-Based Therapeutics for the Treatment of Diffuse Intrinsic Pontine Gliomas. Neuro-Oncology 16(Suppl 3): iii 26

Hawkins, C.; Buczkowicz, P.; Hoeman, C.; Rakopoulos, P.; Pajovic, S.; Morrison, A.; Jones, C.; Bouffet, E.; Bartels, U.; Becher, O. 2014: Detailed Molecular Characterisation of Diffuse Intrinsic Pontine Gliomas Identifies three Molecular Subgroups and a Novel Cancer Driver, Acvr1. Neuro-Oncology 16(Suppl 3): iii 26-iii 27

Kieran, M.W.; Yao, X.; Macy, M.; Leary, S.; Cohen, K.; MacDonald, T.; Allen, J.; Boklan, J.; Smith, A.; Nazemi, K.; Gore, L.; Trippett, T.; DiRenzo, J.; Narendran, A.; Perentesis, J. 2014: Final Results of a Prospective Multi-Institutional Phase Ii Study of Everolimus (Rad001), an Mtor Inhibitor, in Pediatric Patients with Recurrent or Progressive Low-Grade Glioma. A Poetic Consortium Trial. Neuro-Oncology 16(Suppl 3): iii 27

Matsutani, M.; Takami, H.; Fukuoka, K.; Mishima, K.; Nishikawa, R.; Icimura, K. 2014: Potency of Secreting Hcg- in Germinomas. Clinical and Biological Analysis. Neuro-Oncology 16(Suppl 3): iii 27

McLendon, R.E.; Lipp, E.; Gururangan, S.; Fuchs, H.; Zagzag, D.; Herndon, J.; Healy, P. 2014: Prognostic Marker Analysis in Pediatric Posterior Fossa Ependymomas. Neuro-Oncology 16(Suppl 3): iii 27

Nicolaides, T.; Yao, T.W.; Yoshida, Y.; Zhang, J.; Ozawa, T.; James, D. 2014: Targeting Resistance Pathways in Braf-Mutant Pediatric Gliomas. Neuro-Oncology 16(Suppl 3): iii 27-iii 28

Nishikawa, R.; Fukuoka, K.; Ichimura, K. 2014: Intracranial Germ cell Tumors with Mtor Mutation Are Common in Basal Ganglia. Neuro-Oncology 16(Suppl 3): iii 28

Ichimura, K.; Fukushima, S.; Totoki, Y.; Matsushita, Y.; Otsuka, A.; Tomiyama, A.; Niwa, T.; Sakai, R.; Ushijima, T.; Nakamura, T.; Suzuki, T.; Fukuoka, K.; Yanagisawa, T.; Mishima, K.; Nakazato, Y. 2014: Whole Exome Sequencing Identified That The Mapk And Pi3K Pathways Are The Main Targets For Mutations In Intracranial Germ Cell Tumors. Neuro-Oncology 16(Suppl 3): iii 23

Swartling, F.J.; Savov, V.;  an er, M.; Bolin, S.; Fotaki, G.; Dubuc, A.; Remke, M.; Ramaswamy, V.; Weishaupt, H.; Taylor, M.D. 2014: Metastasis and Tumor Recurrence from Rare Sox9-Positive cells in Mycn-Driven Medulloblastoma. Neuro-Oncology 16(Suppl 3): iii 28

Terashima, K.; Chow, K.; Jones, J.; Ahern, C.; Jo, E.; Ellezam, B.; Paulino, A.C.; Okcu, M.F.; Su, J.; Adesina, A.; Mahajan, A.; Dauser, R.; Whitehead, W.; Lau, C.; Chintagumpala, M. 2014: Long-Term Outcome of Centrally Located Low-Grade Glioma in Children. Neuro-Oncology 16(Suppl 3): iii 28

Wechsler-Reya, R.J.; Pei, Y.; Liu, K.-W.; Wang, J.; Esparza, L.A.; Maier, D.L.; Li, X.-N.; Cho, Y.-J. 2014: High-Throughput Drug Screening Identifies Hdac Inhibitors as Candidate Therapeutics for Myc-Driven Medulloblastoma. Neuro-Oncology 16(Suppl 3): iii 29

Huang, A.; Sin-Chan, P.; Jabado, N. 2014: C19Mc Oncomirs Converge On Multiple Cell Cycle Regulators To Modulate Neural Differentiation And The Tumor Epigenome. Neuro-Oncology 16(Suppl 3): iii 29

Cohen, K.J.; Jones, A.; Raabe, E.; Pearl, M. 2014: Highly Selective Intra-Arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (Dipg). Neuro-Oncology 16(Suppl 3): iii 29

Giangaspero, F.; Antonelli, M.; Badiali, M.; Buttarelli, F.R.; Moi, L.; Sanson, M. 2014: Kiaa1549:Braf Fusion Gene In Pediatric Brain Tumors Of Different Histogenesis. Neuro-Oncology 16(Suppl 3): iii 29

Judkins, A.R.; Venneti, S.; Santi, M.; Felicella, M.M.; Sullivan, L.M.; Dolgalev, I.; Martinez, D.; Perry, A.; Lewis, P.W.; Allis, D.C.; Thompson, C.B. 2014: Histopathologic Evaluation Of H3K27Me3 Is A Prognostic Biomarker For Pediatric Glioblastomas. Neuro-Oncology 16(Suppl 3): iii 29-iii 30

Saito, R.; Sonoda, Y.; Tominaga, T. 2014: Convection-Enhanced Delivery of Nimustine Hydrochloride for Brainstem Malignant Glioma: Current Study and Development of New Device. Neuro-Oncology 16(Suppl 3): iii 30

Sugiyama, K.; Kurisu, K.; Yamasaki, F.; Tominaga, A. 2014: Quality of Life of Extremely Long-Time Survivors with Germinoma Mainly Treated with Radiotherapy. Neuro-Oncology 16(Suppl 3): iii 30

Tabori, U.; Castelo-Branco, P.; Lee, D.; Gallo, M.; Limpan, T.; Mangerel, J.; Price, A.; Remke, M.; Zhang, C.; Heidari, A.; Wani, K.; Vanner, R.; Zadeh, G.; Karamchandani, J.; Das, S. 2014: Thor Methylation Provides Insight into the Telomere Maintenance Landscape of Malignant Gliomas. Neuro-Oncology 16(Suppl 3): iii 30

Kool, M.; Sturm, D.; Northcott, P.A.; Jones, D.T.W.; Korshunov, A.; Lichter, P.; Pfister, S. 2014: Molecular (Re-)Classification Of Cns-Primitive Neuroectodermal Tumors. Neuro-Oncology 16(Suppl 3): iii 23

Valera, E.T.; Andrade, P.V.; Andradre, A.F.; Queiroz, R.G.d.P.; Scrideli, C.A.; Tone, L. 2014: Histone Deacetylase Inhibitor Pci-24781 Shows Antiproliferative effects against Pediatric Glioblastoma cells. Neuro-Oncology 16(Suppl 3): iii 30-iii 31

Weiss, W.A.; Wong, R.; Fan, Q.-W.; Ilkhanizadeh, S.; Lu, M.; Beyer, J.; Dube, N.; Forsayeth, J.; Kells, A.; Xu, T.; Bankiewicz, K.; Ducker, G.; Feldman, M.; Shokat, K. 2014: Mtor Kinase Inhibitors and Apoptosis in Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 31

Riggins, G.J.; Borodovsky, A. 2014: Optimization of Demethylating Therapy for Idh1 Mutant Gliomas. Neuro-Oncology 16(Suppl 3): iii 31

Zadeh, G. 2014: Identifying Drug Compounds Targeting Tumor Metabolism in Glioblastomas. Neuro-Oncology 16(Suppl 3): iii 31

Aghi, M.K.; Jahangiri, A.; Mascharak, S.; DeLay, M. 2014: A C-Met-ss1 Integrin Complex Drives Invasive Resistance To Anti-Angiogenic Therapy. Neuro-Oncology 16(Suppl 3): iii 31-iii 32

Bjerkvig, R.; Fack, F.; Frezza, C.; Keunen, O.; Stieber, D.; Lund-Johansen, M.; Miletic, H.; Gottlieb, E.; Niclou, S.P. 2014: Mapping The Glioblastoma Metabolome After Bevacizumab Therapy By 13C6-Glucose Metabolomic Flux Analysis. Neuro-Oncology 16(Suppl 3): iii 32

de Groot, J.; Thomas, C.; Piao, Y.; Nguyen, N.; Drewry, D.; Zuercher, B.; Verhaak, R.; Stephan, C.; Sulman, E.P.; Lang, F.; Yung, A. 2014: High-Throughput Screening of Glioma Stem cell Lines for Drug Structure- and Genotype-Correlated Sensitivity to a Panel of Tyrosine Kinase Inhibitors. Neuro-Oncology 16(Suppl 3): iii 32

Persson, A.I.; Ilkhanizadeh, S.; Miroshnikova, Y.A.; Frantz, A.; Lakins, J.N.; James, C.D.; McKnight, T.R.; Berger, M.S.; Bergers, G.; Weiss, W.A.; Weaver, V.M. 2014: High Interstitial Fluid Pressure Regulates Tumor Growth and Drug Uptake in Human Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 32

Pieper, R.O.; Ohba, S.; Mukherjee, J. 2014: Mutant Idh1-Driven Cellular Transformation Increases Rad51-Mediated Homologous Recombination and Temozolomide (Tmz) Resistance. Neuro-Oncology 16(Suppl 3): iii 33

Pilkington, G.J.; Maherally, Z.; Jassam, S.; Barbu, E.; Fillmore, H. 2014: An All Human 3D In Vitro Model Of The Blood Brain Barrier In Nanoparticle Delivery And Cancer Metastasis Studies. Neuro-Oncology 16(Suppl 3): iii 33

Northcott, P.A.; Lee, C.; Zichner, T.; Lichter, P.; Korbel, J.O.; Wechsler-Reya, R.J.; Pfister, S.M. 2014: Structural Variants Shuffle Chromatin to Activate Gfi1 Family Oncogenes in Medulloblastoma. Neuro-Oncology 16(Suppl 3): iii 24

Sarkaria, J.N.; Pokorny, J.L.; Mladek, A.C.; Parrish, K.; Oberoi, R.; Sio, T.; Mittapalli, R.K.; Elmquist, W.F. 2014: Influence Of Drug Delivery On Therapeutic Benefit In Gbm-Cdk4 And Mdm2 Inhibitor Comparison In Flank Versus Orthotopic Models And Comparison Of Brain Penetrant Versus Impenetrant Pi3K/Mtor Inhibitors. Neuro-Oncology 16(Suppl 3): iii 33

James, C.D.; Lu, Y.-J.; Ozawa, T.; Prados, M.D.; Waldman, T. 2014: Rb1 Suppression is Responsible for Acquired Cdk4/6 Inhibitor Resistance in Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 33-iii 34

Vescovi, A.L.; Binda, E.; Mazza, T.; Dimeco, F. 2014: Ephrina2 Receptor in Human Glioblastoma Cancer Stem cells and Identification of New, Putative Therapeutic Targets. Neuro-Oncology 16(Suppl 3): iii 34

Rutka, J.; Park, J.-B.; Agnihotri, S.; Golbourn, B.; Bertrand, K.; Luck, A.; Sabha, N.; Croul, S.; Smith, C.A. 2014: Transcriptional Profiling of Gbm Invasive Genes Identifies Effective Inhibitors of the Lim Kinase-Cofilin Pathway. Neuro-Oncology 16(Suppl 3): iii 34

Keir, S.T.; Roskoski, M.A.; Gasinski, D.; Kwatra, M.K.; Friedman, H.S.; Bigner, D.D. 2014: Identification and Preliminary Treatment Data of Xenografts Representing Tcga-Defined Subtypes. Neuro-Oncology 16(Suppl 3): iii 35

Weiss, S.; Nguyen, S.; Luchman, A.; Grinshtein, N.; Stechishin, O.; Aman, A.; Uehling, D.; al-Awar, R.; Kaplan, D. 2014: Brain Tumour Initiating cells and Targeting Stat3 Oncogenic Signalling in Gbm. Neuro-Oncology 16(Suppl 3): iii 35

Smith, C.; Faria, C.C.; Dubuc, A.M.; Remke, M.; Golbourn, B.J.; Diaz, R.J.; Agnihotri, S.; Luck, A.; Sabha, N.; Olsen, S.; Wu, X.; Garzia, L.; Ramaswamy, V.; Mack, S.C.; Wang, X. 2014: Foretinib is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Neuro-Oncology 16(Suppl 3): iii 35

Chen, T.C.; Schonthal, A.H.; Hofman, F.M.; Wang, W.; Cho, H. 2014: Neo212: A Novel Temozolomide-Perillyl Alcohol Conjugate Exhibits Superior Activity against Temozolomide Resistant Gliomas and Intracranial Triple Negative Breast Cancer Metastasis. Neuro-Oncology 16(Suppl 3): iii 35-iii 36

Gladson, C.L.; Burgett, M.E.; Lathia, J.D.; Roth, P.; Huang, P.; Vasanji, A.; Li, M.; Bao, S.; Nowacki, A.; RIch, J.N.; Weller, M. 2014: Direct cell Contact between Brain Endothelial cells and Glioma Stem cells Promotes Endothelial cell Migration. Neuro-Oncology 16(Suppl 3): iii 36

Parsons, D.W.; Roy, A.; Monzon, F.A.; Lopez-Terrada, D.H.; Chintagumpala, M.M.; Berg, S.L.; Hilsenbeck, S.G.; Wang, T.; Adesina, A.M.; Li, X.-N.; Kerstein, R.A.; Scollon, S.; Bergstrom, K.; Street, R.L.; McCullough, L.B. 2014: Assessing the Utility of Clinical Tumor Sequencing in the Pediatric Neuro-Oncology Clinic. Neuro-Oncology 16(Suppl 3): iii 24

Kurisu, K.; Takeda, M.; Okazaki, T.; Kawahara, Y.; Yuge, L. 2014: Effects of Simulated Microgravity on Proliferation and Chemosensitivity in Malignant Glioma cells. Neuro-Oncology 16(Suppl 3): iii 36

Mishima, K.; Mishima-Kaneko, M.; Kawata, T.; Saya, H.; Ishimaru, N.; Yamada, K.; Nishikawa, R.; Shigematsu, N. 2014: Mre11-Rad50-Nbs1 Complex Inhibitor Mirin Enhances Radiosensitivity in Human Glioblastoma cells. Neuro-Oncology 16(Suppl 3): iii 36

Senger, D.L.; Rahn, J.J.; Hao, X.; Lun, X.W.X.; Cairncross, J.G.; Weiss, S.; Venugopal, C.; McFarlane, N.M.; Singh, S.K.; Robbins, S.M.; Senger, D.L. 2014: Glioma Specific Peptides: A Platform for Molecular Imaging and Therapeutic Targeting. Neuro-Oncology 16(Suppl 3): iii 37

Westphal, M.; Zamykal, M.; Martens, T.; Lamszus, K. 2014: Different Mechanisms of Tumor Growth Inhibition by Blockade of Igf-Ir in U87-Induced and Stem-Like Cell-Induced Glioblastomas. Neuro-Oncology 16(Suppl 3): iii 37

Darling, J.L.; Rowther, F.B.; Armesilla, A.L.; Dawson, T.P.; Ashton, K.; Warr, T. 2014: Trail Potentiates Panobinostat Cytotoxicity in Glioblastoma Multiforme (Gbm) in Vitro. Neuro-Oncology 16(Suppl 3): iii 37

Ino, Y.; Ito, M.; Todo, T. 2014: Micro RNA Based Strategy for Enhancing the effect of Oncolytic Hsv-1 Virus Therapy. Neuro-Oncology 16(Suppl 3): iii 37

Yung, W.K.A.; Koul, D.; Wu, S.; Fu, J. 2014: Deciphering Intrinsic And Adaptive Resistance To Pi3K Pathway Inhibitors In Glioma. Neuro-Oncology 16(Suppl 3): iii 37-iii 38

Kwatra, M.M.; Brown, K.E.; Chagoya, G.; Keir, S.T.; Bigner, D.D.; Sampson, J.H. 2014: Patient-Derived Xenografts Mirror the Proteomic Profile of Human Glioblastoma: Implications for Personalized Drug Development. Neuro-Oncology 16(Suppl 3): iii 38

Mikkelsen, T.; deCarvalho, A.C.; Arnold, K.; Mueller, C.; Petricoin, E.F.; Poisson, L.M.; Irtenkauf, S.; Hasselbach, L. 2014: Cabozantinib is Effective in a Subset of Xenograft Gbm Tumors and Affects Multiple Signaling Pathways. Neuro-Oncology 16(Suppl 3): iii 38

Quinones-Hinojosa, A.; Shah, S.R.; Park, J.; Levchenko, A.; Quinones-Hinojosa, A. 2014: Yap is a Critical and Novel Regulator of Migration and Invasion and Predicts Poor Outcome in Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 38-iii 39

Pfister, S.M.; Jones, D.T.W.; Capper, D.; Witt, R.; van Tilburg, C.; von Deimling, A.; Eggert, A.; Lichter, P.; Witt, O. 2014: Informing Treatment Decisions in Relapsed Pediatric Malignancies using Next-Generation Diagnostics. Neuro-Oncology 16(Suppl 3): iii 24

Lang, F.F.; Conrad, C.; Gomez-Manzano, C.; Tufaro, F.; Yung, W.; Sawaya, R.; Weinberg, J.; Prabhu, S.; Fuller, G.; Aldape, K.; Fueyo, J. 2014: First-In-Human Phase I Clinical Trial of Oncolytic Delta-24-Rgd (Dnx-2401) with Biological Endpoints: Implications for Viro- Immunotherapy. Neuro-Oncology 16(Suppl 3): iii 39

Walker, P.R.; de Silly, R.V.; Derouazi, M. 2014: The Impact of Oxygen Tension on Cd8+ T cell Function and Interaction with Glioma cells. Neuro-Oncology 16(Suppl 3): iii 40

Archer, G.E.; Reap, E.; Norberg, P.; Cui, X.; Schmittling, R.; Herndon, J.; Chandramohan, V.; Riccione, K.; Kuan, C.-T.; Yan, H.; Bigner, D.D.; Sampson, J.H. 2014: Idh1 Mutations as a Immunotherapeutic Target for Brain Tumors. Neuro-Oncology 16(Suppl 3): iii 40

Debinski, W.; Rodriguez, A.; Gibo, D.; Tatter, S.B.; Mott, R.; Lively, M.; Miller, L.; Seals, D.F. 2014: Functional Presence of M2 Macrophage Markers in Gbm Tumor cells. Neuro-Oncology 16(Suppl 3): iii 40-iii 41

Fueyo, J.; Conrad, C.; Gomez-Manzano, C.; Yung, W.A.; Tufaro, F.; Lang, F. 2014: New Glioma-Associated Auto-Antibodies. Neuro-Oncology 16(Suppl 3): iii 41

Parsa, A.T.; Bloch, O.; Crane, C.; Kaur, R.; Safae, M. 2014: Gliomas Promote Induction of B7-H1/Pd-L1 Expression on Monocytes: Clinical Evidence of an Immunosuppressive Mechanism that can be Targeted with Antibody Blockade. Neuro-Oncology 16(Suppl 3): iii 41

Gromeier, M.; Dobrikova, E.; Dobrikov, M.; Brown, M.; Bryant, J.; Threatt, S.; Boulton, S.; Carter, K.; Herndon, J.; Desjardins, A.; Friedman, H.; Sampson, J.; Friedman, A.; Bigner, D. 2014: Oncolytic Poliovirus Immunotherapy of Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 41

Pietsch, T.; Schmidt, R.; Remke, M.; Korshunov, A.; Hovestadt, V.; Jones, D.T.; Felsberg, J.; Kaulich, K.; Goschzik, T.; Kool, M.; Northcott, P.A.; von Hoff, K.; von Bueren, A.O.; Friedrich, C.; Skladny, H. 2014: Prognostic Significance of Clinical, Histopathological, and Molecular Characteristics of Medulloblastomas in the Prospective Hit2000 Multicenter Clinical Trial Cohort. Neuro-Oncology 16(Suppl 3): iii 24-iii 25

Becher, O.J.; Mittapali, R.; Chung, A.H.; Crabtree, D.; Elmquist, W. 2014: Abcg2 and Mdr Promote Brainstem Gliomagenesis and limit the Efficacy of Dasatinib in a Diffuse Intrinsic Pontine Glioma (Dipg) Mouse Model. Neuro-Oncology 16(Suppl 3): iii 25

Cho, Y.-J.; Tang, Y.; Schubert, S.; Willardson, M.; Bandopadhayay, P.; Bergthold, G.; Nguyen, B.; Masoud, S.; Vue, N.; Balansay, B.; Gholamin, S.; Cheshier, S.H.; Atwood, S.X.; Whitson, R.J.; Lee, A. 2014: Epigenetic Targeting of Hedgehog Pathway Transcriptional Output. Neuro-Oncology 16(Suppl 3): iii 25

Herold-Mende, C.; Mossemann, J.; Jungk, C.; Ahmadi, R.; Capper, D.; von Deimling, A.; Unterberg, A.; Beckhove, P. 2014: Spontaneous Immune Responses in Gbm Patients after Complete Tumor Resection Are Associated with an Improved Survival. Neuro-Oncology 16(Suppl 3): iii 42

Vogelbaum, M.A.; Otvos, B.; Raychaudhuri, B.; Hambardzumyan, D.; Finke, J.; Lathia, J. 2014: The Role of Myeloid Derived Suppressor cells (Mdscs) in Tumor-Induced Immunosuppression in Human and Murine Gliomas. Neuro-Oncology 16(Suppl 3): iii 44

Cairncross, G.; Wang, M.; Jenkins, R.; Shaw, E.; Giannini, C.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L.; Laperriere, N.; Huse, J.T.; Mehta, M. 2014: Beneficial Outcomes after Pcv plus Rt in Oligodendroglial Tumors Are Associated with Detection or Risk of an Idh Mutation. Neuro-Oncology 16(Suppl 3): iii 44-iii 45

Ng, H.K.; Chan, A.; Yao, Y.; Chan, D. 2014: Tert Promoter Mutations Contribute to Prognostic Subgroups of Lower Grade Astrocytomas. Neuro-Oncology 16(Suppl 3): iii 45

Ruda, R.; Bello, L.; Castellano, A.; Bertero, L.; Trevisan, E.; Riva, M.; Falini, A.; Soffietti, R. 2014: Pre-Operative Chemotherapy as a New Strategy of Treatment for low Grade Gliomas in Eloquent Areas. Neuro-Oncology 16(Suppl 3): iii 45

Huse, J.T. 2014: Elucidating the Oncogenic Role of Atrx Deficiency in Glioma. Neuro-Oncology 16(Suppl 3): iii 45

Nam, D.-H.; Kim, J.; Cho, H.J.; Lee, I.-H.; Kong, D.-S.; Seol, H.J.; Lee, J.-I.; Park, W.-Y. 2014: Evolution of the Glioblastoma Genome in Response to Treatments. Neuro-Oncology 16(Suppl 3): iii 45-iii 46

Sloan, A.E.; Nock, C.J.; Supko, J.; Ye, X.; Takebe, N.; Rich, J.; Prados, M.; Grossman, S. 2014: Targeting Glioma Initiating cells in Gbm: Abtc-0904, a Randomized Phase 0/Ii Study Targeting the Sonic Hedgehog-Signaling Pathway. Neuro-Oncology 16(Suppl 3): iii 46

Sonoda, Y.; Shibahara, I.; Sonoda, Y.; Kawaguchi, T.; Saito, R.; Kanamori, M.; Yamashita, Y.; Watanabe, T.; Kumabe, T.; Watanabe, M.; Suzuki, H.; Tominaga, T. 2014: Association of Cd133 Expression and Idh Mutation with Recurrence Pattern in high Grade Gliomas. Neuro-Oncology 16(Suppl 3): iii 46

Weller, M.; Weber, R.G.; Riehmer, V.; Kaulich, K.; Willscher, E.; Wirth, H.; Gietzelt, J.; Hentschel, B.; Westphal, M.; Simon, M.; Schackert, G.; Schramm, J.; Matschke, J.; Sabel, M.C.; Gramatzki, D. 2014: Molecular Genetic Determinants of Long-Term Survival with Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 46-iii 47

Wen, P.Y.; Wen, P.Y.; Yung, W.K.A.; Mellinghoff, I.K.; Ramkissoon, S.; Alexander, B.; Rinne, M.; Colman, H.; Omuro, A.M.; DeAngelis, L.M.; Gilbert, M.R.; DeGroot, J.; Cloughesy, T.F.; Lee, E.Q.; Nayak, L. 2014: Phase Ii Trial Of The Phosphatidyinositol-3 Kinase (Pi3K) Inhibitor Buparlisib (Bkm120) In Recurrent Glioblastoma Conducted By The Ivy Foundation Early Phase Clinical Trials Consortium. Neuro-Oncology 16(Suppl 3): iii 47

Adachi, J..; Mishima, K.; Suzuki, T.; Fujimaki, T.; Nishikawa, R. 2014: Rapid Idh1 Gene Mutation Analysis for Intraoperative Pathological Diagnosis. Neuro-Oncology 16(Suppl 3): iii 47

Bello, L.; Comi, A.; Riva, M.; Pessina, F.; Alfiero, T.; Raneri, F.; Fornia, L.; Ferpozzi, V.; Fava, E.; Cerri, G. 2014: Glioma Surgery: Tailoring Intraoperative Neurophysiological Strategies to Clinical Conditions Enhances Resection, Extends Indications, and Keeps Patient Functional Integrity. Neuro-Oncology 16(Suppl 3): iii 47

Chinot, O.-L.; Boudouresque, F.; Barrie, M.; Matta, M.; Boucard, C.; Loundou, A.; Figarella-Branger, D.; Ouafik, L.; Tabouret, E. 2014: Association of Matrix Metalloproteinase 2 (Mmp2) Baseline Plasma Level with Response and Survival and Change Overtime in Patients Treated with Bevacizumab for Recurrent high Grade Glioma. Neuro-Oncology 16(Suppl 3): iii 48

Clarke, J.L.; Chang, S.; Phillips, J.; Molinaro, A.; Berger, M.; Nelson, S.; Haas-Kogan, D. 2014: Everolimus (Rad001) and the Mtor Pathway in Low-Grade Gliomas. Neuro-Oncology 16(Suppl 3): iii 48

Del Maestro, R.; AlZhrani, G.; Azarnoush, H.; Winkler-Schwartz, A.; Alotaibi, F.; Lajoie, S.P. 2014: Proficiency Performance Benchmarks for Removal of Simulated Brain Tumors using Neurotouch. Neuro-Oncology 16(Suppl 3): iii 48

Megyesi, J.F.; Costello, P.; McDonald, W.; Macdonald, D.; Easaw, J. 2014: A 3-Dimensional Matrix Assay that may Help Predict Treatment Response to Temozolomide in Patients with Gliobastoma: Subgroup Analysis of Patients Undergoing Mgmt Testing. Neuro-Oncology 16(Suppl 3): iii 48

Nagane, M.; Lee, J.; Shishido-Hara, Y.; Suzuki, K.; Shimizu, S.; Umino, M.; Kobayashi, K.; Shiokawa, Y. 2014: Prognostic Factors for Primary Central Nervous System Lymphomas Treated with High-Dose Methotrexate-Based Chemo-Radiotherapy. Neuro-Oncology 16(Suppl 3): iii 49

Prados, M. 2014: A "Precision Medicine" Strategy For Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 49

Ram, Z.; Gonen, T. 2014: Intra-Operative Mapping of Neural Networks during Awake Craniotomy for Resection of Brain Tumors: Work in Progress. Neuro-Oncology 16(Suppl 3): iii 49

Pellegatta, S.; Pessina, S.; Cantini, G.; Kapetis, D.; Cazzato, E.; Finocchiaro, G. 2014: Nk cells from Glioma-Bearing Mice Treated with Temozolomide Are Enriched for Genes Related to Multi-Drug Resistance and Chemotaxis. Neuro-Oncology 16(Suppl 3): iii 42-iii 52

Reifenberger, G.; Malzkorn, B.; Acker, T.; Bettstetter, M.; Buslei, R.; von Deimling, A.; Dietmaier, W.; Dubbink, H.J.; Eigenbrod, S.; Garvalov, B.K.; Gerstenmaier, U.; Giese, A.; Haase, D.; Hasselblatt, M.; Kirches, E. 2014: Results of the International Interlaboratory Comparison of Mgmt Promoter Methylation Analysis Involving Twenty-Three Academic Centers in Germany, Austria and the Netherlands. Neuro-Oncology 16(Suppl 3): iii 49-iii 50

Rosenblum, M.L.; Robin, A.; Walbert, T.; Mikkelsen, T.; Kalkanis, S.; Rosenblum, M. 2014: Brain Tumor Care Through The Patient'S Eyes -- The Value Of A Comprehensive Brain Tumor Center. Neuro-Oncology 16(Suppl 3): iii 50

Sasaki, H.; Hirose, Y.; Yazaki, T.; Kimura, T.; Fujiwara, H.; Kitamura, Y.; Katayama, M.; Toda, M.; Ohira, T.; Yoshida, K. 2014: Molecular-Guided Neoadjuvant Approach for Chemosensitive Gliomas. Neuro-Oncology 16(Suppl 3): iii 50

Schmidt, N.O.; Duhrsen, L.; Reitz, M.; Henze, M.; Sedlacik, J.; Riecken, K.; Fehse, B.; Westphal, M. 2014: Repeated Intranasal Application of Neural Stem Cell-Mediated Enzym/Prodrug Therapy using a Novel Hsv-Thymidine Kinase Variant Improves Therapeutic Efficiency in an Intracranial Glioblastoma Model. Neuro-Oncology 16(Suppl 3): iii 50

Soffietti, R.; Bosa, C.; Bertero, L.; Trevisan, E.; Cassoni, P.; Morra, I.; Ruda, R. 2014: Temozolomide for Recurrent Intracranial Ependymoma of the Adult: Patterns of Response, Survival and Correlations with Mgmt Promoter Methylation. Neuro-Oncology 16(Suppl 3): iii 50-iii 51

Todo, T.; Tanaka, M.; Ito, M.; Ito, H.; Ino, Y. 2014: Clinical Trials of a Third-Generation Recombinant Oncolytic Hsv-1 in Recurrent Glioblastoma and Olfactory Neuroblastoma Patients. Neuro-Oncology 16(Suppl 3): iii 51

Ueki, K.; Aihara, K.; Mukasa, A.; Higuchi, F.; Matsuda, H.; Kim, P. 2014: Genetic And Histological Stability Of Oligodendroglial Tumors With 1P/19Q Co-Deletion Even After Chemotherapy And Or Radiation Therapy. Neuro-Oncology 16(Suppl 3): iii 51

Yoshimoto, K.; Murata, H.; Hatae, R.; Akagi, Y.; Mizoguchi, M.; Iihara, K. 2014: Quantification of Proneural Gene-Expression Signature of Gliomas and Glioblastoma-Derived Spheres. Neuro-Oncology 16(Suppl 3): iii 51

Costello, J.F.; Mazor, T.; Pankov, A.; Johnson, B.E.; Hong, C.; Bell, R.J.A.; Smirnov, I.V.; Reis, G.F.; Phillips, J.J.; Barnes, M.; Bollen, A.W.; Taylor, B.S.; Molinaro, A.M.; Olshen, A.B.; Song, J.S. 2014: Clonal Evolution of Gliomas is Encoded in the Evolutionary Dynamics of DNA Methylation. Neuro-Oncology 16(Suppl 3): iii 51-iii 52

Asai, A.; Iwata, R.; Ito, T.; Oshige, H.; Yoshimura, K.; Takeda, J.. 2014: Effect of Temozomide on Human Dendritic cells. Neuro-Oncology 16(Suppl 3): iii 42-iii 43

Desjardins, A.; Sampson, J.H.; Peters, K.B.; Ranjan, T.; Vlahovic, G.; Threatt, S.; Herndon, J.E.; Boulton, S.; Lally-Goss, D.; McSherry, F.; Friedman, A.H.; Friedman, H.S.; Bigner, D.D.; Gromeier, M. 2014: Oncolytic Polio/Rhinovirus Recombinant (Pvsripo) in Recurrent Glioblastoma (Gbm): First Phase I Clinical Trial Evaluating the Intratumoral Administration. Neuro-Oncology 16(Suppl 3): iii 43

Kuan, C.-T.; Pastan, I.H.; Bigner, D.D. 2014: Next-Generation Recombinant Immunotoxins for Glioblastomas and Melanomas Treatment. Neuro-Oncology 16(Suppl 3): iii 43

Patrick O'Neill, B.; Braggio, E.; O'Neill, B.P.; Van Wier, S.; Ojha, J.; McPhail, E.; Asmann, Y.; Egan, J.; Ayres da Silva, J.; Schiff, D.; Lopes, M.B.; Valdez, R.; Tibes, R.; Eckloff, B.; Stewart, A.K. 2014: Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas (Pcnsl). Neuro-Oncology 16(Suppl 3): iii 43

Rempel, S.A.; Thomas, S.L.; Schultz, C.R.; Mouzon, E.; Golembieski, W.A.; ElNaila, R.; Radakrishnan, A.; Bobbitt, K.R.; Lemke, N.; Gutierrez, J.A.; Poisson, L.M. 2014: Loss of Sparc in P53-Null Astrocytes Promotes Macrophage Activation and Phagocytosis Resulting in Decreased Tumor Size and Tumor cell Survival. Neuro-Oncology 16(Suppl 3): iii 44

Steinbach, J.P.; Zhang, C.; Burger, M.; Jennewein, L.; Schonfeld, K.; Genssler, S.; Sahm, C.; Brendel, C.; Naundorf, S.; Odendahl, M.; Kohl, U.; Nowakowska, P.; Seifried, E.; Bonig, H.; Tonn, T. 2014: Erbb2/Her2-Specific Natural Killer cells for Adoptive Immunotherapy of Glioblastoma. Neuro-Oncology 16(Suppl 3): iii 44

Brandes, A.A.; Finocchiaro, G.; Zagonel, V.; Reni, M.; Fabi, A.; Caserta, C.; Clavarezza, M.; Maiello, E.; Carteni, G.; Rosti, G.; Eoli, M.; Lombardi, G.; Monteforte, M.; Agati, R.; Eusebi, V. 2014: At-11 * Final Results from the Randomized Phase Ii Trial Avareg (Ml25739) with Bevacizumab (Bev) or Fotemustine (Ftm) in Recurrent Gbm. Neuro-Oncology 16(Suppl 5): v10

Brenner, A.; Floyd, J.; Eng, C.; Kroll, S.; Fichtel, L.; Gruslova, A.; Lodi, A.; Tiziani, S. 2014: At-12 * Phase 1/2 Study of Th-302, Investigational Hypoxia-Activated Prodrug, and Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v10-v11

Buckner, J.; Shaw, E.; Pugh, S.; Gilbert, M.; Barger, G.; Coons, S.; Ricci, P.; Bullard, D.; Brown, P.; Stelzer, K.; Brachman, D.; Suh, J.; Schultz, C.; Bahary, J.-P.; Fisher, B. 2014: At-13 * R9802: Phase Iii Study of Radiation Therapy (Rt) with or without Procarbazine, Ccnu, and Vincristine (Pcv) in Low-Grade Qlioma: Results by Histologic type. Neuro-Oncology 16(Suppl 5): v11

Burzynski, S.; Burzynski, G. 2014: At-14 * Long-Term Progression-Free Survival of Recurrent Glioblastoma Multiforme Treated with a Combination of Targeted Agents: A Case Report. Neuro-Oncology 16(Suppl 5): v11

Burzynski, S.; Janicki, T.; Marszalek, A.; Burzynski, G. 2014: At-15 * a Phase Ii Study of Antineoplastons A10 and As2-1 in Patients with Brainstem Gliomas Final Report (Protocol Bt-11). Neuro-Oncology 16(Suppl 5): v11

Chandra, V.; Ou, Y.; Evans, J.; Kalpathy-Cramer, J.; Dietrich, J.; Chi, A.; Wen, P.; Rosen, B.; Batchelor, T.; Gerstner, E. 2014: At-16 * Phase Ii Study of Tivozanib, an Oral Vegfr Inhibitor, in Patients with Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v11

Chinot, O.L.; Wick, W.; van den Bent, M.J.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Revil, C.; Kerloeguen, Y.; Cloughesy, T. 2014: At-17 * Re-Analysis of Pfs/Response using Original Macdonald Criteria and Response Evaluation Criteria in Solid Tumors in the Phase Iii Avaglio Study of Bevacizumab plus Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma. Neuro-Oncology 16(Suppl 5): v12

Cloughesy, T.; Wick, W.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Carpentier, A.F.; Hoang-Xuan, K.; Kavan, P.; Cernea, D.; Brandes, A.A.; Revil, C.; Abrey, L.; Chinot, O.L. 2014: At-18 * Survival Analysis Of Patients With A Pfs Event Who Did Not Receive Post-Progression Therapy In Avaglio (Bevacizumab [Bev] Plus Radiotherapy [Rt] And Temozolomide [Tmz] For Newly Diagnosed Glioblastoma [Gbm]). Neuro-Oncology 16(Suppl 5): v12

Desjardins, A.; Herndon, J.; McSherry, F.; Ravelo, A.; Lipp, E.; Healy, P.; Boulton, S.; Peters, K.; Vlahovic, G.; Sampson, J.; Friedman, A.; Friedman, H. 2014: At-19 * Single Institution Retrospective Comparison of Glioblastoma (Gbm) Patients (Pts) Initiated on Bevacizumab (Bev) before versus after Recurrence in Clinical Practice. Neuro-Oncology 16(Suppl 5): v12

Aghi, M.; Vogelbaum, M.A.; Kesari, S.; Chen, C.C.; Liau, L.M.; Piccioni, D.; Portnow, J.; Chang, S.; Robbins, J.M.; Boyce, T.; Huang, T.T.; Pertschuk, D.; Ostertag, D.; Cloughesy, T.F. 2014: At-02 * Intratumoral Delivery of the Retroviral Replicating Vector (Rrv) Toca 511 in Subjects with Recurrent high Grade Glioma: Interim Report of Phase 1 Study (Nct 01156584). Neuro-Oncology 16(Suppl 5): v8

Desjardins, A.; Herndon, J.; McSherry, F.; Ravelo, A.; Lipp, E.; Healy, P.; Peters, K.; Vlahovic, G.; Sampson, J.; Friedman, A.; Friedman, H. 2014: At-20 * Single Institution Retrospective Review of Performance Status and Corticosteroid Use in Newly Diagnosed Glioblastoma (Gbm) Patients (Pts) Treated on Bevacizumab (Bev). Neuro-Oncology 16(Suppl 5): v12-v13

Desjardins, A.; Sampson, J.; Peters, K.; Vlahovic, G.; Threatt, S.; Herndon, J.; Boulton, S.; Lally-Goss, D.; McSherry, F.; Lipp, E.; Friedman, A.; Friedman, H.; Bigner, D.; Gromeier, M. 2014: At-21 * Final Results of a Phase 1 Trial of an Oncolytic Polio/Rhinovirus Recombinant (Pvsripo) against Recurrent Glioblastoma (Gbm). Neuro-Oncology 16(Suppl 5): v13

Ghiaseddin, A.; Dunn-Pirio, A.; Peters, K.; Vlahovic, G.; Herndon, J.; Threatt, S.; Sampson, J.; Friedman, A.; Friedman, H.; Desjardins, A. 2014: At-22 * Phase Ii Trial of Bevacizumab, Radiation Therapy (Rt) and Temozolomide Followed by Bevacizumab and Temozolomide with Continuation of Bevacizumab beyond Progression. Neuro-Oncology 16(Suppl 5): v13

Gilbert, M.; Yuan, Y.; Wani, K.; Wu, J.; Omuro, A.; Lieberman, F.; Robins, H.I.; Gerstner, E.; Wu, J.; Wen, P.; Mikkelsen, T.; Armstrong, T.; Aldape, K. 2014: At-23 * a Phase Ii Study of Lapatinib and Dose-Dense Temozolomide (Tmz) for Adults with Recurrent Ependymoma: A Cern Clinical Trial. Neuro-Oncology 16(Suppl 5): v13

Goldlust, S.; Nabors, L.B.; Duic, J.P.; Conrad, C.; Silberman, S.; Singer, S.; Farmer, G. 2014: At-24 * Phase 1/2 Trial of Bevacizumab plus Tpi 287, a Novel Brain Penetrable Anti-Microtubule Agent, for the Treatment of Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v13-v14

Han, S.; Martin, A.; Berger, M.; Prados, M.; Chang, S.; Clarke, J.; Bankiewicz, K.; Butowski, N. 2014: At-25 * a Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan using Real-Time Imaging with Gadolinium in Patients with Recurrent high Grade Glioma. Neuro-Oncology 16(Suppl 5): v14

Hundsberger, T.; Tonder, M.; Hottinger, A.; Brugge, D.; Roelcke, U.; Putora, M.; Stupp, R.; Weller, M. 2014: At-26 * Clinical Management and Outcome of Histologically Verified Adult Brainstem Gliomas in Switzerland: A Retrospective Analysis of 21 Patients. Neuro-Oncology 16(Suppl 5): v14

Janicki, T.; Burzynski, G.; Burzynski, S. 2014: At-28 * Long-Term Survival (Over 15 Years) of Pathologically Confirmed Recurrent Glioblastoma Multiforme: A Case Report. Neuro-Oncology 16(Suppl 5): v14-v15

Kalkanis, S.; Jolly, D.J.; Pertschuk, D.; Ostertag, D.; Robbins, J.M.; Huang, T.T.; Gruber, H.; Mikkelsen, T. 2014: At-29 * Intravenous Administration of Toca 511 in Patients with Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v15

Ambady, P.; Kreisl, T.; Warren, K.; McNeill, K.; Fine, H. 2014: At-03 * Phase I Trial of Enzastaurin (Ly 317615) in Combination with Carboplatin in Adults with Recurrent Glioma. Neuro-Oncology 16(Suppl 5): v8

Karajannis, M.; Osorio, D.; Filatov, A.; Hagiwara, M.; Mitchell, C.; Wisoff, J.; Golfinos, J.; Roland, T.; Allen, J. 2014: At-30 * effects of Everolimus on Meningioma Growth in Patients with Neurofibromatosis type 2. Neuro-Oncology 16(Suppl 5): v15

Khan, O.; Mason, W.; Kongkham, P.; Bernstein, M.; Zadeh, G. 2014: At-31 * a Canadian Questionnaire on the Management of Adult Diffuse low Grade Gliomas. Neuro-Oncology 16(Suppl 5): v15

Krauze, A.V.; Myrehaug, S.D.; Chang, M.G.; Holdford, D.J.; Smith, S.; Shih, J.; Tofilon, P.; Fine, H.; Camphausen, K.A. 2014: At-33 * a Phase Ii Study of Concurrent Radiation Therapy, Temozolomide and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 5): v15-v16

Kros, J.M.; French, P.; van den Bent, M.J.; Gorlia, T. 2014: At-34 * Construction of an Integrated Diagnostic Algorithm Consisting of Consensus Histologic and Molecular Parameters of two Eortc Trials on Anaplastic Glioma. Neuro-Oncology 16(Suppl 5): v16

Lassman, A.; Grommes, C.; Panageas, K.; Iwamoto, F.; DeAngelis, L.; Kaley, T.; Gavrilovic, I.; Pentsova, E.; Omuro, A.; Corpuz, C.; Briggs, S.; Otap, D.; Qin, W.; Cross, J.; Mellinghoff, I. 2014: At-35 * Intermittent High Dose (Pulsatile) Erlotinib For EgfrvIii Mutant Recurrent Malignant Gliomas: A Pilot Clinical Trial. Neuro-Oncology 16(Suppl 5): v16

Lee, E.; Reardon, D.; Schiff, D.; Drappatz, J.; Muzikansky, A.; Grimm, S.; Norden, A.; Nayak, L.; Beroukhim, R.; Rinne, M.; Chi, A.; Batchelor, T.; Hempfling, K.; McCluskey, C.; Smith, K. 2014: At-36 * Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma and Anaplastic Glioma. Neuro-Oncology 16(Suppl 5): v16

Lee, E.; Smith, K.; Muzikansky, A.; Gerstner, E.; Kuhn, J.; Reardon, D.; Nayak, L.; Norden, A.; Rifenburg, J.; Pulverenti, J.; Stokes, D.; Lam, P.; Martins, T.; Hempfling, K.; McCluskey, C. 2014: At-37 * Phase I Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Neuro-Oncology 16(Suppl 5): v16-v17

McNeill, K.; Iwamoto, F.; Kreisl, T.; Sul, J.; Shih, J.; Fine, H. 2014: At-39 * a Randomized Phase Ii Trial of Vandetanib (Zd6474) in Combination with Carboplatin versus Carboplatin Alone in Adults with Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v17

Michaud, K.; Lavergne, P.; Cottin, S. 2014: At-40 * Prognosis Factors in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 5): v17

Ambady, P.; Warren, K.; Shih, J.; Kreisl, T.; Fine, H. 2014: At-04 * a Randomized Phase Ii Trial of Vandetanib in Combination with Carboplatin versus Carboplatin Alone Followed by Vandetanib Alone in Adults with Recurrent Anaplastic Astrocytoma. Neuro-Oncology 16(Suppl 5): v8-v9

Miyatake, S.-I.; Arakawa, Y.; Miwa, K.; Tsuboi, K.; Iuchi, T.; Terasaka, S.; Tabei, Y.; Nakamura, H.; Nagane, M.; Sugiyama, K.; Terasaki, M.; Abe, T.; Mukasa, A.; Beppu, T.; Furuse, M. 2014: At-41 * Multi-Center Clinical Trial of Intravenous Administration of Bevacizumab for the Treatment of Radiation Necrosis in the Brain to Obtain Nda Application for on Label Use in Japan. Neuro-Oncology 16(Suppl 5): v17

Moriya, K.; Nitta, M.; Maruyama, T.; Saito, T.; Ikuta, S.; Okada, Y.; Iseki, H.; Muragaki, Y. 2014: At-42 * Factors Associated with Malignant Transformation of Low-Grade Glioma. Neuro-Oncology 16(Suppl 5): v17-v18

Mulholland, P.; Krell, D.; Khan, I.; McBain, C.; Patel, C.; Wanek, K.; Hopkins, K.; Jeffries, S.; Jager, R.; Smith, P.; Liu, Q.; Stupp, R.; Tomlinson, I. 2014: At-43 * Multi-Centre, Randomized, Double-Blind Phase Ii Study Comparing Cediranib (Azd2171) plus Gefitinib (Iressa, Zd1839) with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. Neuro-Oncology 16(Suppl 5): v18

Patel, A.; Sheehan, J.; Glantz, M. 2014: At-44 * Relearning Neuro-Oncology: Bayes' Theorem Provides a New World Order. Neuro-Oncology 16(Suppl 5): v18

Peker, S.; Kabalay, I.A.; Tezcanli, E.; Yilmaz, M.; Sengoz, M. 2014: At-45 * Gamma Knife Radiosurgery for Recurrent high Grade Gliomas. Neuro-Oncology 16(Suppl 5): v18

Peters, K.; Reardon, D.; Randazzo, D.; Dutton, S.; Edwards, A.; Lipp, E.; Herndon, J.; McSherry, F.; Desjardins, A.; Ranjan, T.; Vlahovic, G.; Friedman, H. 2014: At-46 * Vorinostat and Bevacizumab for Recurrent High-Grade Glioma: Interim Analysis of a Phase Ii Clinical Trial. Neuro-Oncology 16(Suppl 5): v18

Raizer, J.; Pentsova, E.; Omuro, A.; Lin, N.; Nayak, L.; Quant, E.; Kumthekar, P. 2014: At-47 * Phase I Trial of Intrathecal Trastuzumab in Her2 Positive Leptomeningeal Metastases. Neuro-Oncology 16(Suppl 5): v19

Ranjan, T.; Peters, k.B.; Vlahovic, G.; Watts, J.; Dutton, S.; Boulton, S.; Lipp, E.; Herndon, J.; Healy, P.; Miller, E.; Friedman, H.; Karmali, R.; Desjardins, A. 2014: At-48 * a Phase 1 Trial of Carboxyamidotriazole Orotate (Cto) in Combination with Bevacizumab for Adult Patients with Recurrent Malignant Glioma Post-Bevacizumab Failure. Neuro-Oncology 16(Suppl 5): v19

Sai, K.; Zhong, M..; Chen, Z.. 2014: At-49 * Safety Evaluation of High-Dose Bcnu-Loaded Biodegradable Implants in Chinese Patients with Recurrent Malignant Gliomas. Neuro-Oncology 16(Suppl 5): v19

Schroeteler, J.; Schipmann, S.; Molina, E.S.; Grauer, O.; Stummer, W.; Ewelt, C. 2014: At-50 * Ala-Based Photodynamic Therapy in Recurrent Malignant Glioma - a Pilot Study. Neuro-Oncology 16(Suppl 5): v19

Aoki, T.; Ueba, T.; Miyatake, S.-I.; Nozaki, K.; Arakawa, Y.; Miyamoto, S.; Tsukahara, T.; Matsutani, M. 2014: At-05 * Phase Ii Study of Ifosfamide, Carboplatin, and Etoposide Inpatients with a First Recurrence of Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 5): v9

Shi, W.; Lawrence, Y.R.; Werner-wasik, M.; Evans, J.; Andrews, D.; Glass, J.; Kim, L.; Ad, V.B.; Moshel, Y.; Judy, K.; Farrell, C.; Simon, N.; Dicker, A. 2014: At-51 * Phase I Study of Panobinostat and Fractionated Stereotactic Re-Irradiation Therapy (Fsrt) for Recurrent high Grade Gliomas. Neuro-Oncology 16(Suppl 5): v19-v20

Shih, H.; Sherman, J.; Nachtigall, L.; Colvin, M.; Fullerton, B.; Winrich, B.; Batchelor, T.; Thornton, L.; Daartz, J.; Mancuso, S.; Oh, K.; Curry, W.; Loeffler, J.; Yeap, B. 2014: At-52 * Prospective Early Results of low Grade Glioma Patients Treated with Proton Therapy. Neuro-Oncology 16(Suppl 5): v20

Shih, K.; Patel, M.; Butowski, N.; Bacha, J.; Brown, D.; Garner, W.; Steino, A.; Schwartz, R.; Kanekal, S.; Lopez, L.; Burris, H.A. 2014: At-53 * Phase I/Ii Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma Multiforme (Gbm). Neuro-Oncology 16(Suppl 5): v20

Stummer, W.; Goldbrunner, R.; Wolfer, J. 2014: At-54 * Thermotherapy with Coated Iron Oxide Nanoparticles Radiotherapy versus Radiotherapy Alone in Recurrent Glioblastoma: An Open-Label Randomized Controlled Study. Neuro-Oncology 16(Suppl 5): v20

Taal, W.; Enting, R.; Taphoorn, M.; Smits, M.; Dubbink, H.; Beerepoot, L.; Hanse, M.; Bralten, L.; Oosterkamp, H.; Walenkamp, A.; Buter, J.; Honkoop, A.; Boerman, D.; de Vos, F.; Bromberg, J. 2014: At-55 * Final Analysis of the Belob Trial (A Randomized Phase Ii Study on Bevacizumab versus Bevacizumab plus Lomustine versus Lomustine Single Agent in Recurrent Glioblastoma) and First Radiology Review Results. Neuro-Oncology 16(Suppl 5): v20-v21

Taal, W.; van der Rijt, K.; Dinjens, W.; Smitt, P.S.; Wertenbroek, A.; Bromberg, J.; van Heuvel, I.; Kros, J.; van den Bent, M. 2014: At-56 * Treatment of Large Low-Grade Oligodendroglial Tumors with Upfront Procarbazine, Lomustine, and Vincristine Chemotherapy with Long Follow-Up: A Retrospective Cohort Study with Growth Kinetics. Neuro-Oncology 16(Suppl 5): v21

Takayuki, Y.; Masayuki, N.; Takashi, M.; Taichi, S.; Satoko, I.; Yoshikazu, O.; Hiroshi, I.; Yoshihiro, M. 2014: At-57 * Long-Term Clinical Results of Extensive Tumor Removal Followed by Acnu-Based Chemoradiotherapy for 147 Anaplastic Gliomas. Neuro-Oncology 16(Suppl 5): v21

Wakabayashi, T.; Natsume, A.; Mizusawa, J.; Katayama, H.; Fukuda, H.; Shibui, S.; Btsg, M.J. 2014: At-58 * Jcog0911 Integra Trial: A Randomized Screening Phase Ii Trial of Chemoradiotherapy with Interferon plus Temozolomide versus Chemoradiotherapy with Temozolomide Alone for Newly-Diagnosed Glioblastoma. Neuro-Oncology 16(Suppl 5): v21

Weller, M.; Thiel, E.; Martus, P.; Mohle, R.; Griesinger, F.; Rauch, M.; Roeth, A.; Hertenstein, B.; Fischer, T.; Hundsberger, T.; Mergenthaler, H.-G.; Junghanss, C.; Birnbaum, T.; Fischer, L.; Jahnke, K. 2014: At-59 * High-Dose Mtx-Based Chemotherapy for Primary Cns Lymphoma: With or without Whole Brain Radiotherapy? Final Analysis of G-Pcnsl-Sg-1. Neuro-Oncology 16(Suppl 5): v21-v22

Aregawi, D.; Kreisl, T.N.; Innis, E.; Fine, H.A. 2014: At-06 * a Phase Ii Trial of Tamoxifen and Bortezomib in Patients with Recurrent high Grade Glioma. Neuro-Oncology 16(Suppl 5): v9

Wong, E.T.; Lok, E.; Gautam, S.; Swanson, K.D. 2014: At-61 * Dexamethasone Exerts Profound Interference on Treatment Efficacy for Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v22

Wright, J.; Tresman, R.; Dubois, C.; Lewis, J.; Surash, S. 2014: At-62 * Analysis of Survival Concerning the Extent of Surgical Resection in New Glioblastoma Multiforme: A Single-Centre Retrospective Audit. Neuro-Oncology 16(Suppl 5): v22

Armstrong, T.S.; Vera-Bolanos, E.; Gilbert, M.; Yuan, Y.; Wani, K.; Wu, J.; Omuro, A.; Lieberman, F.; Robins, H.I.; Gerstner, E.; Wu, J.; Wen, P.; Mikkelsen, T.; Aldape, K.; Mendoza, T. 2014: At-07 * a Phase Ii Study of Lapatinib and Dose-Dense Temozolomide (Tmz) for Adults with Recurrent Ependymoma: Patient Reported Outcomes (Pro) from a Cern Clinical Trial. Neuro-Oncology 16(Suppl 5): v9

Arvold, N.; Cefalu, M.; Wang, Y.; Zigler, C.; Schrag, D.; Dominici, F. 2014: At-08 * Radiotherapy with Vs without Temozolomide in Older Patients with Glioblastoma. Neuro-Oncology 16(Suppl 5): v9

Barrascout, E.; Lamuraglia, M.; Gervais, C.; Tiako, M.; Gaillard, S.; Aldea, S.; Mabro, M.; Gachet, J.; Theodore, C. 2014: At-09 * Bevacizumab and Gliobastoma of the Elderly: A Single-Center Retrospective Analysis. Neuro-Oncology 16(Suppl 5): v10

Ajlan, A.; Thomas, P.; Thomas, R.; Nagpal, S.; Recht, L. 2014: Ai-01 * Are We using Too Much Bevacizumab in Our Gbm Patients?. Neuro-Oncology 16(Suppl 5): v1

Eskilsson, E.; Rosland, G.; Talasila, K.; Jahedi, R.; Leiss, L.; Saed, H.; Keunen, O.; Foerster, S.; Euskirchen, P.; Hossain, J.; Taxt, T.; Jirik, R.; Lund-Johansen, M.; Enger, P.O.; Ritter, C. 2014: Ai-10 * Distinct Egfr Signaling In Glioblastoma: Wild-Type Egfr Promotes Invasion While EgfrvIii Drives Prototypical Sfk c-Src Activation To Foster Angiogenesis. Neuro-Oncology 16(Suppl 5): v3

Huang, M.; Ma, P.; Mitteer, R.; Fan, Y. 2014: Ai-11 * c-Met-Mediated Endothelial-Mesenchymal Transition Drives Glioblastoma Progression And Therapeutic Resistance. Neuro-Oncology 16(Suppl 5): v3

Huang, Y.; Rajappa, P.; Bromberg, J.; Lyden, D.; Greenfield, J. 2014: Ai-12 * Id2/Kdr Drives Formation of Pro-Malignant Myeloid Derived Suppressor cells in Glioma. Neuro-Oncology 16(Suppl 5): v3

Huizer, K.; Sacchetti, A.; Mustafa, D.; van der Weiden, M.; Kros, M. 2014: Ai-13 * Circulating Endothelial Progenitor Cells In Glioblastoma Patients Express Increased Levels Of c-Kit And Scf. Neuro-Oncology 16(Suppl 5): v3-v4

Ishida, J.; Onishi, M.; Kurozumi, K.; Ichikawa, T.; Fujii, K.; Shimazu, Y.; Oka, T.; Otani, Y.; Shimizu, T.; Date, I. 2014: Ai-14 * the Anti Angiogenic and Invasive effects of an Integrin Inhibitor against Bevacizumab-Induced Invasive Glioma. Neuro-Oncology 16(Suppl 5): v4

Ivan, M.; Safaee, M.; Oh, T.; Clark, A.; Sun, M.; Kim, J.; Bloch, O.; Jahangiri, A.; Aghi, M.; Parsa, A. 2014: Ai-15 * Epidermal Growth Factor-Like Module Containing Mucin-Like Hormone Receptor 2 Role in Predicting Survival in Invasive Gliomas. Neuro-Oncology 16(Suppl 5): v4

Jensen, R.; Gillepsie, D. 2014: Ai-16 * Hif-1a Inhibition by RNA Interference Delivered via a Novel Multifunctional Surfactant Attenuates Glioma Growth in an Intracranial Mouse Model. Neuro-Oncology 16(Suppl 5): v4

Kerstetter-Fogle, A.; Harris, P.; Bonda, D.; Barnholtz-Sloan, J.; Couce, M.; Sloan, A. 2014: Ai-17 * Robo2-Slit1 Signaling Implicated in Glioma Invasion. Neuro-Oncology 16(Suppl 5): v4-v5

Ladha, H.; Pawar, T.; Gilbert, M.; O'Brien, B.; Conrad, C.; Fields, M.; Hanna, T.; Loch, C.; Armstrong, T. 2014: Ai-18 * Wound Healing Complications in a Series of Brain Tumor Patients on Bevacizumab. Neuro-Oncology 16(Suppl 5): v5

Liu, Y.; Carson-Walter, E.; Walter, K. 2014: Ai-19 * Chemokine Receptor Cxcr7 is a Functional Receptor for Cxcl12 in Brain Endothelial cells. Neuro-Oncology 16(Suppl 5): v5

Alamsahebpour, A.; Jalali, S.; Singh, S.; Burrell, K.; Zadeh, G. 2014: Ai-02 * Hypoxia as a Measure of Functional Status of Glioblastoma Vasculature. Neuro-Oncology 16(Suppl 5): v1

McKinney, A.; Engler, J.; Phillips, J. 2014: Ai-20 * Mechanisms of Resistance to Egfr Inhibition Associated with an Invasive Phenotype. Neuro-Oncology 16(Suppl 5): v5

Nigim, F.; Cavanaugh, J.; Patel, A.P.; Curry, W.T.; Kasper, E.M.; Chi, A.S.; Martuza, R.L.; Rabkin, S.D.; Wakimoto, H. 2014: Ai-21 * Hif-1A Targeting In An Orthotopic Xenograft Model That Recapitulates The Hypoxic Microenvironment Of Glioblastoma. Neuro-Oncology 16(Suppl 5): v5

Okamoto, S.; Nitta, M.; Maruyama, T.; Muragaki, Y.; Saito, T.; Ikuta, S.; Okada, Y. 2014: Ai-22 * Clinical Outcome of Bevacizumab-Treated Patients with Recurrent Malignant Gliomas. Neuro-Oncology 16(Suppl 5): v5-v6

Park, S.Y.; Piao, Y.; de Groot, J. 2014: Ai-23 * Periostin Regulates Tumor Resistance to Antiangiogenic Therapy through Emt and Angiogenesis-Related Mechanisms in Glioma Stem cell Models. Neuro-Oncology 16(Suppl 5): v6

Pham, K.; Luo, D.; Siemann, D.; Law, B.; Reynolds, B.; Hothi, P.; Foltz, G.; Harrison, J. 2014: Ai-24 * Vegfr Inhibitors Enhance Progression Of Glioblastoma By Upregulating Cxcr4 In A TgfR Signaling-Dependent Manner. Neuro-Oncology 16(Suppl 5): v6

Piao, Y.; Smith, B.; Thomas, C.; Holmes, L.; Henry, V.; Flynn, D.L.; de Groot, J. 2014: Ai-25 * The Novel c-Met Inhibitor Altiratinib (Dcc-2701) Inhibits Tumor Growth And Invasion In A Bevacizumab Resistant Glioblastoma Mouse Model. Neuro-Oncology 16(Suppl 5): v6

Scholz, A.; Cremer, S.; Harter, P.; Mittelbronn, M.; van Slyke, P.; Dumont, D.; Plate, K.H. 2014: Ai-26 * Overcoming Resistance to Vegf-Blockade by Targeting the Angiopoietin/Tie2 Axis. Neuro-Oncology 16(Suppl 5): v6-v7

Speranza, M.C.; Nowicki, M.O.; Antonio Chiocca, E.; Lawler, S.E. 2014: Ai-27 * Bkm-120: An Anti-Invasive Candidate for the Treatment of Glioblastoma. Neuro-Oncology 16(Suppl 5): v7

Tabatabai, G.; Felsberg, J.; Sabel, M.; Kaulich, K.; Hofer, S.; Westphal, M.; Weller, M.; Reifenberger, G. 2014: Ai-28 * Recurrent Glioblastomas after Treatment with Bevacizumab. Neuro-Oncology 16(Suppl 5): v7

Tabouret, E.; Tchoghandjian, A.; Denicolai, E.; Delfino, C.; Metellus, P.; Padovani, L.; Nanni, I.; Barrie, M.; Boucard, C.; Ouafik, L.; Figarella-Branger, D.; Chinot, O. 2014: Ai-29 * Angiogenic Switch from Vegfr2/Hif1 in Newly Diagnosed Glioblastoma (Gb) to Cxcr4-Sdf1 Pathway in Recurrent Paired Tumor after Radiotherapy (Rt)-Temozolomide (Tmz). Neuro-Oncology 16(Suppl 5): v7

Bae, E.; Smith, L.; Muller-Greven, G.; Yamada, R.; Joshi, K.; Nakano-Okuno, M.; Feng, X.; Hambardzumyan, D.; Nakano, I.; Gladson, C.L. 2014: Ai-03 * Targeting Angiogenesis without Increasing the Stromal cell Response or Invasion using Abt-898, a Thrombospondin type 1 Repeat Peptide. Neuro-Oncology 16(Suppl 5): v1

Baker, G.; Yadav, V.; Motsch, S.; Koschmann, C.; Calinescu, A.; Mineharu, Y.; Camelo-Piragua, S.; Orringer, D.; Bannykh, S.; Nichols, W.; deCarvalho, A.; Mikkelsen, T.; Castro, M.; Lowenstein, P. 2014: Ai-04 * Mechanisms of Glioma Formation: Perivascular Glioma Invasion is a Vegf-Independent Mechanism of Tumor Vascularization. Neuro-Oncology 16(Suppl 5): v1-v2

Burrell, K.; Singh, S.; Agnihotri, S.; Hill, R.; Aldape, K.; Zadeh, G. 2014: Ai-05 * Impact of Gbm Microenvironment on Expression Profile of Bone Marrow Derived Progenitor cells. Neuro-Oncology 16(Suppl 5): v2

Cherry, E.; Lee, D.; Jung, J.; Sitcheran, R. 2014: Ai-06 * Non-Canonical Nf-kB Signaling Drives The Aggressive Invasiveness Of Glioblastoma. Neuro-Oncology 16(Suppl 5): v2

Conroy, S.; Wagemakers, M.; Kruyt, F.; Walenkamp, A. 2014: Ai-07 * Glioblastoma Subtypes do not Exploit Differential Angiogenic Signaling Pathways Nor Are the Vessels Functionally different. Neuro-Oncology 16(Suppl 5): v2

D'Asti, E.; Kool, M.; Pfister, S.; Rak, J. 2014: Ai-08 * Subgroup-Specific Deregulation of Coagulation and Angiogenic Gene Expression Profiles in Medulloblastoma- Evidence for Cross-Talk between Growth Factor and Coagulation Pathways. Neuro-Oncology 16(Suppl 5): v2

Escorcia, F.E.; Folkert, M.R.; Spratt, D.E.; Zumsteg, Z.; Chan, T.; Omuro, A.M.; Beal, K.; Gutin, P.H.; Yamada, J. 2014: Ai-09 * Patterns of Salvage Treatment for high Grade Glioma in the Temozolomide Era. Neuro-Oncology 16(Suppl 5): v3

Abel, P. 2014: Bi-01 * Blood Serum and C.S.F. Analytes show Potential for Use as a Diagnostic Biomarker for low and high Grade Glioma. Neuro-Oncology 16(Suppl 5): v23

Harris, R.; Cloughesy, T.; Liau, L.; Lai, A.; Nghiemphu, P.; Li, D.; Pope, W.; Ellingson, B. 2014: Bi-10 * pH-Weighted Mri In Human Gliomas. Neuro-Oncology 16(Suppl 5): v25

Hayes, J.; Thygesen, H.; Droop, A.; Boissinot, M.; Bellamy, C.; Hughes, T.; Westhead, D.; Shaw, L.; Wurdak, H.; Lawler, S.; Short, S. 2014: Bi-11 * Prognostic micro Rnas In Malignant Glioma. Neuro-Oncology 16(Suppl 5): v25

Bell, E.H.; Pugh, S.; Gilbert, M.; Mehta, M.; Klimowicz, A.; Magliocco, A.; Bredel, M.; Robe, P.; Grosu, A.; Stupp, R.; Curran, W.; Corn, B.; Brown, P.; Glass, J.; Souhami, L. 2014: Bi-12 * Rtog 0525 Recursive Partitioning Analysis Based on Clinical and Protein Biomarker Parameters. Neuro-Oncology 16(Suppl 5): v25

Huang, Y.-C.; Chen, H..; Yeh, D..; Wei, K.-C. 2014: Bi-13 * Tissue Transglutminase: A Potential Adjuvant Target for Primary Brain Tumor. Neuro-Oncology 16(Suppl 5): v26

Johnson, J.; Ascierto, M.L.; Newsome, D.; Mittal, S.; Kang, L.; Briggs, M.; Tanner, K.; Berens, M.E.; Marincola, F.M.; Vande Woude, G.F.; Xie, Q. 2014: Bi-14 * Genomic Profiling of a Predictive Signature for Met-Targeted Therapy in Glioblastoma. Neuro-Oncology 16(Suppl 5): v26

Juratli, T.; Geiger, K.; Lautenschlaeger, T.; Schackert, G.; Krex, D. 2014: Bi-15 * Radio- Chemotherapy Improves Survival for Idh Mutant, 1p19q-Non-Codeleted Secondary High-Grade-Astrocytoma. Neuro-Oncology 16(Suppl 5): v26

Lange, R.; Everett, A.; Dulloor, P.; Korley, F.K.; Bettegowda, C.; Blair, C.; Grossman, S.A.; Holdhoff, M. 2014: Bi-16 * Circulating Protein Analysis of Potential Brain Tumor Biomarkers. Neuro-Oncology 16(Suppl 5): v26

Lee, S.-T.; Lee, K.-M.; Kim, J.W.; Park, M.-J.; Lim, J.-A.; Choi, S.-H.; Kim, T.M.; Lee, S.H.; Park, S.-H.; Kim, I.-H.; Park, C.-K. 2014: Bi-17 * Early Cognitive Function tests Predict Early Progression in Newly-Diagnosed Glioblastoma. Neuro-Oncology 16(Suppl 5): v26-v27

Lesser, G.; Harmon, M.; Khan, I.; Whitlow, C.; Brown, W. 2014: Bi-18 * Cellular Microparticles as Blood-Borne Endothelial Biomarkers in Patients with Malignant Gliomas. Neuro-Oncology 16(Suppl 5): v27

Lin, A.; Liu, J.; Huang, J.; Robinson, C.; Simpson, J.; Chicoine, M.; Dacey, R.; Kim, A.; Rich, K.; Leuthardt, E.; Linette, G.; Miller-Thomas, M.; Schmidt, R.; Dahiya, S.; Tran, D. 2014: Bi-19 * Pseudoprogression in Oligodendrogliomas and Mixed Oligoastrocytomas is Associated with Poor Prognosis. Neuro-Oncology 16(Suppl 5): v27

Aiken, C.; Liang, L.; Morrison, L.; Del Bigio, M.; Remke, M.; Taylor, M.; Werbowetski-Ogilvie, T. 2014: Bi-02 * Functional Characterization of Novel Biomarkers in Selecting for Subtype Specific Medulloblastoma Phenotypes. Neuro-Oncology 16(Suppl 5): v23

Ma, D.; Galanis, E.; Peller, P.; Ligon, K.; Giannini, C.; Sarkaria, J. 2014: Bi-20 * Genetic Profiling For Early Everolimus Sensitivity In Newly Diagnosed Glioblastoma Patients Enrolled On Ncctg N057K. Neuro-Oncology 16(Suppl 5): v27

Mistry, M.; Zhukova, N.; Merico, D.; Rakopoulos, P.; Krishnatry, R.; Shago, M.; Stavropoulos, J.; Ray, P.; Mangerel, J.; Remke, M.; Buczkowicz, P.; Ramaswamy, V.; Rutka, J.; Dirks, P.; Taylor, M. 2014: Bi-21 * Braf Mutation And Cdkn2A Deletions Define A Clinically Distinct Subgroup Of Childhood Secondary High Grade Glioma. Neuro-Oncology 16(Suppl 5): v27-v28

Phillips, H.; Sandmann, T.; Li, C.; Cloughesy, T.; Chinot, O.L.; Wick, W.; Nishikawa, R.; Mason, W.; Henriksson, R.; Saran, F.; Lai, A.; Moore, N.; Hegde, P.; Abrey, L.; Bourgon, R. 2014: Bi-22 * Correlation of Molecular Subtypes with Overall Survival (Os) in Avaglio, a Randomized, Placebo-Controlled Study of Bevacizumab (Bev) plus Radiotherapy (Rt) and Temozolomide (Tmz) for Newly Diagnosed Glioblastoma (Gbm). Neuro-Oncology 16(Suppl 5): v28

Planey, K.; Gevaert, O. 2014: Bi-23 * Loss Of Novel lncRna Defines The Glioblastoma Mesenchymal Subtype. Neuro-Oncology 16(Suppl 5): v28

Pointer, K.B.; Eliceiri, K.W.; Clark, P.A.; Kuo, J.S. 2014: Bi-24 * Collagen Plays a Role in Glioblastoma Tumor Invasion and Patient Survival. Neuro-Oncology 16(Suppl 5): v28

Riethdorf, S.; Westphal, M.; Mueller, C.; Holtschmidt, J.; Schulte, A.; Matschke, J.; Auer, M.; Speicher, M.; Lamszus, K.; Pantel, K. 2014: Bi-25 * Circulating Tumor cells in Glioblastoma. Neuro-Oncology 16(Suppl 5): v28-v29

Timmer, M.; Perrech, M.; Rohn, G.; Ruess, D.; Blau, T.; Breuer, N.; Galldiks, N.; Goldbrunner, R.; Ruge, M. 2014: Bi-26 * How Much Insight can a Stereotactic Biopsy Deliver?. Neuro-Oncology 16(Suppl 5): v29

Uckermann, O.; Juratli, T.; Conde, M.; Galli, R.; Krex, D.; Geiger, K.; Schackert, G.; Temme, A.; Steiner, G.; Kirsch, M. 2014: Bi-27 * Analysis of the Biochemical Profile of low Grade Glioma with different Idh1 Mutation Status using Vibrational Spectroscopy. Neuro-Oncology 16(Suppl 5): v29

van den Bossche, W.B.L.; Lamfers, M.L.M.; Vincent, A.J.P.E.; de Bruin Versteeg, S.; Josiassen, K.; Orfao, A.; Dirven, C.M.F.; van Dongen, J.J.M. 2014: Bi-28 * New Monocyte Subtyping Distinguishes Glioma Patients from Healthy Controls. Neuro-Oncology 16(Suppl 5): v29

Virk, S.; Gibson, R.; Barnholtz-Sloan, J.; Quinones-Mateu, M. 2014: Bi-29 * Variant Analysis of Primary and Recurrent Glioblastoma using Ion Ampliseqtm Comprehensive Cancer Panel and Whole Exome Sequencing. Neuro-Oncology 16(Suppl 5): v29-v30

Bronisz, A.; Mineo, M.; Ansari, K.; Rooj, A.; Nakano, I.; Antonio Chiocca, E.; Godlewski, J. 2014: Bi-03 * Glioblastoma-Specific and Glioblastoma Stem cell Subtype-Specific Signatures of Long, Non-Coding Rnas. Neuro-Oncology 16(Suppl 5): v23

Wani, K.; Armstrong, T.S.; Jones, D.T.; Vera-Bolanos, E.; Witt, H.; Capper, D.; Pfister, S.M.; Gilbertson, R.J.; Gilbert, M.R.; Aldape, K. 2014: Bi-30 * Characterization Of L1Cam As A Clinical Marker For The C11orf95-Rela Fusion In Supratentorial Ependymomas. Neuro-Oncology 16(Suppl 5): v30

Weng, L.; Zhai, Y.; D'Apuzzo, M.; Badie, B.; Forman, S.J.; Barish, M.; Brown, C.E. 2014: Bi-31 * Analysis and Quantification of Multiple Antigen Expression in Glioblastoma. Neuro-Oncology 16(Suppl 5): v30

Wick, W.; Hentschel, B.; Gramatzki, D.; Simon, M.; Schackert, G.; Tonn, J.-C.; Westphal, M.; Tatagiba, M.; Sabel, M.; Weyerbrock, A.; Pietsch, T.; Reifenberger, G.; Loeffler, M.; Weller, M. 2014: Bi-32 * Risk Factor Analysis for Patients with Newly Diagnosed Glioblastoma Who Did not Receive Salvage Therapy. Neuro-Oncology 16(Suppl 5): v30

Zhong, J.; Ali, A.; Voloschin, A.; Liu, Y.; Curran, W.; Crocker, I.; Shu, H.-K. 2014: Bi-33 * Bevacizumab-Induced Hypertension is a Predictive Marker for Improved Outcomes in Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v30-v31

Bunevicius, A.; Tamasauskas, S.; Deltuva, V.P.; Tamasauskas, A.; Bunevicius, R. 2014: Bi-04 * Pre-Operative low Tri-Iodothyronine Syndrome is Associated with Greater 6-Month Mortality Rate of Neurosurgical Brain Tumor Patients. Neuro-Oncology 16(Suppl 5): v23

Cardona, A.; Jimenez, E.; Hakim, F.; Useche, N.; Bermudez, S.; Arrieta, O.; Behaine, J.; Rodriguez, J.; Carranza, H.; Otero, J.; Vargas, C.; Rojas, L.; Ortiz, L.D. 2014: Bi-05 * Molecular Profiling of low Grade Gliomas (Lgg) in Colombia (Oncolgroup). Neuro-Oncology 16(Suppl 5): v24

Chang, Q.; Shao, L.; Pan, Y.; Qi, X. 2014: Bi-06 * Atrx Loss in Chinese Adult Diffuse Astrocytomas Correlates with Idh1 and Tp53 Mutation and Predicts Better Outcome in Tp53 Mutated Patients. Neuro-Oncology 16(Suppl 5): v24

Chaumeil, M.; Larson, P.; Woods, S.; Cai, L.; Eriksson, P.; Robinson, A.; Lupo, J.; Vigneron, D.; Nelson, S.; Pieper, R.; Phillips, J.; Ronen, S. 2014: Bi-07 * Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker Of Idh1 Mutational Status In Glioma. Neuro-Oncology 16(Suppl 5): v24

Evans, S.M.; Koch, C.J.; Lustig, R. 2014: Bi-08 * Microvesicles can Distinguish between Tumor Progression and Treatment Effect/Pseudoprogression in Glioblastoma Patients Treated with Radiation and Temozolomide. Neuro-Oncology 16(Suppl 5): v24

Ferluga, S.; Gibo, D.; Debinski, W. 2014: Bi-09 * EphA3 Receptor Is A Molecular Target Expressed In Multiple Compartments Of Gbm. Neuro-Oncology 16(Suppl 5): v25

Abraham, C.; Garsa, A.; Badiyan, S.; Dryzmala, R.; Yang, D.; DeWees, T.; Simpson, J.; Fouke, S.; Robinson, C. 2014: Bm-01 * Dosimetric Hotspots Are the Most Powerful Dosimetric Predictor of Local Control in Nsclc Brain Metastases. Neuro-Oncology 16(Suppl 5): v32

Colaco, R.; Martin, P.; Bond, J.; Bindra, R.; Contessa, J.; Kluger, H.; Yu, J.; Chiang, V. 2014: Bm-10 * Systemic Treatment and Radiation Necrosis following Gksrs in the Treatment of Brain Metastases. Neuro-Oncology 16(Suppl 5): v34

Dardis, C.; Milton, K.; Ashby, L.; Shapiro, W. 2014: Bm-11 * Leptomeningeal Metastases in High-Grade Adult Glioma: Development, Diagnosis, Management and Outcomes in a Series of 34 Patients. Neuro-Oncology 16(Suppl 5): v34

Dredla, B.; Siegel, J.; Jaeckle, K. 2014: Bm-12 * Cerebral Infarction Secondary to Pulmonary Vein Compression and left Atrial Appendage Tumor Infiltration as the Presenting Sign of Metastatic Squamous cell Carcinoma of the Base of the Tongue. Neuro-Oncology 16(Suppl 5): v34

Hanna, A.; Hunter Boggs, D.; Sperduto, P.; Kwok, Y.; Feigenberg, S.; Simard, M.; Mehta, M. 2014: Bm-13 * The (F)Utility Of Predictive Models. Neuro-Oncology 16(Suppl 5): v34-v35

Jackson, P.; Grady, F.; Lester, M.; Kokkinos, E.; Rosenberg, A.; Rockne, R.; Bridge, C.; Marymont, M.; Chandler, J.; Swanson, K.; Kumthekar, P. 2014: Bm-14 * a Paradigm Shift in Determining Brain Metastasis Treatment: Does Number Really Matter?. Neuro-Oncology 16(Suppl 5): v35

Johnson, K.N.; Gooden, G.; Gonzalez, P.; Sepulveda, M.; Gorgol, L.; Petricoin, E.F.; Pierobon, M.; Byron, S.; Glen, J.; Ahluwalia, M.; Bernstein, M.; Toms, S.A.; Salhia, B. 2014: Bm-15 * Targeting Mek is a Novel and Effective Treatment Strategy of Lung Cns Metastasis. Neuro-Oncology 16(Suppl 5): v35

Khoja, L.; Kurtz, G.; Zadeh, G.; Laperriere, N.; Menard, C.; Millar, B.-A.; Bernstein, M.; Kongkham, P.; Joshua, A.; Hogg, D.; Butler, M.; Chung, C. 2014: Bm-16 * increased Acute Radiation effect (Are) with Ipilumumab and Radiosurgery in Patients with Melanoma Brain Metastases. Neuro-Oncology 16(Suppl 5): v35

Kirkpatrick, J.; Wang, Z.; Sampson, J.; McSherry, F.; Herndon, J.; Allen, K.; Duffy, E.; Chang, Z.; Hoang, J.; Kelsey, C.; Yoo, D.; Cabrera, A.; Yin, F.-F. 2014: Bm-17 * Final Results of a Randomized Trial to Identify the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases. Neuro-Oncology 16(Suppl 5): v35

LeRhun, E.; Taillibert, S.; Zairi, F.; Boulanger, T.; Farre, I.; Deligny, N.; Bachelot, T.; Bonneterre, J. 2014: Bm-18 * Prolonged Response with Bevacizumab + Navelbine as Third Line of Treatment of Breast Cancer Leptomeningeal Metastases: A Case Report. Neuro-Oncology 16(Suppl 5): v36

Macalalad, A.; Sasane, M.; Zhang, J.; Culver, K.; Dea, K.; Nitulescu, R.; Wu, E.; Guerin, A. 2014: Bm-19 * Symptomatic and Economic Burden of Brain Metastases in Patients with Alk+ Nsclc. Neuro-Oncology 16(Suppl 5): v36

Ahluwalia, M.; Venur, V.A.; Chi, M.; Chao, S.; Lilyana, A.; Elson, P.; Suh, J.; Barnett, G. 2014: Bm-02 * New Disease Specific Graded Prognostic Assessment of Brain Metastasis from Lung, Breast, Melanoma and Renal Malignancies. Neuro-Oncology 16(Suppl 5): v32

Mohammadi, A.; Abbassy, M.; Schroeder, J.; Missios, S.; Elson, P.; Angelov, L.; Chao, S.; Murphy, E.; Recinos, P.; Yu, J.; Suh, J.; Barnett, G.; Vogelbaum, M. 2014: Bm-20 * Evaluation of Risk Factors for Death within three Months after Stereotactic Radiosurgery for Brain Metastases. Neuro-Oncology 16(Suppl 5): v36

Muggeri, A.; Calabrese, B.; Cerrato, S.; Diez, B. 2014: Bm-21 * Risk of Neoplastic Meningitis from Brain Metastases in Nsclc Initially Treated without Whole Brain Irradiation: A Retrospective Analysis of a Case Series. Neuro-Oncology 16(Suppl 5): v36

Mustafa, D.; Sieuwerts, A.; Smid, M.; de Weerd, V.; Martens, J.; Foekens, J.; Kros, J. 2014: Bm-22 * Boc and Map2 Are Operative in Breast Cancer Metastasis to Brain. Neuro-Oncology 16(Suppl 5): v36-v37

Nasir, A.; Othman, R.; Storer, L.; Onion, D.; Lourdasamy, A.; Grabowska, A.; Coyle, B. 2014: Bm-23 * Twist1 Expression Confirms the Role of an Emt-Like Process in Medulloblastoma Metastasis. Neuro-Oncology 16(Suppl 5): v37

Pangeni, R.P.; Huen, D.; Ashton, K.; Walker, C.; Dawson, T.P.; Davis, C.; Latif, F.; Darling, J.L.; Warr, T.J.; Morris, M.R. 2014: Bm-24 * Multi-Gene Methylation Analysis to Identify Signature Genes for Brain Metastasis from Primary Breast Tumors. Neuro-Oncology 16(Suppl 5): v37

Picotte, K.; Li, L.; Zhao, H. 2014: Bm-25 * Proneural Transcription Factor Atoh1 Drives Leptomeningeal Metastasis of the Sonic Hedgehog Subgroup of Medulloblastoma. Neuro-Oncology 16(Suppl 5): v37

Pilkington, G.; Jassam, S.; Maherally, Z.; Smith, J.; Fillmore, H. 2014: Bm-26 * Cd15 and E-Selectin Mediation of Adhesion of Non-Small cell Lung Cancer cells to Brain Endothelium in Lung-Brain Metastasis. Neuro-Oncology 16(Suppl 5): v26

Quigley, M.; Bello, N.; Jho, D.; Fuhrer, R.; Karlovits, S.; Buchinsky, F. 2014: Bm-27 * Estimating the Additional Benefit of Surgical Excision to Stereotactic Radiosurgery in the Management of Metastatic Brain Disease. Neuro-Oncology 16(Suppl 5): v38

Rogers, L.; Varadan, V.; Palkar, A.; Miskimen, K.; Williams, N.; Morton, M.; Maximuk, S.; Vinayak, S.; Sloan, A.; Barnholtz-Sloan, J.; Gilmore, H.; Harris, L. 2014: Bm-28 * Biological Pathways Associated with Breast Cancer Metastasis to the Brain. Neuro-Oncology 16(Suppl 5): v38

Saad, S.; Wang, T.J.C.; Jani, A.; Qureshi, Y.H.; Yaeh, A.; Nanda, T.; Rozenblat, T.; Sisti, M.B.; Bruce, J.N.; McKhann, G.M.; Lassman, A.B.; Isaacson, S.R. 2014: Bm-29 * Number of Brain Metastases Influences Survival following Gamma Knife Radiosurgery. Neuro-Oncology 16(Suppl 5): v38

Venur, V.A.; Chao, S.; Elson, P.; Ahluwalia, M. 2014: Bm-03 * Revised Graded Prognostic Assessment for Melanoma Patients with Brain Metastasis (Mbm). Neuro-Oncology 16(Suppl 5): v32

Sakji-Dupre, L.; Blanchet, B.; Templier, C.; Desmet, E.; Bonneterre, J.; Mortier, L.; LeRhun, E. 2014: Bm-30 * Intra Cerebropsinal Fluid Concentrations of Vemurafenib in Melanoma. Neuro-Oncology 16(Suppl 5): v38

Sesikeran, N.; Sarma, Y.; Bhattacharya, K.; Reddy, V.; Reddy, V. 2014: Bm-31 * Study of Incidence and Estimation of Risk Factors Associated with Hippocampal Metastasis. Neuro-Oncology 16(Suppl 5): v38-v39

Shaw, A.; Mehra, R.; Tan, D.S.W.; Felip, E.; Chow, L.Q.M.; Ross Camidge, D.; Vansteenkiste, J.; Sharma, S.; DePas, T.; Riely, G.J.; Solomon, B.J.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G. 2014: Bm-32 * Ceritinib (Ldk378) for Treatment of Patients with Alk-Rearranged (Alk+) Non-Small cell Lung Cancer (Nsclc) and Brain Metastases (Bm) in the Ascend-1 Trial. Neuro-Oncology 16(Suppl 5): v39

Sundstrom, T.; Varughese, J.; Azuaje, F.; Prestegarden, L.; Petersen, K.; Tepper, C.; Ingham, E.; Even, L.; Johnson, S.; Skaftnesmo, K.O.; Lund-Johansen, M.; Bjerkvig, R.; Ferrara, K.; Thorsen, F. 2014: Bm-34 * New Uses of Old Drugs for the Clinical Treatment of Brain Metastases. Neuro-Oncology 16(Suppl 5): v39

Veilleux, O.; Cottin, S.; Michaud, K. 2014: Bm-35 * Clinical Factors Impacting Survival in Brain Metastases. Neuro-Oncology 16(Suppl 5): v39

Wheeler, L.A.; Bronisz, A.; Chiocca, E. 2014: Bm-36 * Microenvironment-Dependent Changes To The Mature microRna Expression Profile Of Breast Cancer Cells Metastatic To The Brain. Neuro-Oncology 16(Suppl 5): v39-v40

Zairi, F.; LeRhun, E.; Taillibert, S.; Boulanger, T.; Farre, I.; Bonneterre, J.; Assaker, R.; Chamberlain, M. 2014: Bm-37 * Complications Related to the Use of a Ventricular Device for the Treatment of Leptomeningeal Metastases from Solid Tumors: A Single Center Experience on 112 Patients. Neuro-Oncology 16(Suppl 5): v40

Zhang, Z.; Johnson, J.; Watanabe, Y.; Jackson, S.; Sperduto, P.; Watts, C. 2014: Bm-38 * the Preferred Anatomic Distribution of 1172 Brain Metastases Based on Brain Volume and Regional Blood Flow. Neuro-Oncology 16(Suppl 5): v40

Arauz, R. 2014: Bm-04 * Image Guided Stereotactic Rapid Arc(R) to Single Brain Metastatic Assisted by Intracranial Calcification. Neuro-Oncology 16(Suppl 5): v32-v33

Barkhoudarian, G.; Deutsch, G.; Yost, S.; Duong, H.; Chaloner, C.; Eisenberg, A.; Boasberg, P.; Faries, M.; Hamid, O.; Kelly, D. 2014: Bm-05 * Ipilumumab Therapy for Melanoma Brain Metastases is Associated with increased Radiation Necrosis. Neuro-Oncology 16(Suppl 5): v33

Boire, A.; Zou, Y.; DeAngelis, L.; Massague, J. 2014: Bm-06 * Mechanistic Investigations of Leptomeningeal Metastasis from Solid Tumors. Neuro-Oncology 16(Suppl 5): v33

Brastianos, P.; Carter, S.; Santagata, S.; Taylor-Weiner, A.; Jones, R.; Van Allen, E.; Horowitz, P.; Ligon, K.; Cahill, D.; Dunn, I.; Van Hummelen, P.; Lin, N.; Curry, W.; Stemmer-Rachamimov, A.; Beroukhim, R. 2014: Bm-07 * Genomic Characterization of Brain Metastases Reveals Branched Evolution and Metastasis-Specific Mutations. Neuro-Oncology 16(Suppl 5): v33

Chen, C.; Gonda, D.; Kim, T.; Goetsch, S.; Kawabe, T.; Watanabe, S.; Alksne, J.; Hattangadi, J.; Ott, K.; Hodgens, D.; Carter, B.; Yamamoto, M. 2014: Bm-08 * Prognostic Factors for Srs-Treated Patients with Cerebral Metastasis: Implications on Randomized Control Trial Design and Inter-Institutional Collaborative Efforts. Neuro-Oncology 16(Suppl 5): v33

Chu, R.; Rudnick, J.; Natale, R. 2014: Bm-09 * Use of Neuroendoscopy to Safely Deliver Intrathecal Chemotherapy at the Time of Ommaya Reservoir Placement. Neuro-Oncology 16(Suppl 5): v34

Abaitua, F.; Crook, T.; O'Neill, K.; Syed, N. 2014: Cb-01 * Targeting Collagen Regulation in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 5): v41

Kwiatkowska, A.; Paulino, V.; Dong, Z.; Loftus, J.; Kloss, J.; Ruggieri, R.; Tran, N.; Symons, M. 2014: Cb-11 * Diverse Roles For RhoA And RhoC In Glioblastoma. Neuro-Oncology 16(Suppl 5): v43

Oliva, C.; Reeve, N.; Markert, T.; Griguer, C.E. 2014: Cb-13 * Phenotypic Changes by Nuclear-Encoded Cytochrome C Oxidase Sub-Unit 4, Isoform 1 Supports Poor Prognostic in Gbm Patients. Neuro-Oncology 16(Suppl 5): v43

Penas, C.; Zhang, M.; Clarke, J.; Stathias, V.; Roussel, M.; Hatten, M.; Ayad, N. 2014: Cb-14 * Genomic Approaches to Identify Coding and Noncoding RNA Targets in Medulloblastoma. Neuro-Oncology 16(Suppl 5): v43

Schiapparelli, P.; Magana-Maldonado, R.; Hamilla, S.; Sibener, L.; Martinez-Gutierrez, J.C.; Aranda-Espinoza, H.; Quinones-Hinojosa, A. 2014: Cb-15 * Nkcc1 Regulates Migration Capacity of Glioblastoma Tumor Initiating cells by Modulating Actin Cytoskeleton through small Rho Gtpases. Neuro-Oncology 16(Suppl 5): v43-v44

Turner, S.G.; Kazmi, S.A.; Gergel, T.; Belles, L.; Whitmire, A.; Horn, S.; Lacroix, M.; Toms, S.A. 2014: Cb-16 * Malignant Glioma with Primitive Neuroectodermal Components: Clinical and Pathologic Features of five Cases. Neuro-Oncology 16(Suppl 5): v44

VanBeckum, D.; Studt, J.; Shaffer, D.; Belton, R.; Lawrence, J.; Rovin, R.; Bammert, C.; Winn, R. 2014: Cb-17 * Characterization of Hcmv-Ecoded Chemokine Receptor Us28 Transduced Msu1.1 Human Fibroblast cells. Neuro-Oncology 16(Suppl 5): v44

Watts, C.; Piccirillo, S.; Kearney, L.; Potter, N.; van Delft, F.; Coleman, S.; Lillis, S.; Carnicer, M.-J.; Greaves, M. 2014: Cb-18 * Interrogation of Sub-Clonal Genetic Diversity of Human Gbm Reveals Genetic Heterogeneity in Tumour-Propagating Cells, Which Display Variable Competitive Capacity for Tumour Propagation in Vivo. Neuro-Oncology 16(Suppl 5): v44

Xu, J.; Ren, X.; Tran, A.; Erdreich-Epstein, A. 2014: Cb-19 * Pid1, a New Growth-Inhibitory Gene, Sensitizes Medulloblastoma and Glioma cell Lines to Chemotherapy. Neuro-Oncology 16(Suppl 5): v44

Zhang, K.; Yang, J.; Han, L.; Cui, X.; Sun, X.; Chen, L.; Shi, Z.; Wang, J.; Kang, C.; Li, M. 2014: Cb-20 * Slc39A4 (Zip4) Inhibition Slows Down Gbm Cell Proliferation And Intracranial Tumor Xenograft Growth. Neuro-Oncology 16(Suppl 5): v45

Bier, A.; Finniss, S.; Cazacu, S.; Xiang, C.; Lee, H.K.; Rand, D.; Yalon, M.; Toren, A.; Poisson, L.; Brodie, C. 2014: Cb-02 * MiRna Expression Profiles Of Glioma Stem Cells And Their Association With The Mesenchymal Transformation Of These Cells. Neuro-Oncology 16(Suppl 5): v41

Boissinot, M.; Hayes, J.; Adams, M.; Higgins, J.; Tomlinson, D.; Lawler, S.E.; Short, S.C. 2014: Cb-03 * Identification and Characterisation of Micro Rnas Involved in Glioblastoma cell Proliferation and Survival using High-Throughput Screening. Neuro-Oncology 16(Suppl 5): v41

Chen, C.; Kozono, D.; Li, J.; Nitta, M.; Sampetrean, O.; Gonda, D.; Kushwaha, D.; Vandenberg, S.; Ramakrishnan, V.; Zhu, S.; Furnari, F.; Matsui, H.; Harismendy, O.; Cavenee, W.; Mao, Y. 2014: Cb-04 * Epigenetic Regulation of Glioblastoma Tumorigenicity: A Hybrid Model. Neuro-Oncology 16(Suppl 5): v41

Rasmussen, R.D.; Jensen, K.E.; Gajjar, M.K.; Julie la Cour Karottki, K.; Bartek, J.; Skjoth-Rasmussen, J.; Tluckova, L.; Hamerlik, P.; Bartek, J. 2014: Cb-05 * the Role of Emb-5 in Glioblastoma Maintenance and Therapeutic Resistance. Neuro-Oncology 16(Suppl 5): v42

Deleyrolle, L.; Nabilsi, N.; Griffith, B.; Pasternack, N.; Dajac, K.; Patel, J.; Rohaus, M.; Harding, A.; Kladde, M.; Steindler, D.; Reynolds, B.; Siebzehnrubl, F. 2014: Cb-07 * Distinct Radiation Response of Slow-Dividing Cancer Stem cells. Neuro-Oncology 16(Suppl 5): v42

Hoang-Minh, L.; Deleyrolle, L.; Ugartemendia, G.; Breunig, J.; Semple-Rowland, S.; Reynolds, B.; Sarkisian, M. 2014: Cb-08 * Kif3A Is Essential For Ciliogenesis, Cilia Function And Promotes Glioblastoma Progression. Neuro-Oncology 16(Suppl 5): v42

Jiang, Y.; Marinescu, V.D.; Xie, Y.; Haglund, C.; Jarvius, M.; Lindberg, N.; Olofsson, T.; Hesselager, G.; Alafuzoff, I.; Fryknas, M.; Larsson, R.; Nelander, S.; Uhrbom, L. 2014: Cb-09 * the cell of Origin for Glioblastoma Contributes to the Phenotypic Heterogeneity of Glioma Stem cells. Neuro-Oncology 16(Suppl 5): v42

Koriyama, S.; Masayuki, N.; Muragaki, Y.; Maruyama, T.; Tamura, M.; Ikuta, S.; Takeda, N.; Komori, T.; Shioyama, T.; Taira, T.; Iseki, H.; Okada, Y. 2014: Cb-10 * Intraoperative Flow Cytometry Analysis of Glioma Tissue for Rapid Determination of Tumor Presence and its Histopathological Grade. Neuro-Oncology 16(Suppl 5): v42-v43

Bihannic, L.; Forget, A.; Cigna, S.M.; Lefevre, C.; Remke, M.; Barnat, M.; Dodier, S.; Shirvani, H.; Mercier, A.; Mensah, A.; Garcia, M.; Humbert, S.; Taylor, M.D.; Lasorella, A.; Ayrault, O. 2014: Cs-01 * the Phosphorylation of Atoh1 Leads to its Degradation Mediated by the E3 Ubiquitin Ligase Huwe1 in Granule Neuron Progenitors. Neuro-Oncology 16(Suppl 5): v51

Gjerde, C.H.; Mutlu, E.; Leiss, L.; Enger, P.O. 2014: Cs-10 * Fgfr4 is Expressed in Human Gliomas of different Grades and Histologies. Neuro-Oncology 16(Suppl 5): v53

Goel-Bhattacharya, S.; Kulkarni, S.; Sengupta, S.; Khagi, S.; Cochran, B. 2014: Cs-11 * an Rnai Kinome Screen of Glioblastoma Stem cells under Normoxia and Hypoxia. Neuro-Oncology 16(Suppl 5): v53

Gramatzki, D.; Frei, K.; Tritschler, I.; Schroeder, J.J.; Espinoza, L.; Rushing, E.J.; Weller, M. 2014: Cs-12 * Transforming Growth Factor- Pathway Activity in Glioblastoma. Neuro-Oncology 16(Suppl 5): v53

Hover, L.; Owens, P.; Munden, A.; Abel, T. 2014: Cs-13 * Bone Morphogenetic Protein Signaling Promotes Tumorigenesis in a Transgenic Mouse Model of Glioma. Neuro-Oncology 16(Suppl 5): v53

Kenchappa, R.; Lawn, S.; Krishna, N.; Qu, X.; Fenstermacher, D.; Chan, J.; Forsyth, P. 2014: Cs-14 * Neurotrophin Receptors TrkB And TrkC Are Required For Survival Of Brain Tumor Initiating Cells. Neuro-Oncology 16(Suppl 5): v54

Lee, J.; Song, H.-R. 2014: Cs-15 * Nuclear Factor I-A (Nfia) Promotes Gbm Survival Through NfkB Pathway. Neuro-Oncology 16(Suppl 5): v54

Leung, G.K.K.; Sun, S.; Ho, A.S.W.; Lee, D.; Kiang, K.M.Y.; Xu, F..; Pu, J.K.S.; Zhang, X.. 2014: Cs-17 * Upregulation Of The Endoplasmic Reticulum Chaperone, Prolyl 4-Hydroxylase, Beta Polypeptide (P4Hb) Promotes Invasion, Angiogenesis And Growth Via Egfr/Mapk (Erk) Signalling Pathway In Malignant Glioma. Neuro-Oncology 16(Suppl 5): v54

Lewis-Tuffin, L.; Feathers, R.; Hari, P.; Durand, N.; Li, Z.; Bakken, K.; Carlson, B.; Schroeder, M.; Sarkaria, J.; Anastasiadis, P. 2014: Cs-18 * Src Family Kinases Differentially Influence Glioma Growth and Motility. Neuro-Oncology 16(Suppl 5): v54-v55

Lindberg, N.; Kim, Y.; Halliday, J.; Pitter, K.; Holland, E.C. 2014: Cs-19 * Pdgf Signaling Dependence in Proneural Glioblastoma, the Beginning but not the End. Neuro-Oncology 16(Suppl 5): v55

Bunda, S.; Heir, P.; Burrell, K.; Ohh, M.; Zadeh, G. 2014: Cs-02 * Shp2 Promotes Tumor Progression in Gbm via Ras Activation. Neuro-Oncology 16(Suppl 5): v51

Martinez-Gutierrez, J.C.; Shah, S.R.; Ruiz-Valls, A.; Tippens, N.D.; Quinones-Hinojosa, A. 2014: Cs-20 * Transcriptional Control of the Osmotic Engine by Tead4 Potentiates Invasion and Confers Poor Prognosis in Glioblastoma. Neuro-Oncology 16(Suppl 5): v55

Miao, H.; Gale, N.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Murphy, A.; Valenzuela, D.; Yancopoulos, G.; Hambardzumyan, D.; Lathia, J.; Rich, J.; Lee, J.; Wang, B. 2014: Cs-21 * EphA2 Promotes Infiltrative Invasion Of Glioma Stem Cells In Vivo Through Crosstalk With Akt And Regulates Stem Properties. Neuro-Oncology 16(Suppl 5): v55

Misek, S.; Chen, J.; Gallo, K. 2014: Cs-22 * Mixed Lineage Kinase Signaling is Required for Glioblastoma cell Migration and Invasion. Neuro-Oncology 16(Suppl 5): v55-v56

Mishra, A.; Kong, J.; Brat, D. 2014: Cs-23 * Defining the Networks and Intersection of Egfr Amplification and Nfkbia Deletion in Human Glioma. Neuro-Oncology 16(Suppl 5): v56

Mukherjee, J.; Obha, S.; Pieper, R. 2014: Cs-24 * Pyruvate Kinase M2-Mediated Subcellular Localization Of HuR Regulates Glioma Growth. Neuro-Oncology 16(Suppl 5): v56

Nakada, M.; Obuchi, W.; Ohtsuki, S.; Tanaka, S.; Furuta, T.; Kitabayashi, T.; Sabit, H.; Terasaki, T.; Hayashi, Y. 2014: Cs-25 * Molecular Subclassification of Glioblastoma Based on the Absolute Quantitative Proteomics. Neuro-Oncology 16(Suppl 5): v56

Nandhu, M.; Kwiatkowska, A.; Hu, B.; Viapiano, M. 2014: Cs-26 * Fibulin-3 Regulates Canonical NfkB Signaling In Glioma Cells And Surrounding Stromal Cells To Promote Tumor Invasion. Neuro-Oncology 16(Suppl 5): v56

Nesvick, C.; Zhang, C.; Montgomery, B.; Lee, M.; Yang, C.; Wang, H.; Merrill, M.; Heiss, J.; Ray-Chaudhury, A.; Zhuang, Z. 2014: Cs-27 * Idh1/2 Mutations Influence Zeb1 Expression in Grades Ii and Iii Gliomas. Neuro-Oncology 16(Suppl 5): v57

Rahman, M.A.; Leiss, L.; Lellahi, M.S.; Gjerde, C.H.; Saed, H.S.; Mutlu, E.; Enger, P.O. 2014: Cs-28 * the Transcription Factor Pou3f2 Uniformly Express in Human Gliomas and Promotes Tumorigenesis and Overall Growth Rate in Vivo. Neuro-Oncology 16(Suppl 5): v57

Read, R.; Marquez, J.; Mosley, C. 2014: Cs-29 * A Kinome-Wide Rnai-Screen In Drosophila Glia And Human Gbm Cells Reveals That Stk17A Drives Neoplastic Glial Cell Proliferation And Invasion. Neuro-Oncology 16(Suppl 5): v57

Chen, S.-M.; Wu, C.; Li, Y.-Y.; Feun, L.; Wangpaichitr, M.; Benveniste, R.J.; Savaraj, N. 2014: Cs-03 * Utilizing Collagen and Discoidin Domain Receptor Signaling as a Newtherapeutic Strategy in Human Malignant Glioma. Neuro-Oncology 16(Suppl 5): v51

Rowse, A.; McFarland, B.; Meares, G.; Zheng, Y.; Hjelmeland, A.; Benveniste, E. 2014: Cs-30 * Protein Kinase Ck2 is Important for the Function of Glioblastoma Brain Tumor Initiating cells. Neuro-Oncology 16(Suppl 5): v57

Shah, S.R.; Tippens, N.D.; Park, J.; Mohyeldin, A.; Vela, G.; Levchenko, A.; Quinones-Hinojosa, A. 2014: Cs-31 * a Novel Yap-Driven Migration and Invasion Signaling Pathway Predicts Poor Outcome in Glioblastoma. Neuro-Oncology 16(Suppl 5): v57-v58

Sulaiman, M.K.; Blanco, V.; Chu, Z.; Valabhurapu, S.; Franco, R.; Qi, X. 2014: Cs-32 * SapC-Dops Induces Smac-And Bax-Mediated Mitochondrial Apoptosis In Neuroblastomas. Neuro-Oncology 16(Suppl 5): v58

Tein, A.-C.; Griveau, A.; Hashizume, R.; Rowitch, D. 2014: Cs-34 * Evidence for Oligodendrocyte Origins of Pediatric Glioma. Neuro-Oncology 16(Suppl 5): v58

Tritschler, I.; Seystahl, K.; Szabo, E.; Tabatabai, G.; Weller, M. 2014: Cs-35 * Tgf- Induces and Bmp Suppresses Vegf Release Depending on Smad2/3 versus Smad1/5/8 Signaling in Glioblastoma. Neuro-Oncology 16(Suppl 5): v58

Willems, M.; Kroonen, J.; Dubois, N.; Berendsen, S.; Nguyen, B.; Bredel, M.; Artesi, M.; Kim, H.; Rados, M.; Chakravarti, A.; Bours, V.; Robe, P. 2014: Cs-36 * IkappaB Zeta Overexpression Drives Human Glioma Resistance To Necroptosis. Neuro-Oncology 16(Suppl 5): v58-v59

Zhou, Y.-H.; Hu, Y.; Ke, C.; Ru, N.; Yu, L.; Siegel, E.; Linskey, M. 2014: Cs-37 * Dual Functions of Efemp1 in Malignant Glioma in Respect to Regulation of Egfr and Notch Signaling Pathways. Neuro-Oncology 16(Suppl 5): v59

Zhu, D.; Zhang, Z.; Olson, J.; Van Meir, E. 2014: Cs-38 * Bai1 is a New Tumor Suppressor in Medulloblastoma. Neuro-Oncology 16(Suppl 5): v59

Chesnelong, C.; Luchman, A.; Gregory Cairncross, J.; Weiss, S. 2014: Cs-04 * Stat3 Involvement in an Emt-Like Process in Glioblastoma Brain Tumor Initiating cells. Neuro-Oncology 16(Suppl 5): v51

Erdem-Eraslan, L.; Gao, Y.; Kloosterhof, N.; Atlasi, Y.; Demmers, J.; Sacchetti, A.; Kros, J.; Smitt, P.S.; Aerts, J.; French, P. 2014: Cs-05 * Mutation Specific Functions of Egfr Result in a Mutation-Specific Downstream Pathway Activation. Neuro-Oncology 16(Suppl 5): v52

Feng, H.; Lopez, G.; Kim, C.K.; Alvarez, A.; Duncan, C.; Nishikawa, R.; Nagane, M.; Su, A.-J.; Hedberg, M.; Grandis, J.; Raizer, J.; Gao, W.-Q.; Kim, S.-H.; Minata, M.; Nakano, I. 2014: Cs-06 * Egfr Phosphorylation of Dcbld2 Recruits Traf6 and Stimulates Akt-Promoted Tumorigenesis. Neuro-Oncology 16(Suppl 5): v52

Feroze, A.; Lee, K.-S.; Alrfaei, B.; Gholamin, S.; Azad, T.; Mitra, S.; Lu, B.; Cheshier, S. 2014: Cs-07 * mTorc2/Akt Signaling Is Modulated By Noncanonical Mitochondrial Notch-Pink1 Interaction In Medulloblastoma (Group Iii) Tumorigenesis. Neuro-Oncology 16(Suppl 5): v52

Forget, A.; Bihannic, L.; Cigna, S.; Lefevre, C.; Remke, M.; Barnat, M.; Dodier, S.; Shirvani, H.; Mercier, A.; Mensah, A.; Garcia, M.; Humbert, S.; Taylor, M.D.; Lasorella, A.; Ayrault, O. 2014: Cs-08 * Sonic Hedgehog Signaling Protects Atoh1 from Degradation Mediated by the Hect Domain E3 Ubiquitin Ligase Huwe1 in Cerebellar Granule Neuron Progenitors. Neuro-Oncology 16(Suppl 5): v52

Giladi, N.; Lee, H.K.; Finniss, S.; Cazacu, S.; Xiang, C.; Poisson, L.; Mikkelsen, T.; Ziv-Av, A.; Brodie, C. 2014: Cs-09 * Rtvp-1 Promotes the Mesenchymal Transformation of Glioma Stem cells via the Cxcr4 and Il-6 Pathways. Neuro-Oncology 16(Suppl 5): v52-v53

Brown, R.J.; O'Neil, S.; Finlay, J.L.; Bluml, S. 2014: Cn-01 * Evidence for Active Glycolysis in the White Matter of an Adult Survivor of a Pediatric Brain Tumor with Long-Term Treatment-Related Brain Injury. Neuro-Oncology 16(Suppl 5): v46

Macdonald, D.; Cothros, N.; Conter, H.; Potvin, K. 2014: Cn-11 * Orteronel (Tak-700) and Posterior Reversible Encephalopathy Syndrome (Pres). Neuro-Oncology 16(Suppl 5): v48

Mahtab, N.; Ramamurthy, S.; Willis, N.; Lewis, J.; Lethbridge, E. 2014: Cn-12 * Pineal Parenchymal Tumour of Intermediate Differentiation: Case Series from a Single Institute. Neuro-Oncology 16(Suppl 5): v48

Majd, N.; Neil, E.; Warnick, R.; Tew, J.; Curry, R. 2014: Cn-13 * Recurrent Aseptic Meningitis in Patients with Metastatic Brain Tumors; a Novel Perspective. Neuro-Oncology 16(Suppl 5): v48-v49

Maurice, C.; Mason, W.P. 2014: Cn-14 * Retrospective Analysis of Ischemic Cerebral Strokes in Patients Diagnosed with a Glioblastoma during the Course of a Bevacizumab Treatment. Neuro-Oncology 16(Suppl 5): v49

Pawar, T.; Ladha, H.; Mandel, J.; Gilbert, M.; O'Brien, B.; Hamza, M.; Armstrong, T. 2014: Cn-15 * Adverse effects of Bevacizumab in Brain Tumor Patients. Neuro-Oncology 16(Suppl 5): v49

Seretny, M.; Currie, G.; Sena, E.; Ramnarine, S.; Grant, R.; Macleod, M.; Colvin, L.; Fallon, M. 2014: Cn-16 * Incidence, Prevalence and Predictors of Chemotherapy induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Neuro-Oncology 16(Suppl 5): v49

Strobel, K.; Simpson, P.; Donohoue, P.; Firat, S.; Jogal, S. 2014: Cn-17 * Impact of Age at Diagnosis on Obesity in Pediatric Brain Tumor Survivors. Neuro-Oncology 16(Suppl 5): v49

Tabouret, E.; Reyes-Botero, G.; Dehais, C.; Daros, M.; Barrie, M.; Matta, M.; Petrirena, G.; Autran, D.; Duran, A.; Boucard, C.; Delattre, J.Y.; Chinot, O. 2014: Cn-18 * Relationships between Dose Intensity, Toxicity, and Outcome in Oligodendroglial Tumors (Og) Treated with Pcv Regimen. Neuro-Oncology 16(Suppl 5): v49-v50

Ueki, K.; Matsuda, H.; Higuchi, F.; Udzuka, T.; Kim, P. 2014: Cn-19 * Histological Examination of Enhancing Lesion Adjacent to the Implanted Bcnu- Wafers Suggests Vascular Damage as the Major Underlying Mechanism. Neuro-Oncology 16(Suppl 5): v50

Cachia, D.; Kamiya-Matsouka, C.; Chi, L.; Pinnix, C.; Daver, N.; Woodman, K. 2014: Cn-02 * Myelopathy following Intrathecal Chemotherapy: A Case Series in Adults. Neuro-Oncology 16(Suppl 5): v46

Winkel, D.; Voloschin, A. 2014: Cn-20 * Bevacizumab Causing Recurrent Cerebral Infarction in a Patient with Glioblastoma: A Previously Undocumented Phenomenon. Neuro-Oncology 16(Suppl 5): v50

Zhou, R.; Scheurer, M.; Vera-Bolanos, E.; Gilbert, M.; Bondy, M.; Sulman, E.; Hilsenbeck, S.; Wendland, M.; Brachman, D.; Roof, K.; Komaki, R.; Deutsch, M.; Andrews, D.; Anderson, B.; Lee, R.J. 2014: Cn-21 * Risk Modeling for Temozolomide (Tmz)-Myelotoxicity in Patients with Glioblastoma Treated on Rtog 0825. Neuro-Oncology 16(Suppl 5): v50

Cochrane, A.; Imam, S.; Hiramanek, R.; Cheung, C.; Rangan, K.; Castillo, E.; Freyer, D.; Dhall, G.; Finlay, J. 2014: Cn-03 * Long-Term Follow-Up Of Endocrine Function Among Young Children With Newly-Diagnosed Malignant Central Nervous System (Cns) Tumors Treated With Irradiation-Avoiding Regimens: The Children'S Hospital Los Angeles (Chla) Experience. Neuro-Oncology 16(Suppl 5): v46

Drezner, N.; Wells, E.; Vezina, G.; Ho, C..; Packer, R.; Hwang, E. 2014: Cn-04 * Treatment of Pediatric Cerebral Radiation Necrosis: A Meta-Analysis. Neuro-Oncology 16(Suppl 5): v46-v47

Elsarrag, S.Z.; Eickhoff, J.C.; Puccetti, D.M.; Salih, S.M. 2014: Cn-05 * do Pediatric Brain Tumor Survivors Suffer an increased Risk of Ovarian/Endocrine Dysfunction as Compared to Non-Brain Tumor Survivors?. Neuro-Oncology 16(Suppl 5): v47

Handisurya, A.; Ristl, R.; Henzl, H.; Kautzky-Willer, A.; Dieckmann, K.; Hainfellner, J.; Woehrer, A.; Preusser, M.; Marosi, C. 2014: Cn-06 * is Hypopituitarism Clinically Relevant in Glioma Patients? - a Cross-Selectional Trial in Patients with High-Grade Gliomas. Neuro-Oncology 16(Suppl 5): v47

Huang, J.; Robinson, C.; DeWees, T.; Campian, J.; Mullen, D.; Fergus, S.; Kim, A.; Dunn, G.; Tran, D.; Simpson, J. 2014: Cn-07 * Predictors of Acute Severe Lymphopenia during Radiotherapy and Temozolomide for High-Grade Glioma. Neuro-Oncology 16(Suppl 5): v47

Iwata, R.; Asai, A.; Ito, T.; Oshige, H.; Yoshimura, K.; Nonaka, M. 2014: Cn-08 * Therapeutic Concentration of Temozolomide do not Impair the Function of Human Dendritic cell Subsets. Neuro-Oncology 16(Suppl 5): v47

Kamiya-Matsuoka, C.; Cachia, D.; Armstrong, T.; Gilbert, M. 2014: Cn-09 * Posterior Reversible Encephalopathy Syndrome and Primary Brain Tumors. Neuro-Oncology 16(Suppl 5): v47-v48

Cabrera, O.; Swiney, B.; Smith, J.; Farber, N.; Noguchi, K. 2014: Ds-01 * Glucocorticoids Potently Induce Apoptosis in the Cerebellar External Granule Layer: Implications for Medulloblastoma Treatment. Neuro-Oncology 16(Suppl 5): v65

Natsumeda, M.; Zhang, H.; Kaur, H.; Asnaghi, L.; Eberhart, C.G. 2014: Ds-02 * Induction of Autophagy Markers in Gliomas following Pharmacological Notch Blockade. Neuro-Oncology 16(Suppl 5): v65

Noguchi, K.; Cabrera, O.; Swiney, B.; Smith, J.; Farber, N. 2014: Ds-03 * Sonic Hedgehog Antagonists Potently Induce Apoptosis in the Cerebellar External Granule Layer: Implications for Medulloblastoma Treatment. Neuro-Oncology 16(Suppl 5): v65

Prestegarden, L.; Johannessen, T.-C.; Grudic, A.; Sundstrom, T.; Saed, H.; Varughese, J.; Lund-Johansen, M.; Bjerkvig, R. 2014: Ds-04 * Dopamine Addiction in Glioblastoma Multiforme during Chemotherapy is Mediated by a Drd2/-Arrestin/Akt Signaling Complex. Neuro-Oncology 16(Suppl 5): v65

Chen, C.; Shen, Y.; Nitta, M.; Futalan, D.; Taich, Z.; Treiber, J.; Stevens, D.; Chen, H.-Z.; Carter, B.; Esashi, F.; Sarkaria, J.; Furnari, F.; Cavenee, W.; Desai, A. 2014: Dn-01 * Bypassing Glioblastoma Resistance to Egfr Inhibitors by Synthetic Lethality. Neuro-Oncology 16(Suppl 5): v62

Ohba, S.; Mukherjee, J.; See, W.; Pieper, R. 2014: Dn-03 * Mutant Idh1-Driven Cellular Transformation Increases Rad51-Mediated Homologous Recombination and Temozolomide Resistance. Neuro-Oncology 16(Suppl 5): v62

Allen, B.; Mehta, S.; Ayad, N.; Schurer, S. 2014: Dd-01 * Ligand- and Structure-Based Virtual Screening to Discover Polypharmacological Dual Egfr and Brd4 Inhibitors. Neuro-Oncology 16(Suppl 5): v60

Cavazos, D.; Gruslova, A.; Sun, J.; Floyd, J.R.; Fichtel, L.; Tadi, S.; Lodi, A.; Tiziani, S.; Hart, C.P.; Eng, C.; Brenner, A. 2014: Dd-02 * Pharmacodynamic Biomarker Assessments in a Phase I/Ii Trial of the Hypoxia-Activated Prodrug Th-302 and Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v60

Chang, E.; Abbasi, T.; D'Souza, A.; Gowrishankar, G.; Mallick, P.; Gambhir, S.S. 2014: Dd-03 * the Naturally Occurring Steroid, Withaferin A, in Synergistic Concert with Her2/Egfr Inhibitors Abrogates Proliferation of Human Glioblastoma cell Cultures at Nanomolar Concentrations. Neuro-Oncology 16(Suppl 5): v60

Chung, S.; Decollogne, S.; Luk, P.; Shen, H.; Ha, W.; Day, B.; Stringer, B.; Hogg, P.; Dilda, P.; McDonald, K. 2014: Dd-04 * Penao: A Potent Mitochondrial Targeted Inhibitor for Glioblastoma. Neuro-Oncology 16(Suppl 5): v60-v61

Fueur, T.; Nakada, M.; Hemragul, S.; Dong, Y.; Miyashita, K.; Minamoto, T.; Hayashi, Y. 2014: Dd-05 * Gsk3Beta Inhibitory Drugs Attenuate Invasion Of Glioblastoma Cells. Neuro-Oncology 16(Suppl 5): v61

Kolb, A.; Watts, C.; Piccirillo, S. 2014: Dd-06 * Potentiating the Therapeutic Efficiency of the Alkylating Chemotherapy Temozolomide in Patients with Glioblastoma. Neuro-Oncology 16(Suppl 5): v61

Pham, L.; Liang, Y.; Guo, S.; Murphy, S.; Sheng, Z. 2014: Dd-07 * a Kinome RNA Interference Screen Identifies Novel Therapeutic Targets for Glioblastoma. Neuro-Oncology 16(Suppl 5): v61

Ware, M.; Weiner, R.; Friedlander, P.; Gordon, C.; Saenger, Y.; Mahmood, T.; Rodgers, A.; Bastian, G.; Urien, S.; Lee, ; Morgan, R. 2014: Dd-08 * Phase I Cancer Clinical Trial for 4-Demethyl-4-Cholesteryloxycarbonylpenclomedine (Dm-Choc-Pen). Neuro-Oncology 16(Suppl 5): v61

Cato-Addison, W.B.; Hussain, M.A.D.; Kane, P.J.; Giles, M.; Scoones, D.; Varma, A. 2014: P01 * an Unusual Case of a Metastatic Adenocarcinoma of the Prostate into an Intracranial Meningioma. Neuro-Oncology 16(Suppl 6): vi 1

Benghiat, H.; Sanghera, P.; Cook, M.; Nightingale, P.; Hartley, A. 2014: P10 * Correlation between Biologically Effective Dose (Bed) and Local Control of Brain Metastases Post Stereotactic Radiotherapy. Neuro-Oncology 16(Suppl 6): vi 2

Jebar, A.; West, E.; Scott, K.; Thomson, S.; Corns, R.; Mathew, R.; SivaKumar, G.; Coffey, M.; Nuovo, G.; Rose, A.; Ralph, C.; Twelves, C.; Anthoney, A.; Griffin, S.; Short, S. 2014: P12 * a Phase I Trial of Intravenous Oncolytic Reolysin(R) in Patients with Brain Tumours. Neuro-Oncology 16(Suppl 6): vi 3

Mathew, T.; Clenton, S.; Bradshaw, A.G. 2014: P13 * Changing Dose Bandings to Improve Compliance with Temozolomide Concomitant with Radiotherapy for high Grade Glioma; an Analysis of Safety. Neuro-Oncology 16(Suppl 6): vi 3

Das, P.; Conkey, D.S.; Harney, J.A. 2014: P14 * Localised Radiation Therapy for Pineal Parenchyma Tumour with Intermediate Differentiation: A Single Institute Experience. Neuro-Oncology 16(Suppl 6): vi 3

Dixit, S.; Mohan, A.; Aziz, ; Achawal, S.; O'Rielley, G.; Rajaraman, C.; Baker, L.; Gill, L.; Hingorani, M. 2014: P15 * Comparative Outcomes of Bevacizumab and Pcv Chemotherapy in Patients with Recurrent and Progressive Glioblastoma: A Retrospective Study. Neuro-Oncology 16(Suppl 6): vi 3

Waqar, M.; Hanif, S.; Rathi, N.; Das, K.; Zakaria, R.; Brodbelt, A.R.; Walker, C.; Jenkinson, M. 2014: P17 * Management and Outcomes of Midline Low-Grade Gliomas. Neuro-Oncology 16(Suppl 6): vi 4

Newman, F.; Critchley, G. 2014: P18 * Long Term Survival of high Grade Glioma: A Single Institution Study. Neuro-Oncology 16(Suppl 6): vi 4

Zhang, C.H.; Price, S.J. 2014: P20 * Variations in Management of low Grade Gliomas across Uk Neurosurgical Units. Neuro-Oncology 16(Suppl 6): vi 4

Lo, W.B.; Archer, J.; Carey, M.; Chasty, R.; Albanese, E. 2014: P02 * Primary Central Nervous System Lymphoma (Pcnsl) in the Cerebellum: Report of two Rare Cases and a ten Year Multi-Centre Review of Pcnsl. Neuro-Oncology 16(Suppl 6): vi 1

Gilani, S.; Giridharan, S. 2014: P22 * a Retrospective Review of Grade 3 Supratentorial Gliomas with Spinal Metastatic Relapse. Neuro-Oncology 16(Suppl 6): vi 4-vi 5

Srikandarajah, N.; Zakaria, R.; Barborie, A.; Husband, D.J.; Jenkinson, M.D. 2014: P23 * Management and Outcome of Adult Medulloblastomas: Are We following Recommended Guidelines?. Neuro-Oncology 16(Suppl 6): vi 5

Leggate, A.; Ioannou, T.; Eadsforth, T.; Law, J.; Hall, G. 2014: P24 * a Retrospective Analysis of the Transformation of Low-Grade Gliomas into High-Grade from a Single Institution. Neuro-Oncology 16(Suppl 6): vi 5

Ghosh, A.; Critchley, G.; Brock, J.; Walsh, G. 2014: P26 * a Management Algorithm for Elderly Patients with high Grade Glioma. Neuro-Oncology 16(Suppl 6): vi 5

Barua, N.U.; Woolley, M.; Hopkins, K.; Bienemann, A.S.; Cronin, D.; Gill, S.S. 2014: P27 * Development of an Implantable Catheter and Bone-Anchored Port for Intermittent Convection-Enhanced Delivery of Carboplatin for Recurrent high Grade Glioma. Neuro-Oncology 16(Suppl 6): vi 5

Yousaf, J.; Chamilos, C.; Mallucci, C.L.; Jenkinson, M.D. 2014: P31 * Medium-Term Outcome following Interhemispheric Transcallosal Approach for Intraventricular Tumours in Children and Adults. Neuro-Oncology 16(Suppl 6): vi 6

Vaqas, B.; O'Neill, K.; Awad, M. 2014: P32 * Increased Percentage Resection Of Tumour Volume Using Neuronavigational 3D Intraoperative Ultrasound: A Single Unit Experience. Neuro-Oncology 16(Suppl 6): vi 6

Naylor, G.J.; Murray, A.D.; Chalmers, A.J. 2014: P03 * Association of Sheltens Scale and Survival in Glioblastoma Patients. Neuro-Oncology 16(Suppl 6): vi 1

Arora, M.; Alder, J.; Lawrence, C.; Davis, C.; Dawson, T.; Hall, G.; Shaw, L. 2014: P41 * Identification of Glioma Specific Aptamer Targets. Neuro-Oncology 16(Suppl 6): vi 6-vi 7

Baldi, C.; Minasi, S.; Gianno, F.; Giangaspero, F.; Massimino, M.; Buttarelli, F.R. 2014: P43 * Fstl5 Expression is a Marker of Group C in Metastatic Medulloblastomas. Neuro-Oncology 16(Suppl 6): vi 7

Millner, T.O.; Pohl, U. 2014: P44 * Clinical Audit: Assessment Of Use And Benefit Of Immunohistochemistry With The Novel Antibody Isocitrate Dehydrogenase 1 (R132H) In Astrocytic Brain Tumour Pathology. Neuro-Oncology 16(Suppl 6): vi 7

Hatchell, H.; Hill, M.; Lawrence, C.; Rolph, C. 2014: P45 * Lipid Signatures in Meningioma - Metabolic Clues to Reveal Potential Therapeutic Targets. Neuro-Oncology 16(Suppl 6): vi 7

Laxton, R.; Doey, L.; Murphy-Stout, A.; Davis, E.; Bhangoo, R.; Gullan, R.; Ashkan, K.; Al-Sarraj, S. 2014: P46 * the Ki-67 Labelling Index with Maximally Selected Cut-Offs is Better at Predicting Recurrence than the Who Grading System of Meningiomas. Neuro-Oncology 16(Suppl 6): vi 7

Norris, K.; Shaw, L.; Alder, J.E.; Lawrence, C.L. 2014: P47 * the Identification of Novel Aptamers to Glioma. Neuro-Oncology 16(Suppl 6): vi 7-vi 8

Smith, J.R.; Maherally, Z.; Ghoneim, M.K.; Dickson, J.L.; An, Q.; Fillmore, H.L.; Pilkington, G.J. 2014: P48 * Afm Stiffness Measurements of Glioma cells and Cytoskeletal Protein Analysis following Cd44 Knockdown: Implications for Glioma cell Invasion. Neuro-Oncology 16(Suppl 6): vi 8

Kumar, S.; Shaw, L.; Lawrence, C.; Lea, R.; Alder, J. 2014: P50 * Developing a Physiologically Relevant Blood Brain Barrier Model for the Study of Drug Disposition in Glioma. Neuro-Oncology 16(Suppl 6): vi 8

Thakor, F.; Welsby, P.J.; Wan, K.-W.; Welsby, G. 2014: P51 * Preparation of Asiatic Acid Loaded Nanoparticles for Delivery across the Blood Brain Barrier and its effects on Glioblastoma cells in Vitro. Neuro-Oncology 16(Suppl 6): vi 8

Linay, K.J.L.; Bernardo, M.C.F.; Maranan, E. 2014: P04 * a Rare Case of Primary Cns Angiosarcoma Presenting as an Incomplete Gerstmann Syndrome: A Case Report and Review of Literature. Neuro-Oncology 16(Suppl 6): vi 1

Abaitua, F.; Crook, T.; O'Neill, K.; Syed, N. 2014: P52 * Targeting Collagen Regulation in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 6): vi 8-vi 9

Swampillai, A.; Brierley, D.; Galavotti, S.; Lampada, A.; Shaked-Rabi, M.; McEvoy, A.; Brandner, S.; Martin, S.-A.; Short, S.; Salomoni, P. 2014: P53 * the Metabolic Autophagy Pathway Regulates the Response to Temozolomide in Glioblastoma Multiforme-Initiating Stem cells. Neuro-Oncology 16(Suppl 6): vi 9

Rudd, M.; Lea, R.; Goodwin, W. 2014: P54 * the Use of Folate to Reduce cell Viability in Glioma cells. Neuro-Oncology 16(Suppl 6): vi 9

Arshad, A.; Yang, B.; Bienemann, A.; Barua, N.; Gill, S. 2014: P56 * Convection-Enhanced Delivery (Ced) of Carboplatin Nanospheres for the Treatment of Glioblastoma. Neuro-Oncology 16(Suppl 6): vi 9

Baty, R.; Pisconti, A.; Turnbull, J. 2014: P57 * Stem cell Plasticity and Tumorigenisis: Regulatory Roles of Heparan Sulphate in the Cancer Stem cell Niche. Neuro-Oncology 16(Suppl 6): vi 9

Richards, R.; See, V. 2014: P58 * Brain Tumour cells can Survive and Thrive in the Hypoxic Solid Tumour Microenvironment. Neuro-Oncology 16(Suppl 6): vi 9-vi 10

Mudariki, T.; Lea, R.W.; Clemens, G.; Baker, M.J. 2014: P59 * Diagnostic Application of Vibrational Spectroscopy for the Segregation of Brain Tumour cell Lines Coupled with Multivariate Statistics. Neuro-Oncology 16(Suppl 6): vi 10

Hirst, T.C.; Vesterinen, H.M.; Conlin, S.; Egan, K.J.; Antonic, A.; McLean, A.L.; Macleod, M.R.; Whittle, I.R.; Grant, R.; Brennan, P.M.; Sena, E.S. 2014: P60 * Why Animal Models of Gene Therapy Have Let Glioma Patients down. Neuro-Oncology 16(Suppl 6): vi 10

Briggs, S.; Stevenson, K.; Verbov ek, U.; Yin, L.H.; Pilkington, G.; Lah, T.; Fillmore, H.L. 2014: P61 * Cathepsin K in an in Vitro Model of Glioma Angiogenesis. Neuro-Oncology 16(Suppl 6): vi 10

Hamdan, A.; Kane, P. 2014: P05 * Variability in Follow up Imaging Guidelines after the Completion of Primary Therapy in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 6): vi 1-vi 2

Laxton, R.; Doey, L.; Aizpurua, M.; Bodi, I.; King, A.; Chandler, C.; Bhangoo, R.; Beaney, R.; Brazil, L.; Ashkan, K.; Al-Sarraj, S. 2014: P64 * Quantitative Mgmt Methylation Analysis By Pyrosequencing Reveals A Strong Correlation Between 1P/19Q Co-Deletion And High Level Methylation In High Grade Gliomas. Neuro-Oncology 16(Suppl 6): vi 10-vi 11

Tumilson, C.; Alder, J.; Lea, R.; Shaw, L. 2014: P65 * Deregulated Micrornas in Serum as Biomarkers for Glioma. Neuro-Oncology 16(Suppl 6): vi 11

Mudariki, T.; Lea, R.W.; Griffiths, D.; Clemens, G.; Baker, M.J. 2014: P66 * an Investigation into Substrate effects and Tissue Pre-Processing in Spectral Histopathology using Raman Spectroscopy. Neuro-Oncology 16(Suppl 6): vi 11

Meijer, L.; Veal, G.; Grundy, R.; Konczalik, W.; Ivanov, D.; Garnett, M.; Kearns, P.; Walker, D. 2014: P67 * Defining A Target Intra-Cerebrospinal Fluid Steady State Etoposide Concentration [Csf Etoposide] For Phase I Study In Children With Leptomeningeal Metastasis (Lm): Intrepid, A First In Man Study. Neuro-Oncology 16(Suppl 6): vi 11

Qiao, B.; Oneill, K.; Syed, N. 2014: P69 * Scotin Expression and Survival in Gbm. Neuro-Oncology 16(Suppl 6): vi 11-vi 12

Eralil, G.; Jones, T.L.; Howe, F.A.; Barrick, T.R.; MacKinnon, A.D. 2014: P06 * Supratentorial Pnet in Adults: Mri can Help Distinguish from Glioblastoma - Dwi is Key. Neuro-Oncology 16(Suppl 6): vi 2

Barnes, C.; Varma, A.; Kane, P. 2014: P07 * Are All Patients with Suspected Brain Tumour on Cranial Imaging Referred Promptly for Mdt Discussion?. Neuro-Oncology 16(Suppl 6): vi 2

Zebian, B.; Stagno, V.; Parks, C.J.; Pettorini, B.; Mallucci, C.; Pizer, B.; Abernethy, L.; Avula, S. 2014: P08 * Intra-Operative Mri: The Alder Hey Experience So Far. Neuro-Oncology 16(Suppl 6): vi 2

Crossley, D.R.; Henshaw, M.; Hill, M.; Foran, D.B. 2014: P09 * can Rapidarc(R) Improve the Outcome of Gliomas Treated with Radiotherapy?. Neuro-Oncology 16(Suppl 6): vi 2

Price, S.J. 2014: O01 * a Meta-Analysis of the Diagnostic Ability, Efficacy, Safety and Cost Effectiveness of 5-Aminolevulinic Acid Guided Resection of high Grade Gliomas. Neuro-Oncology 16(Suppl 6): vi 13

Ricci, B.; Ceric, D.; Barnes, M.; Marino, S. 2014: O10 * a Novel Polycomb Feed Forward Loop in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 6): vi 14

Piccirillo, S.G.M.; Spiteri, I.; Sottoriva, A.; Touloumis, A.; Curtis, C.; Marioni, J.; Tavaer, S.; Watts, C. 2014: O11 * Transcriptional Profiling of Distinct Compartments in Human Glioblastoma Reveals Key Dysregulated Pathways. Neuro-Oncology 16(Suppl 6): vi 14-vi 15

Channathodiyil, P.; Kardooni, H.; Potter, N.; Darling, J.; Morris, M.; Warr, T. 2014: O12 * Genetic Characterisation Of Pi3K-Related Pathways In Paediatric Gbm In Vitro. Neuro-Oncology 16(Suppl 6): vi 15

Greenberg, D.; Winters, T.; Brodbelt, A.; Williams, M.; Vernon, S.; Flowers, J.; Collins, P. 2014: O02 * the Incidence and Outcome for Patients with Glioblastoma in England: 2007 - 2011. Neuro-Oncology 16(Suppl 6): vi 13

Sidlauskas, K.; Li, N.; Lau, J.; Ferreira, A.; Brandner, S. 2014: O03 * Idh1 Mutations in Neural Stem cells Promote Migration and Invasion and Act Synergistically with P53 and Pten Loss in Murine Tumour cells. Neuro-Oncology 16(Suppl 6): vi 13

Zakaria, R.; Radon, M.; Bhojak, M.; Sluming, V.; Das, K.; Jenkinson, M.D. 2014: O04 * Diffusion Weighted Mri Discriminates Primary Cancer type and Outcome in Brain Metastases. Neuro-Oncology 16(Suppl 6): vi 13

Bulstrode, H.; Pollard, S. 2014: O05 * Foxg1 is a Candidate Transcriptional Master Regulator in Neural Stem cells and Glioblastoma. Neuro-Oncology 16(Suppl 6): vi 13

Brierley, D.J.; Locke, M.; Merve, A.; Marino, S.; Martin, S.A. 2014: O06 * Targeting Foxm1 as a Novel Therapeutic Strategy for the Treatment of Msh6 Deficient Temozolomide-Resistant Glioblastoma. Neuro-Oncology 16(Suppl 6): vi 14

Boonzaier, N.R.; Larkin, T.; Lupson, V.; Thomas, O.; Young, A.; Price, S.J. 2014: O07 * Characterising Regional Heterogeneity of Glioblastoma using Multimodal Imaging: Regions of Aggressive Growth. Neuro-Oncology 16(Suppl 6): vi 14

Chua, K.; Chang, Y.C.; Gaze, M.N.; Short, S.C.; Fersht, N. 2014: O08 * Haematological Toxicities in Craniospinal Radiotherapy: A 10-Year Review. Neuro-Oncology 16(Suppl 6): vi 14

Ares, C.; Albertini, F.; Frei-Welte, M.; Bolsi, A.; Grotzer, M.; Schneider, R.; Goitein, G.; Weber, D.C. 2014: O09 * Clinical Outcome of 50 Children with Intracranial Ependymoma Treated with Pencil Beam Scanning Proton Therapy. Neuro-Oncology 16(Suppl 6): vi 14

Payne, H.L.; Martin, S.-A.; Short, S.C. 2014: Op01 * Mismatch Repair Deficiency Confers increased Sensitivity to Ionising Radiation (Xr) in Glioblastoma. Neuro-Oncology 16(Suppl 6): vi 16

Merve, A.; Acquati, S.; Marino, S. 2014: Op10 * Role of C-Myc in Choroid Plexus Tumours. Neuro-Oncology 16(Suppl 6): vi 17-vi 18

Waqar, M.; Javadpour, M.; Barbagallo, G.M.V.; McManus, R.; Certo, F.; Jenkinson, M.D. 2014: Op11 * Atypical Meningioma: Is Adjuvant Radiotherapy Necessary?. Neuro-Oncology 16(Suppl 6): vi 18

Cruickshank, G.; Detta, A.; Ngoga, D.; Lockyer, N.; Pheonix, B.; Ghani, Z.; Green, S. 2014: Op12 * Boron Neutron Capture Therapy (Bnct): Optimisation of Boron Uptake and Patient Stratification by Lat1 Improves Biological Targeting with Reduced Radiation Time, and increased Chance of Tumour Control. Neuro-Oncology 16(Suppl 6): vi 18

Pangeni, R.P.; Ashton, K.; Walker, C.; Dawson, T.; Davis, C.; Latif, F.; Darling, J.L.; Warr, T.J.; Morris, M.R. 2014: Op13 * Identification of Genes Epigenetically Deregulated in Brain Metastasis from Primary Breast Tumours. Neuro-Oncology 16(Suppl 6): vi 18

Zakaria, R.; Rathi, N.; Crooks, D.; Brodbelt, A.; Rudland, P.R.; Jenkinson, M.D. 2014: Op14 * Metastasis Inducing Proteins Predict the Invasiveness and Clinical Outcomes of Brain Metastases. Neuro-Oncology 16(Suppl 6): vi 18

Valvona, C.; Donovan, L.; Higgins, S.; Fillmore, H.L.; Pilkington, G.J. 2014: Op15 * Lactate Dehydrogenase a (Ldha) and Childhood Medulloblastoma. Neuro-Oncology 16(Suppl 6): vi 18-vi 19

Aptekar, S.; Shaw, L.; Alder, J.; Lea, R. 2014: Op16 * Selective Targeting of Glioma with Nucleic Acid Aptamers. Neuro-Oncology 16(Suppl 6): vi 19

Jeyapalan, J.N.; Jones, T.A.; Tatevossian, R.G.; Qaddoumi, I.; Ellison, D.W.; Sheer, D. 2014: Op17 * Microrna Profiling using small Rna-Seq in Paediatric low Grade Gliomas. Neuro-Oncology 16(Suppl 6): vi 19

Boissinot, M.; Hayes, J.; Adams, M.; Higgins, J.; Tomlinson, D.; Lawler, S.E.; Short, S. 2014: Op18 * Identification and Characterisation of Micrornas Involved in Glioblastoma cell Proliferation and Survival. Neuro-Oncology 16(Suppl 6): vi 19

Pettorini, B.; Pizer, B.; Kanwar, A.; Chamilos, C.; Zebian, B.; Parks, C.; Avula, S.; Mallucci, C. 2014: Op02 * Thalamic Tumours in Children: Evaluation of Surgical Strategy. Neuro-Oncology 16(Suppl 6): vi 16

Abel, P. 2014: Op20 * Blood Serum and Csf Analytes show Potential for Use as a Diagnostic Biomarker for low and high Grade Glioma. Neuro-Oncology 16(Suppl 6): vi 19-vi 20

Day, J.C.; Berntzen, B.; Rooney, A.; Derry, C.; Caldwell, E.; Rhia, R.; Grant, R. 2014: Op21 * Assessing Associated Symptoms Of Fatigue: Trialling A 'Symptoms Mdm' In Edinburgh For Primary Brain Tumour. Neuro-Oncology 16(Suppl 6): vi 20

Ngoga, D.; Evison, F.; Tennant, D.; Cruickshank, G. 2014: Op22 * Social Deprivation Shortens Survival in Patients with high Grade Glioma. Neuro-Oncology 16(Suppl 6): vi 20

Knighton, C.; Logan, J.; Hurwitz, V.; King, A.; Hodgkiss, A.; Cikurel, K.; Beaney, R.; Brazil, L. 2014: Op23 * an Audit to Assess Psychiatric Conditions that Manifest in Patients with High-Grade Brain Tumours during Treatment. Neuro-Oncology 16(Suppl 6): vi 20

Talibi, S.S.; Qureshi, H.U.; James, C.; Giridharan, S.; Brydon, H. 2014: Op25 * Time from Referral to First Definitive Treatment of Patients Diagnosed with High-Grade (Who Grade Iii or Iv) Intra-Cranial Glial Tumours at a Regional Neurosurgical Centre. Neuro-Oncology 16(Suppl 6): vi 20

Meijer, L.; Veal, G.; Walker, D.; Grundy, R. 2014: Op27 * Etoposide Pharmacokinetics following Intra-Cerebrospinal Fluid Administration in Patients with Leptomeningeal Metastases. Neuro-Oncology 16(Suppl 6): vi 20-vi 21

Mathew, R.K.; Alli, S.; Hayes, J.; Parslow, R.; Chumas, P.D. 2014: Op28 * the Role of Gender in Cns Tumour Incidence and Survival. Neuro-Oncology 16(Suppl 6): vi 21

Lemberger, J.; Hindley, A. 2014: Op29 * Primary Brain Lymphoma: The Reality for Patients. Neuro-Oncology 16(Suppl 6): vi 21

Aggarwal, A.; Herz, N.; Arkush, L.; Short, S.; Rees, J. 2014: Op30 * Diagnostic Delay And Survival In High Grade Gliomas - Evidence Of The "Waiting Time Paradox". Neuro-Oncology 16(Suppl 6): vi 21

Ashton, K.M.; Brodbelt, A.; Davis, C.; Dawson, T.P.; Lea, R.W.; Walker, C.; Stables, R.; Vicinanza, D.; Jenkinson, M.D.; Clemens, G.; Baker, M.J. 2014: Op31 * the Sound of Science: Developing the Spectral Light Orchestra. Neuro-Oncology 16(Suppl 6): vi 21

Zhang, C.; Frary, A.; Bonzaier, N.R.; Larkin, T.; Price, S.J. 2014: Op03 * Border Transition across the Invasive Margin of Glioblastomas do not Provide Measures of Tumour Invasion: A Diffusion Tensor Study. Neuro-Oncology 16(Suppl 6): vi 16

Faulkner, C.; Shaw, A.; Wragg, C.; Greenslade, M.; Haynes, H.; Williams, H.; Lowis, S.; Williams, M.; Kurian, K.M. 2014: Op32 * a Combined Strategy for the Detection of Braf Fusions in Pilocytic Astrocytoma using Rt-Pcr and Fish. Neuro-Oncology 16(Suppl 6): vi 21

Tams, D.M.; Murray, C.; Barry, S.T.; Lawler, S.; Bruning-Richardson, A.; Short, S. 2014: Op33 * Glycogen Synthase Kinase Inhibitors Reduce 3D Migration Of Patient Derived Glioblastoma Multiforme Stem Cells. Neuro-Oncology 16(Suppl 6): vi 22

King, H.; Wright, A.; Patel, A.; Short, S. 2014: Op34 * Targeting Rad51 to Radiosensitise Glioblastoma Stem cells. Neuro-Oncology 16(Suppl 6): vi 22

Collins, J.E.C.; Santarius, T.; Watts, C.; Walter, F.M.; Price, S.J.; Joannides, A.J. 2014: Op36 * Concordance of Patient and Clinician Reported Presenting Symptoms at Initial Neuro-Oncology Assessment. Neuro-Oncology 16(Suppl 6): vi 22

Tanti, M.; Marson, A.G.; Jenkinson, M.D. 2014: Op37 * Benign Meningioma and Quality of Life: What Influence does Epilepsy Have on Quality of Life?. Neuro-Oncology 16(Suppl 6): vi 22

Barua, N.U.; Lowis, S.P.; Woolley, M.; Cronin, D.; Edwards, R.J.; Gill, S.S. 2014: Op38 * Robot-Assisted Convection-Enhanced Delivery of Carboplatin for Progressive Dipg - a Safety and Feasibility Report of 5 Cases. Neuro-Oncology 16(Suppl 6): vi 23

Millward, C.P.; Ellenbogen, J.R.; Perez da Rosa, S.; Didi, M.; Avula, S.; Mallucci, C. 2014: Op39 * the Role of Early Intra-Operative Mri in Subtotal Resection of Optic-Hypothalamic Gliomas in Children. Neuro-Oncology 16(Suppl 6): vi 23

Khor, H.H.; Bryne, P.; Basu, S. 2014: Op40 * Post-Operative T2 Hyperintensity in Peri Resection Margin following Awake Macroscopic Intragyral Total Resection of low Grade Glioma is not a Reliable Marker of Residual Tumour. Neuro-Oncology 16(Suppl 6): vi 23

Abernethy, L.J.; Vidyasagar, R.; Pizer, B.L.; Mallucci, C.L.; Avula, S.; Parkes, L.M. 2014: Op04 * Quantitative Measurement of Blood Flow in Paediatric Brain Tumours - a Comparative Study of Dynamic Susceptibility Contrast and Multi-Timepoint Arterial Spin Label Imaging. Neuro-Oncology 16(Suppl 6): vi 16

Price, S.J.; Boonzaier, N.; Lupson, V.; Larkin, T. 2014: Op05 * Idh-1 Mutated Glioblastomas Exhibit a less Invasive Phenotype with Diffusion Tensor Imaging. Neuro-Oncology 16(Suppl 6): vi 16-vi 17

Langer, J.K.; Chan, E.C.Y.; Antti, H.; Want, E.; ONeill, K.; Syed, N. 2014: Op06 * Metabolomic Analysis of Glioblastoma Multiforme upon Arginine Deprivation Treatment. Neuro-Oncology 16(Suppl 6): vi 17

Hill, L.J.; Botfield, H.; Hossain-Ibrahim, M.K.; Logan, A.; Cruickshank, G.S. 2014: Op07 * the Immunomodulatory effects of Decorin - a Novel Agent for the Treatment of Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 6): vi 17

Kolb, A.; Trecharichi, A.; Piccirillo, S.; Watts, C.; Price, S. 2014: Op08 * Characterisation of Residual cells in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 6): vi 17

Helbrow, J.; McBain, C.; Gattamaneni, R.; Tran, A.; McCarthy, C.; Edwards, R.; Redikin, J.; Handley, J.; O'Hara, C.; Kennedy, J.; Mills, S.; Soh, C.; Leggate, J.; Whitfield, G. 2014: Op09 * Stereotactic Radiosurgery for Brain Metastases at the Christie at Salford Royal Hospital: Our Two-Year Experience. Neuro-Oncology 16(Suppl 6): vi 17

Gojo, J.; Lotsch, D.; Pirker, C.; Araki, A.; Peyrl, A.; Chocholous, M.; Stefanits, H.; Czech, T.; Haberler, C.; Slavc, I.; Berger, W. 2014: Dr-01 * Novel Pediatric Ependymoma Models show high Chemotherapy-Resistance and Hyperactivation of Abc-Transporters. Neuro-Oncology 16(Suppl 5): v63

Jing, Z.; Li, L.; Liu, J.; Wang, M.; Ban, Y.; Wu, A. 2014: Dr-02 * Temozolomide Sensitizes Glioma Stem Cells To Trail-Induced Apoptosis Through Upregulation Of c-Cbl. Neuro-Oncology 16(Suppl 5): v63

Johns, T. 2014: Dr-03 * Mechanisms that Cause Resistance to Egfr Targeted Therapies in Glioma. Neuro-Oncology 16(Suppl 5): v63

Mascaro-Cordeiro, B.; Oliveira, I.; Alves, M.T.; Saba-Silva, N.; Capellano, A.; Cavalheiro, S.; Dastoli, P.; Toledo, S. 2014: Dr-04 * Valproic Acid and Hedgehog Pathway: A Possible Drug Resistance Mechanism in Medulloblastoma?. Neuro-Oncology 16(Suppl 5): v63-v64

Sakruti, S.; Vyshak, A.; Griffith, S.; Stevens, G.; Peereboom, D.; Ahluwalia, M. 2014: Dr-05 * Treatment and Prognosis after Bevacizumab Failure in Recurrent Glioblastoma: The Cleveland Clinic Experience. Neuro-Oncology 16(Suppl 5): v64

Singer, E.; Judkins, J.; Salomonis, N.; Soteropoulos, P.; McAllister, S.; Soroceanu, L. 2014: Dr-06 * Reactive Oxygen Species Mediate Therapeutic Response and Resistance in Glioblastoma. Neuro-Oncology 16(Suppl 5): v64

Velpula, K.K.; Asuthkar, S.; Lathia, J.D.; Tsung, A.J. 2014: Dr-07 * Targeting Egfr-Viii with Dichloroacetate in Temozolomide Resistant Glioblastoma Models. Neuro-Oncology 16(Suppl 5): v64

Wu, S.; Zheng, S.; Verhaak, R.; Koul, D.; Yung, W.K.A. 2014: Dr-08 * Msk1/ -Catenin Signaling Mediates Resistance To Pi3K/mTor Inhibitors In Glioblastoma. Neuro-Oncology 16(Suppl 5): v64

Asante, A.; Lin, J.; Zagardo, M.; Gujrati, M.; Fernandez, K.; Antony, R. 2014: Ed-01 * Medulloblastoma Presenting as an Intracranial Hemorrhage. Neuro-Oncology 16(Suppl 5): v66

Johnson, K. 2014: Ed-10 * Associations between Maternal and Inherited Genetic Variation in Folate Metabolism Genes and Pediatric Brain Tumors in a high Risk Population: A Pilot Study. Neuro-Oncology 16(Suppl 5): v68

Kumthekar, P.; Singh, S.; Smiley, N.P.; Lulla, R. 2014: Ed-12 * Widespread Systemic Metastases from Medulloblastoma without Evidence of Active Cns Involvement: A Case Series. Neuro-Oncology 16(Suppl 5): v68

Kurako, K.; Kurako, V.; Salgado, E. 2014: Ed-13 * Posttraumatic Glioma: Literature Review. Neuro-Oncology 16(Suppl 5): v68-v69

Kurako, K.; Lowe, J.; Kurako, V.; Salgado, E. 2014: Ed-14 * Quality of Life in Adults with Gliomas: Literature Review. Neuro-Oncology 16(Suppl 5): v69

Lapointe, S.; Florescu, M.; Nguyen, D.K.; Djeffal, C.; Belanger, K. 2014: Ed-15 * Long-Term Prophylactic Antiepileptic Drugs Use in Patients with Gliomas: A 7 Year Retrospective Analysis in a Tertiary Care Center. Neuro-Oncology 16(Suppl 5): v69

Lee, S.; Slagle-Webb, B.; Sheehan, J.; Zhu, J.; Muscat, J.; Glantz, M.; Connor, J. 2014: Ed-16 * Hfe Polymorphisms affect Survival of Brain Tumor Patients. Neuro-Oncology 16(Suppl 5): v69

Liu, Y.; Zhou, R.; Sulman, E.; Scheurer, M.; Boehling, N.; Gilbert, M.; Armstrong, T.; Bondy, M.; Wefel, J. 2014: Ed-17 * Genetic Modulation of Neurocognitive Function and Outcomes in Glioma Patients. Neuro-Oncology 16(Suppl 5): v69

Maher, O.M.; Khatua, S.; Zaky, W. 2014: Ed-18 * Primary Intracranial Soft Tissue Sarcoma in Children and Young Adults: Retrospective Analysis - Md Anderson Cancer Center Experience. Neuro-Oncology 16(Suppl 5): v69-v70

Malik, S.; Pervaiz, S.; Khan, K.; Jabbar, A.A. 2014: Ed-19 * Incidence and Pattern of Secondary Glioblastoma Multiforme at a Tertiary Care Hospital in Pakistan. Neuro-Oncology 16(Suppl 5): v70

Burton, E.; Ugiliweneza, B.; Woo, S.; Skirboll, S.; Boakye, M. 2014: Ed-02 * a Seer-Medicare Data Analysis of Elderly Glioblastoma Patients: Treatment Patterns, Outcomes and Cost. Neuro-Oncology 16(Suppl 5): v66

Mukherjee, S.; peddaboina, C.S.; Ebwe, E.; Udaikumar, J.; Shephard, R.; Newell-Rogers, K.; Singel, S.; Fonkem, E. 2014: Ed-20 * the Incidence of Pediatric Brain Tumors within the Scott and White Integrated Healthcare Health System. Neuro-Oncology 16(Suppl 5): v70

Neil, E.; Majd, N.; Morris, J.; Karim, N.; Molano, J.; Colapietro, P.; Curry, R. 2014: Ed-22 * Concurrence of Gliomas in Patients with Multiple Sclerosis: Case Report and Literature Review. Neuro-Oncology 16(Suppl 5): v70

Patil, S.; Zaky, W.; Park, M.; Liu, D.; Khatua, S. 2014: Ed-24 * Gangliogliomas in Children- the Md Anderson Cancer Center Experience. Neuro-Oncology 16(Suppl 5): v71

Porter, A.; Johnson, D. 2014: Ed-25 * Socioeconomic Status Modifies the Impact of Race/Ethnicity on Glioblastoma Prognosis. Neuro-Oncology 16(Suppl 5): v71

Rivas, R.; Carrasco, P.; Ayach, F. 2014: Ed-26 * Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in a 27-Years Old Patient. Neuro-Oncology 16(Suppl 5): v71

Sadighi, Z.; Zabrowski, J.; Broniscer, A.; Gajjar, A.; Khan, R. 2014: Ed-27 * Clinical Characteristics and Long-Term Outcome in Movement Disorder in Childhood Thalamic Tumors. Neuro-Oncology 16(Suppl 5): v71-v72

Sayeed, W.; Musto, G.; Pitz, M. 2014: Ed-28 * effect of Valproic Acid Exposure on Survival in Low-Grade Glioma Patients: A Retrospective Analysis. Neuro-Oncology 16(Suppl 5): v72

Shephard, R.; Singel, S.; Fonkem, E. 2014: Ed-29 * the Incidence of Adult and Pediatric Intracranial Ependymomas within the Scott and White Integrated Healthcare System. Neuro-Oncology 16(Suppl 5): v72

Chiang, J.; Kwok, L.-L.; See, S.J.; Tham, C.K. 2014: Ed-03 * the Impact of Valproic Acid Use on high Grade Glioma. Neuro-Oncology 16(Suppl 5): v66

Tathireddy, H.; Lin, J.; Gujrati, M.; Zagardo, M.; Fernandez, K.; Antony, R. 2014: Ed-31 * Recurrent Pilocytic Astrocytoma of the Corpus Callosum in a Patient with Neurofibromatosis type 1. Neuro-Oncology 16(Suppl 5): v72

Upadhyaya, S.; Muraszko, K.; Garton, H.; Maher, C.; Robertson, P. 2014: Ed-32 * Outcomes of Pediatric Brainstem low Grade Gliomas: A Single Institution Series. Neuro-Oncology 16(Suppl 5): v73

Salgado, M.A.V.; del Toro, J.M.; Cerco, J.A.G.; Urzaiz, L.L.; Mena, A.C.; Pian, H.; Olmos, V.P.; Rueda, A.G.; de Pedro, M.D.A. 2014: Ed-33 * Elderly Patients with Glioblastoma: Should be Treated in a different Way?. Neuro-Oncology 16(Suppl 5): v73

Villano, J.; Huang, B.; Thakkar, J.; Chen, Q.; Hatfield, M.; Pittman, T.; Dolecek, T. 2014: Ed-34 * Identification of Factors in Glioblastoma not Receiving Upfront Radiation Therapy. Neuro-Oncology 16(Suppl 5): v73

Vyas, O.; Arkun, K.; Taylor, L. 2014: Ed-35 * Primary Spinal Cord Melanoma (Pscm): A Case Report and Literature Review. Neuro-Oncology 16(Suppl 5): v73

Walsh, K.; Codd, V.; Smirnov, I.; Rice, T.; Decker, P.; Hansen, H.; Molinaro, A.; Pekmezci, M.; Tihan, T.; Berger, M.; Chang, S.; Prados, M.; Lachance, D.; O'Neill, B.P.; van der Harst, P. 2014: Ed-36 * Inherited Variants near Terc and Tert Are Associated with Longer Telomeres and increased Glioma Risk: Genome-Wide Association Results from the Ucsf Adult Glioma Study and the Engage Consortium Telomere Group. Neuro-Oncology 16(Suppl 5): v73-v74

Wong, E.T.; Engelhard, H.H.; Tran, D.D.; Kew, Y.; Mrugala, M.M.; Cavaliere, R.; Villano, J.L.; Bota, D.A.; Rudnick, J.; Sumrall, A.L.; Zhu, J.J. 2014: Ed-38 * An Updated Analysis Of Patient Registry Data On Novottf-100A Alternating Electric Fields Therapy For Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v74

Zieman, G.; Dardis, C.; Gomes, A.; Scheck, A.; Eschbacher, J.; Coons, S.; Ashby, L. 2014: Ed-39 * Ganglioglioma in Children; Identification of Cases at Risk of Death Due to Progression following Initial Surgery. Neuro-Oncology 16(Suppl 5): v74

Egan, K.; Nabors, L.B.; Olson, J.; LaRocca, R.; Thompson, Z.; Madden, M.; Thompson, R. 2014: Ed-05 * Gender and Reproductive Factors in relation to Survival in Glioblastoma. Neuro-Oncology 16(Suppl 5): v66-v67

Garren, N.; Harris, S.; Baker, E.; Kreisl, T.; Warren, K. 2014: Ed-06 * Brainstem Gliomas in Adults: Do Adult Diffuse Intrinsic Pontine Gliomas Exist?. Neuro-Oncology 16(Suppl 5): v67

Hooten, K.; Neal, D.; Espadin, R.L.; Gil, J.; Azari, H.; Rahman, M. 2014: Ed-08 * Insurance Status Influences the Rates of Reportable Quality Metrics in Brain Tumor Patients: A Nationwide Inpatient Sample Study. Neuro-Oncology 16(Suppl 5): v67

Ippen, F.M.; Pfannl, R.; Rojas, R.; Mahadevan, A.; Kasper, E. 2014: Ed-09 * Tancytic Ependymoma: Presentation of a Rare Cystic Disease Variant and Review of Literature. Neuro-Oncology 16(Suppl 5): v68

Channathodiyil, P.; Kardooni, H.; Khozoie, C.; Nelofer, S.; Darling, J.; Morris, M.; Warr, T. 2014: Eg-01 * Epigenetic Inactivation of Arginine Biosynthesis Pathway in Paediatric high Grade Glioma. Neuro-Oncology 16(Suppl 5): v75

Pastori, C.; Kapranov, P.; Penas, C.; Laurent, G.S.; Ayad, N.; Wahlestedt, C. 2014: Eg-10 * Long Non-Coding Rnas in Glioblastoma. Neuro-Oncology 16(Suppl 5): v77

Rapkins, R.W.; Hitchins, M.P.; McDonald, K.L. 2014: Eg-11 * Dysregulation of Mgmt in Glioblastoma: Friend or Foe?. Neuro-Oncology 16(Suppl 5): v77

Saito, K.; Mukasa, A.; Nagae, G.; Aihara, K.; Otani, R.; Takayanagi, S.; Omata, M.; Tanaka, S.; Shibahara, J.; Takahashi, M.; Momose, T.; Shimamura, T.; Miyano, S.; Narita, Y.; Ueki, K. 2014: Eg-13 * Genome-Wide Methylation Analysis Identifies Genomic DNA Demethylation during Malignant Progression of Gliomas. Neuro-Oncology 16(Suppl 5): v77

Salinas, R.; Liu, J.; Delgado, R.; Park, K.Y.; Price, J.; Ramos, A.; Phillips, J.; Lim, D. 2014: Eg-14 * Epigenetic Dysregulation Of The HoxA Locus And Other Homeobox Genes Driven By Ink4a/arf Deficiency And Egfrviii. Neuro-Oncology 16(Suppl 5): v78

Shimizu, Y.; Kurimoto, T.; Kondo, A.; Arai, H. 2014: Eg-15 * the Methylation Status of Mgmt in Medulloblastoma. Neuro-Oncology 16(Suppl 5): v78

Van Meter, T.E.; Khan, A.; Fitzmartin, K.; Taylor, M.D.; Mack, S.; Cote, J. 2014: Eg-16 * Aberrant Myst4/Brpf1 Signaling Misdirects Regional Neurogenesis Programs, Sustaining Expression of Self-Renewal Genes in Pediatric Brain Cancers. Neuro-Oncology 16(Suppl 5): v78

Van Meter, T.E.; Terry, J.; Rockwell, N.; Goggin, S.; Nethala, P.; Khan, A. 2014: Eg-17 * Suv420-Mediated Heterochromatin Changes in Pediatric Brain Cancers. Neuro-Oncology 16(Suppl 5): v78

Fakkert, M.; de Leng, W.; de Weger, R.; Willems, S.; Spliet, W.; van Hecke, W.; de Vos, F. 2014: Eg-02 * Correlation of Mgmt Promoter Methylation Status Analysis using 6 Ms-Mlpa Probes and Clinical Response of Temozolomide in Glioblastoma Patients. Neuro-Oncology 16(Suppl 5): v75

Han, X.; Li, R.; Zhang, W.; Yang, X.; Fathallah-Shaykh, H.; Gillespie, Y.; Nabors, B. 2014: Eg-03 * Expression of Prmt5 Correlates with Malignant Grade in Gliomas and Plays a Pivotal Role in Tumor Growth. Neuro-Oncology 16(Suppl 5): v75

Johnstone, S.; Johhnsone, A.; Penas, C.; Stathias, V.; Brothers, S.; Ayad, N.; Wahlestedt, C.; Albert, J. 2014: Eg-04 * Development of Highly Potent, Selective Bet Bromodomain Inhibitors that Are Cns Penetrant and Effective in Rodent Models of Brain Cancer. Neuro-Oncology 16(Suppl 5): v75

Kurscheid, S.; Bady, P.; Sciuscio, D.; Samarzija, I.; Shay, T.; Vassallo, I.; Van Criekinge, W.; Domany, E.; Stupp, R.; Delorenzi, M.; Hegi, M. 2014: Eg-05 * Combination of Gene Copy Gain and Epigenetic Deregulation Are Associated with the Aberrant Expression of a Stem cell Related Hox-Signature in Glioblastoma. Neuro-Oncology 16(Suppl 5): v75-v76

Leung, G.K.K.; Zhang, X..; Kiang, K.K.Y. 2014: Eg-06 * Idh1-Mutation-Associated Long Non-Coding RNA Expression Changes in Glioma. Neuro-Oncology 16(Suppl 5): v76

Mazor, T.; Pankov, A.; Johnson, B.E.; Hong, C.; Bell, R.J.A.; Smirnov, I.V.; Reis, G.F.; Phillips, J.J.; Barnes, M.; Bollen, A.W.; Taylor, B.S.; Molinaro, A.M.; Olshen, A.B.; Song, J.S.; Berger, M.S. 2014: Eg-07 * cell Cycle Signature and Tumor Phylogeny Are Encoded in the Evolutionary Dynamics of DNA Methylation in Glioma. Neuro-Oncology 16(Suppl 5): v76

Nicholas, M.K.; Joseph, L.; Venneti, S.; Daher, A.; Pytel, P. 2014: Eg-08 * Idh Mutations in Gliomas Associated with Enchondromatosis. Neuro-Oncology 16(Suppl 5): v76

Olar, A.; Wani, K.; Mansouri, A.; Zadeh, G.; Wilson, C.; DeMonte, F.; Fuller, G.; Jones, D.; Pfister, S.; von Deimling, A.; Sulman, E.; Aldape, K. 2014: Eg-09 * Epigenetic Profiling Reveals A CpG Hypermethylation Phenotype (Cimp) Associated With Worse Progression-Free Survival In Meningioma. Neuro-Oncology 16(Suppl 5): v76-v77

Achutha, M.; Siedlecki, C.; Glantz, M.; Xu, L.; Connor, J. 2014: Et-01 * Il-13 Conjugated Quantum Dots for the Identification and Characterization of Glioma Stem Cells, Soluble Receptors and Exosomes Released by Gbm Tumors. Neuro-Oncology 16(Suppl 5): v79

Chen, S.-M.; Li, Y.-Y.; Lui, T.-N.; Hsieh, L..L. 2014: Et-10 * the Synergistic effect of Inhibitor of Inhibitor of Apoptosis Proteins- Lcl161 and Standard Anti-Cancer Agents on Medulloblastoma cells. Neuro-Oncology 16(Suppl 5): v81

Clark, P.; Bhattacharya, S.; van Ginkel, P.; Darjatmoko, S.; Elmayam, A.; Polans, A.; Kuo, J. 2014: Et-11 * Resveratrol Regulates Glioblastoma And Glioblastoma Stem-Like Cells Via Anti-Tumorigenic Akt Dephosphorylation And p53 Activation. Neuro-Oncology 16(Suppl 5): v81

Cloughesy, T.; Finocchiaro, G.; Belda-Iniesta, C.; Recht, L.; Brandes, A.A.; Pineda, E.; Mikkelsen, T.; Chinot, O.; Balana, C.; Macdonald, D.; Westphal, M.; Hopkins, K.; Weller, M.; Bruey, J.-M.; Liu, B. 2014: Et-12 * Phase Ii Study of Onartuzumab plus Bevacizumab versus Placebo plus Bevacizumab in Patients with Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v81

Collins, S.; Logg, C.; Inagaki, A.; Kamijima, S.; Lehouritis, P.; Searle, P.; Tangney, M.; Kasahara, N. 2014: Et-13 * Retroviral Replicating Vector (Rrv)-Mediated Prodrug Activator Gene Therapy with Codon-Optimized Nitroreductase in Experimental Glioma. Neuro-Oncology 16(Suppl 5): v81-v82

Cruickshank, G.; Detta, A.; Green, S.; Lockyer, N.; Ngoga, D.; Ghani, Z.; Phoenix, B. 2014: Et-14 * Optimisation of Boronophenylalanine (Bpa) Delivery and Lat1 Expression for the Clinical Application of Boron Neutron Capture Therapy (Bnct) in Glioblastoma. Neuro-Oncology 16(Suppl 5): v82

Deleyrolle, L.; Martuscello, R.; Griffith, B.; Futch, H.; Skinner, C.; McGuiness, J.; Louviere, C.; Reynolds, B. 2014: Et-15 * Application of a Combinatorial Natural Product Therapy for the Treatment of High-Grade Gliomas. Neuro-Oncology 16(Suppl 5): v82

Di, K.; Gong, X.; Nguyen, H.; Trikha, M.; Bota, D. 2014: Et-16 * Marizomib (Npi-0052) Activity as a Single Agent in Malignant Glioma. Neuro-Oncology 16(Suppl 5): v82

Esaki, S.; Rabkin, S.D.; Martuza, R.L.; Wakimoto, H. 2014: Et-17 * Transient Fasting Enhances Replication and Therapeutic Activity of Oncolytic Hsv in Glioblastoma Therapy. Neuro-Oncology 16(Suppl 5): v82-v83

Fouse, S.; Steino, A.; Butowski, N.; Bacha, J.; Brown, D.; Costello, J. 2014: Et-18 * Val-083 is a Novel N7 Alkylating Agent that Inhibits the Growth of Glioma Stem and Non-Stem Cultures, Including Temozolomide-Resistant Lines. Neuro-Oncology 16(Suppl 5): v83

Gan, H.K.; Fichtel, L.; Lassman, A.B.; Merrell, R.; van den Bent, M.; Kumthekar, P.; Scott, A.M.; Pedersen, M.; Gomez, E.; Fischer, J.; Ames, W.; Xiong, H.; Dudley, M.; Munasinghe, W.; Roberts-Rapp, L. 2014: Et-19 * a Phase 1 Study Evaluating Abt-414 with Temozolomide (Tmz) or Concurrent Radiotherapy (Rt) and Tmz in Glioblastoma (Gbm). Neuro-Oncology 16(Suppl 5): v83

Alfonso-Pecchio, A.; Bago', J.; Okolie, O.; Dumitru, R.; Hingtgen, S. 2014: Et-02 * Therapeutically Engineered induced Neural Stem cells Are Tumor-Homing and Inhibit Progression of Glioblastoma. Neuro-Oncology 16(Suppl 5): v79

Garrett, D.; Mukherjee, S.; Tobin, R.; Rogers, S.; Henderson, S.; Motal, H.; Kain, J.; Fonkem, E.; Newell-Rogers, M.K. 2014: Et-20 * Interfering with Glioblastoma Multiforme Metabolism to Complement Therapeutic effects of Temozolomide. Neuro-Oncology 16(Suppl 5): v83

Geletneky, K.; Angelova, A.; Leuchs, B.; Bhat, R.; Just, A.; Capper, D.; Krebs, O.; Dahm, M.; Huber, B.; Unterberg, A.; Hajda, J.; Rommelaere, J. 2014: Et-21 * Combination of Intravenous and Intracerebral Injection of Oncolytic Parvovirus H-1 in a Phase I/Iia Clinical Trial of Patients with Recurrent Glioblastoma Multiforme: Penetration of H-1 Virus across the Blood-Brain Barrier. Neuro-Oncology 16(Suppl 5): v83-v84

Halle, B.; Thisgaard, H.; Aaberg-Jessen, C.; Olsen, B.; Dam, J.; Langkjaer, N.; Munthe, S.; Nagren, K.; Hoilund-Carlsen, P.F.; Kristensen, B. 2014: Et-22 * Convection-Enhanced Delivery Of The Auger-Electron-Emitter 125I-UdR: A Highly Efficient Therapy In An Orthotopic Glioblastoma Xenograft Model. Neuro-Oncology 16(Suppl 5): v84

Inagaki, A.; Hiraoka, K.; Kamijima, S.; Robbins, J.; Jolly, D.; Gruber, H.; Kasahara, N. 2014: Et-23 * Therapeutic Efficacy of Retroviral Replicating Vectors in Human Breast Cancer Cns Metastasis Model. Neuro-Oncology 16(Suppl 5): v84

Jonas, O.; Sengupta, S.; Calligaris, D.; Poe, M.; Methuku, K.; Francois, J.P.; Cook, J.; Agar, N.; Pomeroy, S.; Langer, R. 2014: Et-24 * a Novel Trojan Horse for In-Vivo Sensitivity Testing of Medulloblastoma Therapies. Neuro-Oncology 16(Suppl 5): v84

Kania, K.; Pollok, K.; Gelbert, L.; Shannon, H.; Bailey, B.; Batuello, C. 2014: Et-25 * Therapeutic Modulation of Mdm2 in Neuroblastoma. Neuro-Oncology 16(Suppl 5): v84-v85

Karpel-Massler, G.; Halatsch, M.-E.; Westhoff, M.-A.; Siegelin, M.D. 2014: Et-26 * Combined Treatment with Abt263 and Gx15-070 Yields a Synergistic Antiproliferative effect in Glioblastoma. Neuro-Oncology 16(Suppl 5): v85

Kaufmann, J.K.; Nakashima, H.; Nguyen, T.; Wang, P.-Y.; Nakano, I.; Cripe, T.P.; Chiocca, E.A. 2014: Et-27 * Replication and Spread of Oncolytic Herpes Virus in Glioma Stem cells can be Enhanced by Specific Inhibition of Histone Deacetylase 6. Neuro-Oncology 16(Suppl 5): v85

Keir, S.; Roskoski, M.; Gasinski, D.; Friedman, H.; Bigner, D. 2014: Et-28 * Combination Therapy with Met Tyrosine Kinase Inhibitor Emd1214063 and Bevacizumab. Neuro-Oncology 16(Suppl 5): v85

Kim, J.W.; Kane, J.R.; Young, J.S.; Morshed, R.A.; Chang, A.A.; Ahmed, A.U.; Balyasnikova, I.V.; Lesniak, M.S. 2014: Et-29 * an Optimized Oncolytic Adenovirus for Glioma Therapy: Specific Targeting, Efficient Infection, and Restricted Replication in Glioma. Neuro-Oncology 16(Suppl 5): v85-v86

Alkins, R.; Huang, Y.; Hynynen, K. 2014: Et-03 * Cavitation-Based Third Ventriculostomy using Mri-Guided Focused Ultrasound. Neuro-Oncology 16(Suppl 5): v79

Kreisl, T.N.; Peer, C.; Brown, J.; Figg, W.D.; Fine, H.A. 2014: Et-30 * a Phase I Trial of Azd7451, a Tropomyosin-Receptor Kinase (Trk) Inhibitor, for Adults with Recurrent Glioblastoma Multiforme (Gbm). Neuro-Oncology 16(Suppl 5): v86

Lee, H.K.; Buchris, E.; Finniss, S.; Cazacu, S.; Xiang, C.; Poisson, L.; Brodie, C. 2014: Et-33 * Placenta-Derived Mesenchymal Stem cells and their Secreted Exosomes Inhibit the Self-Renewal and Stemness of Glioma Stem cells in Vitro and in Vivo. Neuro-Oncology 16(Suppl 5): v86-v87

Li, A.; Marzulli, M.; Mazzacurati, L.; Kaur, B.; Bolyard, C.; Cohen, J.; Goins, W.; Zhang, M.; Glorioso, J.; Grandi, P. 2014: Et-34 * Highly Selective Hsv Virotherapy for Treatment of Glioblastoma. Neuro-Oncology 16(Suppl 5): v87

Luchman, A.; Aman, A.; Al-Awar, R.; Weiss, S. 2014: Et-35 * Pacritinib: A Novel Jak/Stat Inhibitor with Translational Relevance for Gbm. Neuro-Oncology 16(Suppl 5): v87

Man, J.; Shoemake, J.; Rizzo, A.; Godley, A.; Wu, Q.; Ma, T.; Bao, S.; Rich, J.; Yu, J. 2014: Et-36 * Hyperthermia Improves the Radiosensitivity of Glioma Stem cells by Inhibition of Akt Signaling. Neuro-Oncology 16(Suppl 5): v87

Mangraviti, A.; Jin, Y.; Sy, J.; Wang, Y.; Raghavan, T.; Hastings-Spaine, L.; Olivi, A.; Tyler, B.; Brem, H. 2014: Et-37 * Efficacy of Intracranial Delivery of Dichloroacetate and Carboplatin via an Lcp Polymer Microcapsule Device in an Experimental Glioma Model. Neuro-Oncology 16(Suppl 5): v87

Mastorakos, P.; Zhang, C.; Berry, S.; Kim, A.; Woodworth, G.; Suk, J.S.; Hanes, J. 2014: Et-38 * Brain Penetrating Non-Viral Gene Vectors for Efficient Gene Transfer to Brain Tumors. Neuro-Oncology 16(Suppl 5): v87-v88

McConnell, M.; Grasso, C.; Fabre, M.-S.; Collis, S.; Castro, L.; Schleich, N.; Herst, P. 2014: Et-39 * Repeated Pharmacological Doses of Ascorbate Protects Tumours from Radiation Damage in an Intracranial Mouse Glioma Model. Neuro-Oncology 16(Suppl 5): v88

Bai, R.; Staedtke, V.; Rudin, C.; Bunz, F.; Riggins, G. 2014: Et-04 * Mebendazole is Efficacious in Diverse Medulloblastoma Tumor Models and Inhibits Tumor Angiogenesis. Neuro-Oncology 16(Suppl 5): v79

Muili, K.; Bolyard, C.; Jaime-Ramirez, C.; Yoo, J.Y.; Kaur, B. 2014: Et-40 * Oncolytic Virus induced Hmgb1 Secretion and its Impact on Tumor Angiogenesis. Neuro-Oncology 16(Suppl 5): v88

Mukherjee, S.; Tobin, R.; Rogers, S.; Dao, L.; Kain, J.; Dusio, G.; Singel, S.; Fonkem, E.; Newell-Rogers, M.K. 2014: Et-41 * Temozolomide Cytotoxicity is Potentiated by Metabolic Modifications in Glioblastoma Multiforme (Gbm). Neuro-Oncology 16(Suppl 5): v88

Nandhu, M.; Behera, P.; Chiocca, E.A.; Viapiano, M. 2014: Et-42 * Development of a Novel, Function-Blocking Anti-Fibulin-3 Antibody as Targeted Reagent for Glioblastoma. Neuro-Oncology 16(Suppl 5): v88

Piao, Y.; Thomas, C.; Holmes, L.; Henry, V.; de Groot, J. 2014: Et-45 * Knockdown Of Tnfsf13B Induces Glioma Stem Cell Apoptosis. Neuro-Oncology 16(Suppl 5): v89

Pisklakova, A.; McKenzie, B.; Kenchappa, R.; McFadden, G.; Forsyth, P. 2014: Et-46 * Oncolytic Viral Therapy For Malignant Gliomas Using Myxoma Virus Deleted For Anti-Apoptotic M11L Gene. Neuro-Oncology 16(Suppl 5): v89

Ramachandran, C.; Lollett, I.; Quirin, K.-W.; Escalon, E.; Khatib, Z.; Melnick, S. 2014: Et-49 * Anticancer Potential and Mechanism of Action of Mango Ginger (Curcuma Amada Roxb.) Supercrtical Extracts in Human Glioblastoma cell Lines. Neuro-Oncology 16(Suppl 5): v89

Saito, N.; Aoki, K.; Hirai, N.; Ishii, M.; Tani, M.; Sato, K.; Nakayama, H.; Harashina, J.; Izukura, H.; Ito, K.; Sakurai, T.; Iwabuchi, S. 2014: Et-50 * Levetiracetam Downregulates O6-Methylguanine DNA Methyltransferase Expression and Sensitizes Temozolomide-Resistant Glioma cells. Neuro-Oncology 16(Suppl 5): v89-v90

Sarfraz, Y.; Alotaibi, F.M.; Ortenzi, V.; Tayyib, A.T.; Douglas, G.J.; Chevalier, E.; Romagnoli, B.; Tuffin, G.; Gagner, J.-P.; Zagzag, D. 2014: Et-51 * Combined Therapy with a Novel Cxcr4 Antagonist and an Anti-Vegf Antibody Impairs the Growth of Gliomas. Neuro-Oncology 16(Suppl 5): v90

Sarkar, G.; Curran, G.; Jenkins, R. 2014: Et-52 * Simultaneous Brain Delivery of a three Anti-Cancer Drug Combination via a Peptide Carrier-Mediated Intravenous Injection of the Three-Drug Cocktail. Neuro-Oncology 16(Suppl 5): v90

Balyasnikova, I.; Dey, M.; Tobias, A.; Kanojia, D.; Lee, G.; Han, Y.; Zhang, L.; Ahmed, A.; Aboody, K.; Lesniak, M. 2014: Et-05 * Intranasal Delivery of Neural Stem cells Loaded with Oncolytic Adenovirus Extends Survival of Mice with Intracranial Glioma. Neuro-Oncology 16(Suppl 5): v79-v80

Schaff, L.R.; Lassman, A.B.; Goldlust, S.A.; Cloughesy, T.; Singer, S.; Schwartz, G.K.; Iwamoto, F.M. 2014: Et-53 * Ipilimumab for Recurrent Glioblastoma (Gbm). Neuro-Oncology 16(Suppl 5): v90

Schijns, V.; Pretto, C.; Devillers, L.; Pierre, D.; Hofman, F.; Kruse, C.; Chen, T.; Oertel, J.; Hantos, P.; Bota, D.; Stathopoulos, A. 2014: Et-54 * Immunotherapy Based on Tumor Transplant Antigen Recognition Emerges as a Promising Strategy for Recurrent Glioblastoma Multiforme (Gbm) Patients. Neuro-Oncology 16(Suppl 5): v90-v91

Schnell, O.; Oehlschlaegel, F.; Tonn, J.-C.; Kreth, F.-W. 2014: Et-55 * the Long Term Risk of Tumor Progression Has not Changed over Time for Supratentorial Grade Ii Gliomas and is not Influenced by the Mode of Surgical Treatment. Neuro-Oncology 16(Suppl 5): v91

Shen, H.; Hau, E.; Dilda, P.; McDonald, K. 2014: Et-56 * Sensitization of Glioblastoma cells to Irradiation by Modulating the Glucose Metabolism. Neuro-Oncology 16(Suppl 5): v91

Sonabend, A.M.; Carminucci, A.S.; Amendolara, B.; Bansal, M.; Praver, M.; Realubit, R.; Li, H.; Karan, C.; Banu, M.; Lei, L.; Califano, A.; Canoll, P.; Bruce, J. 2014: Et-57 * Topoisomerase Ii in Proneural Gliomas, a Modulator of Transcription and a Therapeutic Target. Neuro-Oncology 16(Suppl 5): v91

Staedtke, V.; Bai, R.; Kinzler, K.; Zhou, S.; Vogelstein, B.; Riggins, G. 2014: Et-58 * the Genetically Engineered Clostridium Novyi-Nt is Efficacious in the Treatment of Intracranial Glioblastomas. Neuro-Oncology 16(Suppl 5): v91-v92

Studebaker, A.; Bid, H.; Phelps, D.; Houghton, P. 2014: Et-59 * Development and Characterization of a Mek1 Inhibitor (Azd6244) Sensitive Childhood Astrocytoma cell Line. Neuro-Oncology 16(Suppl 5): v92

Takahashi, M.; Valdes, G.; Inagaki, A.; Kamijima, S.; Hiraoka, K.; Micewicz, E.; McBride, W.H.; Iwamoto, K.S.; Hermann, K.; Collins, S.; Tam, Q.; Gruber, H.E.; Robbins, J.M.; Jolly, D.J.; Kasahara, N. 2014: Et-60 * Enhanced Therapeutic Efficacy of Prodrug Activator Gene Therapy with a Non-Lytic Retroviral Replicating Vector (Toca 511) Combined with Radiation Therapy in Experimental Glioma. Neuro-Oncology 16(Suppl 5): v92

Ashizawa, A.T.; Steindler, D. 2014: Et-61 * Novel Lipid Nanoparticles for the Delivery of Nucleic Acids to Glioblastoma. Neuro-Oncology 16(Suppl 5): v92

Verreault, M.; Levasseur, C.; Schmitt, C.; Guehennec, J.; Labussiere, M.; Marie, Y.; Haidar, S.; Mokhtari, K.; Hoang-Xuan, K.; Sanson, M.; Ligon, K.; Delattre, J.-Y.; Idbaih, A. 2014: Et-62 * Highly Selective Activity of Mdm2 Inhibitor Rg7112 against Mdm2-Amplified/Tp53 Wild-Type Glioblastomas. Neuro-Oncology 16(Suppl 5): v92-v93

Barton, K.; Misuraca, K.; Becher, O. 2014: Et-06 * Preclinical Testing of the Histone Deacetylase Inhibitor, Panobinostat, in a Genetically Engineered Diffuse Intrinsic Pontine Glioma Mouse Model. Neuro-Oncology 16(Suppl 5): v80

Weiss, W.; Fan, Q.-W.; Baldwin, A.; Wong, R.; Shokat, K. 2014: Et-63 * Targeting the Egfr-Stat-Nf-B Axis in Glioblastoma. Neuro-Oncology 16(Suppl 5): v93

Wells, E.; Khambampati, M.; Yadavilli, S.; Damsker, J.; Hoffman, E.; Packer, R.; Nazarian, J. 2014: Et-64 * Pre-Clinical Assessment of Dissociative Steroids as Dexamethasone Substitute for Treatment in Diffuse Intrinsic Pontine Glioma (Dipg). Neuro-Oncology 16(Suppl 5): v93

Woolf, E.C.; Curley, K.L.; Vatsa, R.; Charlton, J.A.; Woodrow, C.J.; Scheck, A.C. 2014: Et-65 * the Ketogenic Diet Reduces Carbonic Anhydrase 9 and Alters the Expression of Proteins Involved with Glioma Growth and Progression in Hypoxic Conditions. Neuro-Oncology 16(Suppl 5): v93

Xipell, E.; Martinez-Velez, N.; Vera-Cano, B.; Idoate, M.A.; Garzon, A.G.; Acanda, A.M.; Fueyo, J.; Gomez-Manzano, C.; Alonso, M.M. 2014: Et-66 * Er-Stress Inducing Drugs Sensitizes Gbm to Temozolomide through Downregulation of Mgmt and Induction of Regulated Necrosis. Neuro-Oncology 16(Suppl 5): v93

Yamasaki, T.; Wakao, S.; Kawaji, H.; Suzuki, T.; Kamio, Y.; Amano, S.; Sameshima, T.; Sakai, N.; Tokuyama, T.; Dezawa, M.; Namba, H. 2014: Et-67 * Suicide Gene Therapy for Glioma using Multilineage-Defferentiating Stress Enduring (Muse) cells. Neuro-Oncology 16(Suppl 5): v94

Yang, A.; Holtzman, T.; Lee, S.X.; Wong, E.; Swanson, K. 2014: Et-68 * Alternating Electric Fields Perturb the Localization of Cytokinetic Furrow Proteins and Cause Aberrant Mitotic Exit. Neuro-Oncology 16(Suppl 5): v94

Yang, L.; Zhou, Z.; Yao, D.; Xu, W.; Zhao, H. 2014: Et-69 * Specific Wip1 Inhibitor, Cct007093 Abrogate cell Proliferation, Migration and Invasion induced by the Uvc Radiation in Human Glioblastoma cells. Neuro-Oncology 16(Suppl 5): v94

Yoo, J.Y.; Banasavadi-Siddegowda, Y.Y.; Relation, T.; Aghi, M.; Kaur, B. 2014: Et-70 * Combination Of oHsv With Integrin 1 Neutralizing Antibody (Os2966) Augments oHsv Therapy. Neuro-Oncology 16(Suppl 5): v94

Zhang, B.; Shah, S.; Prince, J.; Walters, W.; Bregy, A.; Guo, Y.; J Komatar, R.; Graham, R.M. 2014: Et-71 * the Antitumor effects of Withaferin a in Glioblastoma Stem cells. Neuro-Oncology 16(Suppl 5): v94-v95

Blanchette, M.; Gascon, S.; Tremblay, S.; Tremblay, L.; Guerin, B.; Lepage, M.; Lecomte, R.; Fortin, D. 2014: Et-07 * does Osmotic Blood-Brain Barrier Disruption Allows Efflux Pump Substrates Delivery to the Tumor and Cns?. Neuro-Oncology 16(Suppl 5): v80

Borodovsky, A.; Riggins, G. 2014: Et-08 * Demethylating Therapy Induces Differentation and Therapeutic Response in Idh1 Mutant Malignant Gliomas. Neuro-Oncology 16(Suppl 5): v80

Canello, T.; Ovadia, H.; Refael, M.; Zrihan, D.; Siegal, T.; Lavon, I. 2014: Et-09 * Decoy Oligonucleotide Derived from Mgmt Enhancer Has an Antineoplastic Activity In-Vitro and In-Vivo. Neuro-Oncology 16(Suppl 5): v80-v81

Ames, H.; Vizcaino, M.A.; Rodriguez, F. 2014: Ge-01 * Molecular And Pathologic Subsets Of Low Grade Gliomas And Glioneuronal Tumors Identified By microRna Profiling. Neuro-Oncology 16(Suppl 5): v96

Eraslan, L.E.; van den Bent, M.; Kros, J.; Oosterkamp, H.; Walenkamp, A.; Beerepoot, L.; Hanse, M.; Buter, J.; Honkoop, A.; van der Holt, B.; Vernhout, R.M.; Smitt, P.S.; Taal, W.; French, P. 2014: Ge-10 * Identification of Patients with Recurrent Gbm that Benefit from Bevacizumab. Neuro-Oncology 16(Suppl 5): v98

Frentzen, ,B.; Mitchell, ,D.; Friedman, W.A.; Yachnis, A.; McTiernan, R. 2014: Ge-11 * the Florida Center for Brain Tumor Research (Fcbtr): Building Infrastructure to Find a Cure. Neuro-Oncology 16(Suppl 5): v98

Gill, B.; Pisapia, D.; Malone, H.; Goldstein, H.; Lei, L.; Sonabend, A.; Yun, J.; Samanamud, J.; Banu, M.; Dovas, A.; Sims, J.; Teich, A.; Sheth, S.; McKhann, G.; Sisti, M. 2014: Ge-12 * Radiographically-Localized Biopsies Reveal Subtype-Specific Patterns in Molecular and Cellular Composition at the Infiltrative Margins of Glioblastoma. Neuro-Oncology 16(Suppl 5): v98-v99

Hanmantgad, S.; Khakoo, Y. 2014: Ge-13 * a Novel Association of Primary Cns Germinoma in a Patient with Nail Patella Syndrome. Neuro-Oncology 16(Suppl 5): v99

Hu, X.; Kim, H.; Zheng, S.; Mikkelsen, T.; Scarpace, L.; Wang, Q.; Yoshihara, K.; Weinstein, J.N.; Verhaak, R.G.W. 2014: Ge-14 * Transcriptomicplasticityis Associated with the Tumor Microenvironment in Glioblastoma. Neuro-Oncology 16(Suppl 5): v99

Johnson, B.; Mazor, T.; Hong, C.; Barnes, M.; Yamamoto, S.; Ueda, H.; Tatsuno, K.; Aihara, K.; Asthana, S.; Dayal, M.; Nelson, S.; Phillips, J.; Bollen, A.; Mukasa, A.; Saito, N. 2014: Ge-15 * Clonal Evolution and Intratumoral Heterogeneity of Low-Grade Glioma Genomes. Neuro-Oncology 16(Suppl 5): v99

Kanemura, Y.; Ichimura, K.; Shofuda, T.; Nishikawa, R.; Yamasaki, M.; Taylor, M.D.; Arai, H.; Shibui, S. 2014: Ge-16 * Japanese Pediatric Molecular Neuro-Oncology Group (Jpmng): Establishment of a Nationwide Molecular Diagnostic Network for Pediatric Malignant Brain Tumors in Japan. Neuro-Oncology 16(Suppl 5): v99-v100

Kim, H.; Zheng, S.; Amini, S.; Virk, S.; Mikkelsen, T.; Brat, D.; Sougnez, C.; Muller, F.; Hu, J.; Sloan, A.; Cohen, M.; Van Meir, E.; Scarpace, L.; Lander, E.; Gabriel, S. 2014: Ge-17 * Alteration Of The p53 Pathway And Ancestral Progenitors Are Associated With Tumor Recurrence In Glioblastoma. Neuro-Oncology 16(Suppl 5): v100

Ma, D.; Sarkaria, J.; Peng, S.; Byron, S.; Craig, D.; Carpten, J.; Berens, M.; O'Neill, B.; Schroeder, M.; Tran, N. 2014: Ge-19 * Genomics Guided Therapeutic Approach for the Treatment of Glioblastoma Multiforme (Gbm) using next Generation Sequencing (Ngs) Technologies. Neuro-Oncology 16(Suppl 5): v100

Michelhaugh, S.; Bollig-Fischer, A.; Alosh, B.; Ali-Fehmi, R.; Mittal, S. 2014: Ge-20 * Genomic Characterization of Breast Cancer Brain Metastases. Neuro-Oncology 16(Suppl 5): v100

Bandopadhayay, P.; Chi, S.; Janeway, K.; Pinches, N.; Malkin, H.; Manley, P.; Goumnerova, L.; Chang, M.; Kieran, M.; Harris, M.; Ramkissoon, S.; Ligon, K. 2014: Ge-02 * Clinical Targeted Exome-Based Sequencing for Children Diagnosed with Brain Tumors: Initial Results of an Institute-Wide Project on Personalized Medicine. Neuro-Oncology 16(Suppl 5): v96

Morrissy, S.; Garzia, L.; Remke, M.; Ramaswamy, V.; Jorgensen, F.; Wu, X.; Shah, S.; Ma, Y.; Mungall, K.; Van Meter, T.; Cho, Y.-J.; Collins, P.; MacDonald, T.; Li, X.-N.; Moore, R. 2014: Ge-21 * Drastic Genomic Divergence of Recurrent Medulloblastoma Invalidates Targeted Therapies Discovered at Diagnosis. Neuro-Oncology 16(Suppl 5): v100-v101

Nishihara, H.; Miyazaki, M.; Kobayashi, H.; Terasaka, S.; Tanaka, S. 2014: Ge-22 * Immunohistochemical Molecular Expression Profiling for Glioblastoma. Neuro-Oncology 16(Suppl 5): v101

Northcott, P.; Lee, C.; Zichner, T.; Lichter, P.; Korbel, J.; Wechsler-Reya, R.; Pfister, S. 2014: Ge-23 * Enhancer Hijacking Activates Gfi1 Family Oncogenes in Medulloblastoma. Neuro-Oncology 16(Suppl 5): v101

Panditharatna, E.; Kambhampati, M.; Ho, C.-Y.; Gordish-Dressman, H.; Siu, A.; Hwang, E.; Stampar, M.; Packer, R.; Nazarian, J. 2014: Ge-24 * Characterizing Intratumor Heterogeneity and Tumor Extension in Pediatric Diffuse Intrinsic Pontine Glioma. Neuro-Oncology 16(Suppl 5): v101

Pietsch, T.; Gessi, M.; Muehlen, A.z.; Doerner, E.; Mancini, M.; Last, A.; Sundar, P. 2014: Ge-25 * next Generation Copy Number Analysis by Molecular Inversion Profiling - a Helpful Tool in Diagnostics and Prognostification of Tumors of the Cns. Neuro-Oncology 16(Suppl 5): v101-v102

Ramaswamy, V.; Remke, M.; Adamski, J.; Bartels, U.; Tabori, U.; Huang, A.; Taylor, M.; Bouffet, E. 2014: Ge-27 * Therapeutic Implications of Medulloblastoma Subgroups in Children over Age 3: A Single Centre Population Based Experience. Neuro-Oncology 16(Suppl 5): v102

Remke, M.; Jorgensen, F.M.G.; Morrissy, A.S.; Ramaswamy, V.; Jones, D.T.W.; Marra, M.; Packer, R.; Bouffet, E.; Pfister, S.M.; Jabado, N.; Taylor, M.D. 2014: Ge-28 * Integrated Genomics Demonstrate Relative Spatial Homogeneity in Pediatric Brain Tumors. Neuro-Oncology 16(Suppl 5): v102

Robin, A.; Raghunathan, A.; Leung, D.; Burmeister, C.; Poisson, L.; Scarpace, L.; Walbert, T.; Mikkelsen, T.; Lee, I. 2014: Ge-29 * Expression Subclass Profile in Pseudoprogression and True Progression in Newly Diagnosed Gbm. Neuro-Oncology 16(Suppl 5): v102-v103

Sahm, F.; Reuss, D.; Koelsche, C.; Capper, D.; Schittenhelm, J.; Heim, S.; Herold-Mende, C.; Wick, W.; Mueller, W.; Hartmann, C.; Paulus, W.; von Deimling, A. 2014: Ge-30 * Oligoastrocytoma does not Exist: In-Situ Molecular Genetics Favors Classification as Either Oligodendroglioma or Astrocytoma. Neuro-Oncology 16(Suppl 5): v103

Berens, M.; Armstrong, B.; Peng, S.; Ross, J.; Salhia, B.; Byron, S.; Virk, S.; Dhruv, H.; Tran, N.; Sloan, A.; Ostrom, Q.; Barnholtz-Sloan, J. 2014: Ge-03 * Genomic Characterization of Survival Outliers in Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 5): v96

Shelton, S.; Oldham, M. 2014: Ge-31 * Deconstructing Tumor Heterogeneity through Differential Gene Coexpression Analysis of Serial Sections (Dgcass). Neuro-Oncology 16(Suppl 5): v103

Stathias, V.; Pastori, C.; Komotar, R.J.; Zhang, M.; Clarke, J.; Ayad, N.G. 2014: Ge-32 * an Intergraded Bioinformatics Approach for Identifying Novel Gene Networks in Glioblastoma. Neuro-Oncology 16(Suppl 5): v103

Strong, M.J.; Blanchard, G.; Baddoo, M.; Morris, C.; Taylor, C.M.; Ware, M.L.; Flemington, E.K. 2014: Ge-33 * a Comprehensive Assessment of Viral Transcripts in Dna- and Rna-Seq Datasets from High-Grade Gliomas Reveals no Association. Neuro-Oncology 16(Suppl 5): v103

Suzuki, H.; Aoki, K.; Ohka, F.; Motomura, K.; Fujii, M.; Sanada, M.; Nakamura, H.; Mizoguchi, M.; Abe, T.; Muragaki, Y.; Wakabayashi, T.; Ogawa, S.; Natsume, A. 2014: Ge-34 * the Mutational Landscape and Temporal and Spatial Clonal Evolution to Progression in 351 Low-Grade Gliomas. Neuro-Oncology 16(Suppl 5): v103-v104

Suzuki, M.; Kondo, A.; Ogino, I.; Fujimura, J.; Sakaguchi, S.; Miyajima, M.; Arai, H. 2014: Ge-35 * the Therapeutic Changes of Atypical Teratoid/Rhabdoid Tumor in Molecular Characters. Neuro-Oncology 16(Suppl 5): v104

Tanaka, S.; Sasaki, H.; Kimura, T.; Kameyama, K.; Nakamura, T.; Kitamura, Y.; Miwa, T.; Hirose, Y.; Yoshida, K. 2014: Ge-36 * Molecular-Genetic And Clinical Characteristics Of The "Astrocytic" Gliomas With Total 1p19q Loss. Neuro-Oncology 16(Suppl 5): v104

Verhaak, R.; Iavarone, A. 2014: Ge-37 * Integrated Genomic Analysis of low Grade Glioma and Glioblastoma Reveals Molecular Stratification by Idh Status across Grades and Histologies. Neuro-Oncology 16(Suppl 5): v104

Wang, Q.; Ezhilarasan, R.; Zheng, S.; Gumin, J.; Heffernan, T.; Draetta, G.; Lang, F.; Verhaak, R.; Sulman, E. 2014: Ge-38 * Identifying the Treatment-Resistant Mesenchymal Signature by Comparative Analyses between Glioma Sphere-Forming cells and their Glioblastomas of Origin. Neuro-Oncology 16(Suppl 5): v104-v105

Wang, Q.; Ezhilarasan, R.; Zheng, S.; Gumin, J.; Heffernan, T.; Draetta, G.; Lang, F.; Verhaak, R.; Sulman, E. 2014: Ge-39 * Validation of Glioma Sphere-Forming cells as Models of Glioblastoma and Identification of Novel Drivers of Tumorigenesis through Comprehensive Genomic Characterization. Neuro-Oncology 16(Suppl 5): v105

Wei, L.; Murphy, B.L.; Parker, M.; Wu, G.; Easton, J.; Roussel, M.F.; Zhang, J. 2014: Ge-40 * Comparative Genomic Analyses Identifies Non-Silent Mutations Present in Both Murine and Human Medulloblastoma. Neuro-Oncology 16(Suppl 5): v105

Blumenthal, D.; Bokstein, F.; Zelikovitsh, B.; Mordechai, A.; Lossos, A.; Taliansky, A.; Zach, L.; Tzuk-Shina, T.; Lavon, I. 2014: Ge-04 * Mgmt Methylation is a Positive Prognostic Marker in Patients with Anaplastic Astrocytoma Treated with Concurrent Temozolomide and Radiation. Neuro-Oncology 16(Suppl 5): v96-v97

Yung, W.K.A.; Verhaak, R.; Cooper, L.; Salama, S.; Aldape, K.; Brat, D. 2014: Ge-41 * Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas. Neuro-Oncology 16(Suppl 5): v105

Nagarajan, R.; Barajas, R.; Mazor, T.; Phillips, J.; Ma, J.; Hong, C.; Johnson, B.; Dayal, M.; Cha, S.; Nakamura, J.; Berger, M.; Chang, S.; Furnari, F.; Taylor, B.; Costello, J. 2014: Ge-42 * Integrated Radiographic and Phylogenetic Case Study of a Primary and Contralateral Recurrent Glioma. Neuro-Oncology 16(Suppl 5): v105-v106

Brastianos, P.; Taylor-Weiner, A.; Manley, P.; Jones, R.; Dias-Santagata, D.; Thorner, A.; Rodriguez, F.; Bernardo, L.; Schubert, L.; Stewart, C.; Kieran, M.; Louis, D.; Getz, G.; Santagata, S. 2014: Ge-05 * Exome Sequencing Reveals Braf Mutations in Papillary Craniopharyngiomas. Neuro-Oncology 16(Suppl 5): v97

Chamberlain, M. 2014: Ge-06 * Prognostic Significance of Relative 1p19q Codeletion in Oligodendroglial Tumors. Neuro-Oncology 16(Suppl 5): v97

Chmielecki, J.; Frampton, G.; Morosini, D.; Ali, S.; Lipson, D.; Yelensky, R.; Ross, J.; Miller, V.; Stephens, P. 2014: Ge-07 * the Genomic Landscape of Diverse Brain Tumors Reveals Known and Novel Oncogenic Alterations Frequently Associated with Sensitivity to Targeted Inhibitors. Neuro-Oncology 16(Suppl 5): v97

Dubbink, H.; Atmodimedjo, P.; French, P.; Kros, J.; Wesseling, P.; Enting, R.; Spliet, W.; Tijssen, C.; Idbaih, A.; Dinjens, W.; Gorlia, T.; van den Bent, M. 2014: Ge-08 * Targeted next Generation Sequencing of Archival Ffpe Samples from Eortc Study 26951 Shows Strong Prognostic Value of a Molecular Classification in Locally Diagnosed Grade Iii Oligodendroglioma. Neuro-Oncology 16(Suppl 5): v97

Eckel-Passow, J.; Lachance, D.; Walsh, K.; Decker, P.; Sicotte, H.; Pekmezci, M.; Molinaro, A.; Rice, T.; Kosel, M.; Smirnov, I.; Sarkar, G.; Caron, A.; Kollmeyer, T.; Giannini, C.; Huse, J. 2014: Ge-09 * Tert Promoter Mutation, Idh Mutation and 1p/19q Codeletion Define five Glioma Molecular Groups with Specific Clinical Characteristics and Germline Variant Associations. Neuro-Oncology 16(Suppl 5): v98

Baker, G.; Chockley, P.; Yadav, V.; Doherty, R.; Ritt, M.; Sivaramakrishnan, S.; Castro, M.; Lowenstein, P. 2014: Ib-01 * Glioma-Derived Galectin-1 is a Potent Suppressor of Nk Immunosurveillance. Neuro-Oncology 16(Suppl 5): v107

Renner, D.; Jin, F.; Parney, I.; Pirko, I.; Pavelko, K.; Johnson, A. 2014: Ib-10 * a Duality of Roles for Perforin in Cd8+ T Cell- Glioma Interactions: Contributions to Cytotoxicity and Altered Vascular Permeability. Neuro-Oncology 16(Suppl 5): v109

Sturla, L.; Donahue, J.; Machan, J.; Delamonte, S.; Jeyapalan, S. 2014: Ib-11 * Pseudo-Progression (PsdPg) Is A Harbinger Of A More Effective Anti-Tumor Response. Neuro-Oncology 16(Suppl 5): v109

Umemura, Y.; Bujarski, K.; Ronan, L. 2014: Ib-12 * Lung Mass and Immunosuppressant Responsive Seizures: Vgkc Autoimmunity Masquerading as Etiology or Acting as Reactive Marker?. Neuro-Oncology 16(Suppl 5): v109

Werner, J.; Rohn, G.; Goldbrunner, R.; Timmer, M. 2014: Ib-13 * Differences in the Expression of Cd184, Cd95, Cd178 and Cd40 in Human Gliomas of Various Grades, before and after Chemotherapy. Neuro-Oncology 16(Suppl 5): v109

Berghoff, A.S.; Kiesel, B.; Widhalm, G.; Rajky, O.; Ricken, G.; Wohrer, A.; Oberndorfer, F.; Dieckmann, K.; Filipits, M.; Marosi, C.; Holler, C.; Wick, W.; Preusser, M. 2014: Ib-02 * Role of Tumor Infiltrating Lymphocytes and Pdl1 Expression in Glioblastoma (Gbm) and Brain Metastases (Bm): Comparative Analysis. Neuro-Oncology 16(Suppl 5): v107

Brancho, M.; Chang, Y.; Zhang, X.; Okada, H.; Li, A.; Grandi, P.; Lotze, M.; Amankulor, N. 2014: Ib-03 * Idh Mutant Gliomas Are Resistant to Natural Killer Cell-Mediated Cytolysis. Neuro-Oncology 16(Suppl 5): v107

Chen, X.; Zhang, L.; Zhang, I.; Liang, J.; Weng, L.; Yamamoto, Y.; Yamamoto, H.; Natarajan, R.; Badie, B. 2014: Ib-04 * Expression of Rage by Tumor Macrophages Promotes Angiogenesis in Gliomas. Neuro-Oncology 16(Suppl 5): v107

Kaminska, B.; Wisniewski, P.; Kijewska, M.; Ellert-Miklaszewska, A.; Pszczolkowska, D.; Gajdanowicz, P.; Gieryng, A. 2014: Ib-05 * Tumor-Processed Osteopontin/Spp1 Shapes Microglia Polarization and Immune Microenvironment of Glioma. Neuro-Oncology 16(Suppl 5): v107-v108

Kannan, G.; Somanchi, S.; Lee, D. 2014: Ib-06 * the Role of Tgf in Nk Cell-Mediated Cytotoxicity in Medulloblastoma. Neuro-Oncology 16(Suppl 5): v108

Minasian, T.; Hariri, O.; Dyurgerova, A.; Miulli, D.; Siddiqi, J. 2014: Ib-07 * Histoplasmosis with Cns Involvement: Case Presentation with Discussion and Literature Review. Neuro-Oncology 16(Suppl 5): v108

Narang, S.; Rao, G.; Heimberger, A.; Martinez, J.; Rao, A. 2014: Ib-08 * Computational Imaging Features Derived from Mri Images of the Brain can Discriminate Immune Signature Status in Glioblastoma Multiforme (Gbm). Neuro-Oncology 16(Suppl 5): v108

Ohkuri, T.; Ghosh, A.; Kosaka, A.; Zhu, J.; Ikeura, M.; David, M.; Watkins, S.; Sarkar, S.; Okada, H. 2014: Ib-09 * Sting Agonist Induces Potent Anti-Glioma Immunity via Induction of Type-I Ifn Signals in the Tumor Microenvironment. Neuro-Oncology 16(Suppl 5): v108

Antonios, J.; Soto, H.; Harris, R.; Nathanson, D.; Sadeghi, S.; Ellingson, B.; Liau, L.; Prins, R. 2014: It-01 * Pd1/Pdl1 Interactions Mediate Suppression of Anti-Tumor Immune Activity in Glioma. Neuro-Oncology 16(Suppl 5): v110

Hu, J.; Yu, J.; Black, K.; Rudnick, J. 2014: It-13 * Ipilimumab for Recurrent High-Grade Glioma: A Single-Institution Case Series. Neuro-Oncology 16(Suppl 5): v112

Iwata, R.; Asai, A.; Oshige, H.; Yoshimura, K.; Nonaka, M.; Nakano, I. 2014: It-14 * Mesenchymal Glioma Stem cell Express Icosl. Neuro-Oncology 16(Suppl 5): v112

Jiang, H.; Lang, F.; Fan, X.; Gumin, J.; Bover, L.; Clise-Dwyer, K.; Toniatti, C.; Ruisaard, K.; Conrad, C.; Vence, L.; Gomez-Manzano, C.; Fueyo, J. 2014: It-15 * Delta-24-Rgdox: Targeting Co-Stimulatory Immune Checkpoint Proteins with Oncolytic Adenoviruses. Neuro-Oncology 16(Suppl 5): v112

Kleijn, A.; van den Bossche, W.; Haefner, E.; Belcaid, Z.; Kloezeman, J.; Dirven, C.; Lamfers, M. 2014: It-16 * Combination Treatment with Delta24-Rgd and Temozolomide Improves Survival and Affects Intratumoral Immune cell Subsets in a Murine Malignant Glioma Model. Neuro-Oncology 16(Suppl 5): v112-v113

Kohanbash, G.; Straw, E.; Averick, A.; Ahn, B.; Smith-Cohn, M.; Ohkuri, T.; Kosaka, A.; Okada, H. 2014: It-17 * Ono-Ae3-208 Inhibits Myeloid-Derived Suppressor cells and Glioma Growth. Neuro-Oncology 16(Suppl 5): v113

Lamb, L.; Pereboeva, L.; Gillespie, G.; Langford, S.; Cloud, G.; Spencer, H. 2014: It-19 * Temozolamide Resistant Innate Lymphocytes Administered during Chemotherapy Improve Survival in High-Grade Glioma. Neuro-Oncology 16(Suppl 5): v113

Mangraviti, A.; Sengupta, S.; Paldor, I.; Rowshanshad, D.; Sampath, P.; Olivi, A.; Tyler, B.; Brem, H. 2014: It-20 * Overexpression Of Il13Ra2: Assessment Of Pro-Aggressive And Pro-Invasive Phenotypes Of Malignant Glioma In A Syngeneic Animal Model. Neuro-Oncology 16(Suppl 5): v113-v114

Mathios, D.; Phallen, J.; Park, C.-K.; Jackson, C.; Nicholas, S.; Tyler, B.; Pardoll, D.; Brem, H.; Lim, M. 2014: It-21 * Pd-1 Blockade Shows Synergistic Survival, Anti-Tumor Immune Response and Long-Term Memory with Interstitial but not Systemic Chemotherapy: Study in a Murine Glioblastoma Model. Neuro-Oncology 16(Suppl 5): v114

Nduom, E.K.; Wei, J.; Kong, L.-Y.; Xu, S.; Gabrusiewicz, K.; Ling, X.; Huang, N.; Qiao, W.; Zhou, S.; Ivan, C.; Chen, J.Q.; Ji, Y.; Radvanyi, L.; Fuller, G.N.; Gilbert, M. 2014: It-22 * Targeting The Immune Checkpoint Network With miR-138 Exerts Therapeutic Efficacy In Murine Models Of Glioma. Neuro-Oncology 16(Suppl 5): v114

Pham, C.; Flores, C.; Pei, Y.; Wechsler-Reya, R.; Mitchell, D. 2014: It-25 * Developmentally Regulated Antigens for Immunologic Targeting of Medulloblastoma Subtypes. Neuro-Oncology 16(Suppl 5): v115

Phuphanich, S.; Yu, J.; Bannykh, S.; Zhu, J.-J. 2014: It-26 * Identification of Pseudo-Progression in New Diagnosed Glioblastoma (Gbm) in a Randomized Phase 2 of Ict-107: Mri and Pathology Correlation. Neuro-Oncology 16(Suppl 5): v115

Qiao, J.; Dey, M.; Chang, A.; Woongki, K.; Han, Y.; Zhang, L.; Lesniak, M. 2014: It-27 * Oncolytic Adenoviruses-Mediated Immune Responses in Syngeneic Murine Glioma Model. Neuro-Oncology 16(Suppl 5): v115

Reardon, D.; Gokhale, P.; Ligon, K.; Liao, X.; Rodig, S.; Zhou, J.; Qin, L.; Hodi, S.; Jones, K.; Sauer, A.; Kohl, N.; Dranoff, G.; Freeman, G. 2014: It-29 * Immune Checkpoint Blockade for Glioblastoma: Preclinical Activity of Single Agent and Combinatorial Therapy. Neuro-Oncology 16(Suppl 5): v116

Sayour, E.; DeLeon, G.; Pham, C.; Sanchez-Perez, L.; Snyder, D.; Kemeny, H.; Flores, C.; Mitchell, D. 2014: It-31 * Harnessing the Immunologic Capacity of the Liver against Glioblastoma Multiforme. Neuro-Oncology 16(Suppl 5): v116

Brown, C.; Starr, R.; Aguilar, B.; Chang, B.; Sarkissian, A.; Naranjo, A.; Chang, W.-C.; Jensen, M.; D'Apuzzo, M.; Barish, M.; Badie, B.; Forman, S. 2014: It-03 * Adoptive Transfer Of Il13R2-Specific T Cells For The Treatment Of Glioblastoma: Building On Clinical Achievements With Second-Generation Cars. Neuro-Oncology 16(Suppl 5): v110

Sims, J.; Grinshpun, B.; Feng, Y.; Neira, J.; Samanamud, J.; Amendolara, B.; Canoll, P.; Sims, P.; Shen, Y.; Bruce, J. 2014: It-32 * Divergence of Intratumoral and Systemic T cell Repertoires Reflects Local Monocyte Profiles during Glioma Progression. Neuro-Oncology 16(Suppl 5): v116-v117

Smith-Cohn, M.; Kohanbash, G.; Muthuswamy, R.; Ohkuri, T.; Kosaka, A.; Amankulor, N.; Engh, J.; Potter, D.; Kalinski, P.; Okada, H. 2014: It-33 * Use of Ifn-Alpha and Poly-Iclc as Chemokine Modulators for Immunotherapy in Gliomas. Neuro-Oncology 16(Suppl 5): v117

Vlahovic, G.; Archer, G.; Lally-Goss, D.; Reap, E.; Batich, K.; Desjardins, A.; Peters, K.; Ranjan, T.; Healy, P.; Herndon, J.; Friedman, A.; Friedman, H.; Bigner, D.; Sampson, J. 2014: It-34 * Pilot Study of Combination of Antitumor Immunotherapy Targeted against Cytomegalovirus (Cmv) plus Regulatory T-Cell Inhibition in Patients with Newly-Diagnosed Glioblastoma Multiforme (Gbm). Neuro-Oncology 16(Suppl 5): v117

Zakharia, Y.; Johnson, T.; Colman, H.; Vahanian, N.; Link, C.; Kennedy, E.; Sadek, R.; Kong, F.-M.; Vender, J.; Munn, D.; Rixe, O. 2014: It-36 * Phase 1/2 Study of the Combination of Indoximod and Temozolomide for Adult Patients with Temozolomide-Refractory Primary Malignant Brain Tumors. Neuro-Oncology 16(Suppl 5): v117-v118

Cloughesy, T.F.; Kesari, S.; Kalkanis, S.; Mikkelsen, T.; Landolfi, J.; Elder, J.B.; Liau, L.M.; Chen, C.C.; Bloomfield, S.; Piccioni, D.; Chiocca, E.A.; Foltz, G.; Robbins, J.M.; Ostertag, D.; Jolly, D.J. 2014: It-05 * Administration of Toca 511 to Subjects with Recurrent Hgg Undergoing Repeat Resection. Neuro-Oncology 16(Suppl 5): v110-v111

DeLeon, G.; Nair, S.; Xie, W.; Drake, J.; Mitchell, D. 2014: It-06 * Personalized Immunotherapy for the Treatment of Glioblastoma. Neuro-Oncology 16(Suppl 5): v111

Flores, C.; Pham, C.; Snyder, D.; Yang, S.; Sanchez-Perez, L.; Sayour, E.; Cui, X.; Kemeny, H.; Friedman, H.; Bigner, D.; Sampson, J.; Mitchell, D. 2014: It-10 * Synergistic Cellular Interactions in Adoptive Immunotherapy Leads to Immunologic Rejection of Malignant Glioma. Neuro-Oncology 16(Suppl 5): v111

Ghiaseddin, A.; Snook, R. 2014: Ll-01 * The Relationship Between B2M And Cns Lymphoma. Neuro-Oncology 16(Suppl 5): v119

Krishnamurthy, J.; Greiner, T.; Bhatt, V.; White, M.; Bierman, P. 2014: Ll-02 * Temozolomide in Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (Cns-Ptld): A Case Series. Neuro-Oncology 16(Suppl 5): v119

Kumar, R.; Laack, N.; Pollock, B.; Link, M.; O'Neill, B.; Parney, I. 2014: Ll-03 * Stereotactic Radiosurgery for Salvage Treatment of Recurrent Cns Lymphoma. Neuro-Oncology 16(Suppl 5): v119

Achutha, M.; Slagle-Webb, B.; Rizk, E.; Payne, R.; Harbaugh, K.; Connor, J. 2014: Ms-01 * Development of Malignant Peripheral Nerve Tumor Model for Evaluating a Tumor Targeted Liposome-Based Therapy. Neuro-Oncology 16(Suppl 5): v127

Juratli, T.; Geiger, K.; Lautenschlaeger, T.; Hagen, M.V.d.; Schackert, G.; Kirsch, M. 2014: Ms-11 * Clear cell Petro-Clival Meningioma in a five Year Old Child - Histopathological Diagnosis and Long-Term Clinical Follow-Up. Neuro-Oncology 16(Suppl 5): v129

Kamiya-Matsuoka, C.; Cachia, D.; Waguespack, S.G.; McCutcheon, I.E.; Mahajan, A.; Brown, P.D.; Groves, M.D.; Penas-Prado, M. 2014: Ms-12 * Temozolomide-Based Therapy for the Management of Progressive Pituitary Carcinoma. Neuro-Oncology 16(Suppl 5): v129

Kim, B.Y.S.; Jiang, W.; Gullane, P.; Gentili, F.; DeMonte, F. 2014: Ms-13 * Non-Contiguous Leptomeningeal Metastasis of Olfactory Neuroblastomas: A Long-Term Multi-Institutional Experience. Neuro-Oncology 16(Suppl 5): v129

Kittel, J.; Kumar, A.; Zimmerman, A.; Woody, N.M.; Murphy, E.S.; Barnett, G.H.; Stevens, G.; Recinos, P.F.; Suh, J.H.; Chao, S.T. 2014: Ms-14 * Patients with Recurrent Atypical Meningioma after Upfront Surgical Resection Salvaged with Radiosurgery Require more Salvage Procedures than Patients Salvaged with Conventional Radiation. Neuro-Oncology 16(Suppl 5): v129

Klironomos, G.; Larjani, S.; Mansouri, A.; Ghare, A.; Kilian, A.; Aldape, K.; Zadeh, G. 2014: Ms-15 * the Impact of Histopathologic and Radiologic Characteristics in Clinical Outcome of Patients Who Underwent Surgery for Intracranial Meningiomas. Neuro-Oncology 16(Suppl 5): v129-v130

Linay, K.J.; Bernardo, M.C.; Maranan, E. 2014: Ms-16 * a Rare Case of Primary Cns Angiosarcoma Presenting as an Incomplete Gerstmann Syndrome: A Case Report and Review of Literature. Neuro-Oncology 16(Suppl 5): v130

Maher, O.M.; Sandberg, D.I.; Kannan, G.; McGovern, S.; Ketonen, L.; Khatua, S.; Zaky, W. 2014: Ms-17 * Primary Leptomeningeal Primitive Neuroectodermal Tumor. Neuro-Oncology 16(Suppl 5): v130

Mansouri, A.; Larjani, S.; Klironomos, G.; Zadeh, G. 2014: Ms-18 * Predictors of Response and Adverse Events for Meningiomas Managed with Gamma Knife Radiosurgery. Neuro-Oncology 16(Suppl 5): v130

Mowery, Y.; Wright, A.; Desjardins, A.; Peters, K.; Ranjan, T.; Vlahovic, G.; Friedman, H.; Zomorodi, A.; Kaylie, D.; Adogwa, O.; Nimjee, S.; Sperduto, W.; Chagoya, G.; Fatemi, P.; McLendon, R. 2014: Ms-19 * Long-Term Outcomes for Patients with Intracranial Meningiomas: A Single-Institution Retrospective Analysis. Neuro-Oncology 16(Suppl 5): v130-v131

Penas-Prado, M.; Puduvalli, V.K.; Mahajan, A.; Rao, G.; Brown, P.D.; Yung, A.W.K. 2014: Ms-20 * Leptomeningeal Dissemination in Relapsed Adult Medulloblastoma: Patterns of Disease and Role of Intrathecal Chemotherapy. Neuro-Oncology 16(Suppl 5): v131

Agnihotri, S.; Burell, K.; Jalali, S.; Alamsahebpour, A.; Sabha, N.; Krischek, B.; Aldape, K. 2014: Ms-02 * Transcriptome Analysis Identifies The Pi3K/Akt/mTor Pathway As A Targetable Pathway In Schwannoma. Neuro-Oncology 16(Suppl 5): v127

Praver, M.; D'Amico, R.; Canoll, P.; Bruce, J. 2014: Ms-21 * Subependymomas Demonstrate Lineage Markers Suggesting an Origin within Multipotential Progenitors of the Subventricular Zone. Neuro-Oncology 16(Suppl 5): v131

Ruda, R.; Magistrello, M.; Bertero, L.; Bosa, C.; Pellerino, A.; Nicolotto, E.; Moretto, F.; Garbossa, D.; Soffietti, R. 2014: Ms-22 * Neoplastic Meningitis from Ependymomas of the Adult: A Retrospective Analysis. Neuro-Oncology 16(Suppl 5): v131

Singel, S.; Hicks, S.; Dawson, A.; Fonkem, E.; Noonan, P. 2014: Ms-23 * Improving Forward Infusion Pressure in Vascular Brain Tumors using a Double Catheter and Coil Technique. Neuro-Oncology 16(Suppl 5): v131

Soffietti, R.; Magistrello, M.; Trevisan, E.; Bertero, L.; Pellerino, A.; Ruda, R. 2014: Ms-24 * Systemic Treatment of Meningiomas: Is There a Role for Long-Acting Somatostatin?. Neuro-Oncology 16(Suppl 5): v131-v132

Straza, M.; Garcia, G.; Hariri, B.; Patel, R.; Albano, K.; Schultz, C.; Friedland, D.; Bovi, J. 2014: Ms-25 * Gamma Knife Radiosurgery for Vestibular Schwannoma: Assessment of Quality and Outcomes. Neuro-Oncology 16(Suppl 5): v132

Syed, F.; Lachi, P.; Chakravarthy, P.; Uppin, S.; Syed, A.; Nair, D.; Joseph, D.; Irrakula, M.; Pamidighantam, S.; Naidu, K. 2014: Ms-26 * Extra Cranial Metastasis in a Case of Cerebral Meningioma: A Rare Case Report. Neuro-Oncology 16(Suppl 5): v132

Wang, F.; Roy, A.; Badkul, R.; John, P.; Kumar, P.; Staecker, H. 2014: Ms-27 * the Impact of Hypofractionated Linac-Based Stereotactic Radiosurgery upon Early Auditory Functions in the Treatment of Vestibular Schwannomas. Neuro-Oncology 16(Suppl 5): v132

Wilisch-Neumann, A.; Pachow, D.; Kirches, E.; Mawrin, C. 2014: Ms-29 * Sorafenib and Regorafenib Inhibit Growth and Migration of Meningioma cells. Neuro-Oncology 16(Suppl 5): v132

Young, R.; Mourad, W.F.; Graber, J.; Patel, S.; Glanzman, J.; Kabaritti, R.; Santiago, T.; Kalnicki, S.; Garg, M. 2014: Ms-30 * Meningeal Melanocytoma with Multifocality, Rapid Cns Seeding, and Systemic Metastases. Neuro-Oncology 16(Suppl 5): v133

Zhen, H.; Zhao, W.; Yang, X.; Wang, J.; Zhao, J.; Huo, J.; Zhang, X.; Fei, Z. 2014: Ms-31 * Intracranial Meningiomas Complicated by Hypertension: Four Case Reports. Neuro-Oncology 16(Suppl 5): v133

Alzate, J.; Young, R.; Rovin, R. 2014: Ms-04 * a Novel Minimally Invasive Approach for the Resection of Intraventricular Tumors. Neuro-Oncology 16(Suppl 5): v127

AlZhrani, G.; AlOtaibi, F.; Azarnoush, H.; Winkler-Schwartz, A.; Sabbagh, A.; Lajoie, S.; Del Maestro, R. 2014: Ms-05 * Utilizing a Virtual Reality Simulator, Neurotouch, to Determine Proficiency Performance Benchmarks for Resection of Simulated Brain Tumors. Neuro-Oncology 16(Suppl 5): v127-v128

Chavredakis, E.; Brodbelt, A.; Jenkinson, M. 2014: Ms-06 * Defining the Optimal Follow-Up Schedule following Surgical Resection of Grade I Meningioma. Neuro-Oncology 16(Suppl 5): v128

Gump, W. 2014: Ms-07 * Meningioma of the Pediatric Skull Base: A Review. Neuro-Oncology 16(Suppl 5): v128

Hashmi, F.A.; Bari, E.; Khan, S.A. 2014: Ms-08 * Gliosarcoma: Features and Outcomes in a Tertiary Care Hospital in Pakistan. Neuro-Oncology 16(Suppl 5): v128

Hashmi, F.A.; Khan, S.A.; Bari, M.E.; Ahmed, A. 2014: Ms-09 * Prognostic Implications of Histological Clear cells in high Grade Intracranial Ependymal Tumors: A Retrospective Analysis from a Tertiary Care Hospital in Pakistan. Neuro-Oncology 16(Suppl 5): v128

Hashmi, F.A.; Khan, S.A.; Waqas, M.; Bari, M.E.; Ahmed, A. 2014: Ms-10 * Clear cell Ependymoma: A Rare Variant First Time Reported by a Tertiary Care Hospital in Pakistan. Neuro-Oncology 16(Suppl 5): v128

Barish, M.; Baghdadchi, N.; Dickan, A.; Khosh, N.; Mahadev, V.; Forman, S.; Brown, C. 2014: Me-01 * Glioma cell Adhesion and Invasion Regulated by Proinflammatory Cytokine in a Novel Surface/Matrix Culture System. Neuro-Oncology 16(Suppl 5): v120

Kwiatkowska, A.; Nandhu, M.; Hecker, C.; Viapiano, M. 2014: Me-11 * Reduction Of NfkB In The In The Tumor Microenvironment Alters The Neural Extracellular Matrix And Reduces Glioblastoma Growth And Dispersion. Neuro-Oncology 16(Suppl 5): v122

Mao, F.; Holmlund, C.; Faraz, M.; Bergenheim, T.; Johansson, M.; Henriksson, R.; Hedman, H. 2014: Me-12 * the Tumor Suppressor Lrig1 is Downregulated by Hypoxia and Regulates Glioblastoma cell Invasion. Neuro-Oncology 16(Suppl 5): v122

McFarland, B.C.; Marks, M.P.; Rowse, A.L.; Gerigk, M.; Walker, P.M.; Qin, H.; Benveniste, E.N. 2014: Me-13 * Loss of Socs3 in Myeloid cells Delays Tumor Growth and Prolongs Survival in a Syngeneic Model of Glioblastoma. Neuro-Oncology 16(Suppl 5): v122

Mega, A.; Sleire, L.; Hagerstrand, D.; Enger, P.O.; Nister, M.; Ostman, A. 2014: Me-14 * Pro-Migratory and -Proliferative effects of Astrocytes on Gbm cells. Neuro-Oncology 16(Suppl 5): v122-v123

Otvos, B.; Alvarado, A.; Hale, J.; Stoltz, K.; Sinyuk, M.; Rayman, P.; Flavahan, W.; Wu, Q.; Jarrar, A.; Rich, J.; Ransohoff, R.; Finke, J.; Vogelbaum, M.; Lathia, J. 2014: Me-15 * Interaction between Cancer Stem cells and Myeloid Derived Suppressor cells Drives Immunosuppression and Glioblastoma Growth. Neuro-Oncology 16(Suppl 5): v123

Pollo, B.; Mazzetti, S.; Patane, M.; Calatozzolo, C.; DiMeco, F.; Silvani, A. 2014: Me-16 * is Aquaporin4 (Aqp4) Involved in Adult Human Medulloblastoma Dissemination or in a Beneficial Barrier Formation?. Neuro-Oncology 16(Suppl 5): v123

Rajappa, P.; Huang, Y.; Vartanian, E.; Pisapia, D.; Lyden, D.; Bromberg, J.; Greenfield, J. 2014: Me-17 * Jak 1/2 Inhibition following Bone Marrow Transplantation Mitigates Cd11b + /Gr1+ Mediated Low-Grade Glioma Neoangiogenesis. Neuro-Oncology 16(Suppl 5): v123

Rodriguez, A.; Gibo, D.; Debinski, W. 2014: Me-18 * Induction of M2 type Macrophages by Gbm cells. Neuro-Oncology 16(Suppl 5): v123

Wang, K.; Florczyk, S.; Kievit, F.; Zhang, M. 2014: Me-20 * Culture of Human Gbm cells on Ecm-Mimicking Chitosan-Hyaluronic Acid Scaffolds Increases Malignancy and Drug Resistance. Neuro-Oncology 16(Suppl 5): v124

Burrell, K.; Singh, S.; Agnihotri, S.; Hill, R.; Aldape, K.; Zadeh, G. 2014: Me-03 * Bone Marrow Derived Microglia and their Function within Tumor Microenvironment. Neuro-Oncology 16(Suppl 5): v120

Caretti, V.; Bugiani, M.; Freret, M.; Schellen, P.; Jansen, M.; van Vuurden, D.; Kaspers, G.; Fisher, P.G.; Hulleman, E.; Wesseling, P.; Vogel, H.; Monje, M. 2014: Me-04 * Subventricular Spread of Diffuse Intrinsic Pontine Glioma. Neuro-Oncology 16(Suppl 5): v120

Cortes-Santiago, N.; Hossain, M.B.; Gabrusiewicz, K.; Fan, X.; Jiang, H.; Shifat, R.; Alonso, M.M.; Fueyo, J.; Gomez-Manzano, C. 2014: Me-05 * Counterattacking the Force behind Glioma Invasion. Neuro-Oncology 16(Suppl 5): v120

Glass, R. 2014: Me-06 * Endogenous Neural Precursor cells Induce cell Death of High-Grade Astrocytomas and Have a Tropism to Tumors in the Human Brain. Neuro-Oncology 16(Suppl 5): v121

Irvin, D.; Schmid, R.; Bash, R.; Miller, C.R. 2014: Me-07 * Influence of Regional Microenviroment and Astrocyte Heterogeneity on Astrocytoma Development. Neuro-Oncology 16(Suppl 5): v121

Johung, T.; Venkatesh, H.; Caretti, V.; Noll, A.; Monje, M. 2014: Me-08 * Neurons Promote Glioma Growth in an Activity-Dependent Manner. Neuro-Oncology 16(Suppl 5): v121

Juliano, J.; Gil, O.; Hawkins-Daarud, A.; Rockne, R.; Gallaher, J.; Massey, S.; Anderson, A.; Bruce, J.; Canoll, P.; Swanson, K. 2014: Me-09 * Dynamic Evidence of Tumor induced Microglia Activation at the Infiltrative Margins of Glioma. Neuro-Oncology 16(Suppl 5): v121

Kamran, N.; Ayala, M.; Li, Y.; Assi, H.; Candolfi, M.; Dzaman, M.; Lowenstein, P.; Castro, M. 2014: Me-10 * Tumor Microenvironment Infiltrating Myeloid Derived Suppressor cells Inhibit Anti-Tumor T cell Responses. Neuro-Oncology 16(Suppl 5): v121-v122

Alvarado, A.; Li, M.; Sathyan, P.; Majumder, S.; Rich, J.; Lathia, J. 2014: Mr-01 * MicroRna-145 Regulates Jam-A Expression And Compromises Glioblastoma Maintenance. Neuro-Oncology 16(Suppl 5): v125

Kushwaha, D.; Ramakrishnan, V.; Ng, K.; Steed, T.; Nguyen, T.; Futalan, D.; Akers, J.; Tao, J.; Chowdhury, D.; Carter, B.; Chen, C. 2014: Mr-02 * A Genome-Wide miRna Screen Revealed Mir-603 As A Mgmt-Regulating miRna In Glioblastomas. Neuro-Oncology 16(Suppl 5): v125

Munthe, S.; Zabludoff, S.; Karmali, P.; Kaimal, V.; Poulsen, F.R.; Kristensen, B.W. 2014: Mr-03 * MicroRna Profile Of Migrating Glioblastoma Cells Kept In Stem Cell Medium. Neuro-Oncology 16(Suppl 5): v125

Singh, S.; Burrell, K.; Alamhabspour, A.; Agnihotri, S.; Vartanian, A.; Jalali, S.; Gumin, J.; Sulman, E.; Lang, F.; Zadeh, G. 2014: Mr-04 * Dicer Regulates Glioma Stem cell State. Neuro-Oncology 16(Suppl 5): v125

Singh, S.; Burrell, K.; Alamsahebpour, A.; Koch, E.; Agnihotri, S.; Gumin, J.; Sulman, E.; Lang, F.; Wouters, B.; Aldape, K.; Zadeh, G. 2014: Mr-05 * Glioma Stem Cell Specific microRna-mRna Interaction Network. Neuro-Oncology 16(Suppl 5): v126

Smrcka, M.; Sana, J.; Lakomy, R.; Fadrus, P.; Slampa, P.; Kren, L.; Svoboda, M.; Hajduch, M.; Slaby, O. 2014: Mr-06 * MicroRna Signature Associated With Poor Outcome Of Glioblastoma Patients. Neuro-Oncology 16(Suppl 5): v126

Banerjee, P.; Leu, K.; Harris, R.; Cloughesy, T.; Bookheimer, S.; Liau, L.; Nghiemphu, P.; Lai, A.; Ellingson, B. 2014: Nc-01 * Attentional and Language Functioning in Adult Patients with Glioma: A Voxel-Based Lesion-Symptom Mapping Study. Neuro-Oncology 16(Suppl 5): v134

Mabbott, D.; Riggs, L.; Piscione, J.; Laughlin, S.; Cunningham, T.; Timmons, B.; Courneya, K.; Bartels, U.; Skocic, J.; Liu, F.; Scantlebury, N.; Bouffet, E. 2014: Nc-10 * Training the Brain to Repair Itself: An Exercise Trial in Pediatric Brain Tumor Survivors. Neuro-Oncology 16(Suppl 5): v136

Meskal, I.; Gehring, K.; van der Linden, S.; Rutten, G.-J.; Sitskoorn, M. 2014: Nc-11 * Computerized Testing in Patients with Meningiomas: Improvement of Cognitive Functioning after Surgery. Neuro-Oncology 16(Suppl 5): v136

Noll, K.; Garbarino, A.; Turner, C.; Verhaak, A.M.S.; Wefel, J. 2014: Nc-12 * Depression and Executive Functioning in relation to Survival among Patients with Glioblastoma. Neuro-Oncology 16(Suppl 5): v136

Redmond, K.; Mahone, M.; Sair, H.; Vannorsdall, T.; Terezakis, S.; Kleinberg, L.; McNutt, T.; Wharam, M.; Horska, A. 2014: Nc-13 * Cranial Radiation Encompassing the Genu is Associated with Neuro-Psychological Sequelae in Children: A Prospective Study of Diffusion Tensor Imaging (Dti) and Proton Mr Spectroscopy (Mrs). Neuro-Oncology 16(Suppl 5): v137

Rotta, R.; Tummala, S.; Guillory, S.; Prabhu, S.; Rao, G.; Levine, N.; Suki, D.; Lang, F.; Weinberg, J.; Sawaya, R. 2014: Nc-14 * Speech Maps Generated By nTms And Correlation With Direct Intraoperative Electrical Stimulation. Neuro-Oncology 16(Suppl 5): v137

Wefel, J.; Noll, K.; Rao, G.; Cahill, D. 2014: Nc-15 * Relationships between Neurocognitive Functioning and Idh1 Genetic Mutation Status in Malignant Astrocytoma. Neuro-Oncology 16(Suppl 5): v137

Yang, C.-Y.; Yang, S.-H.; Yang, C.-C. 2014: Nc-16 * Predictors of Post-Surgical Quality of Life in Patients with Non-Functional Pituitary Adenoma: The Influence of Neurobehavioral Functions. Neuro-Oncology 16(Suppl 5): v137

Chiu, C.-H.; Chen, P.-Y.; Wu, Y.-X.; Wei, K.-C.; Yang, C.-C. 2014: Nc-02 * Improvements in Neurocognitive Functions and Quality of Life in Patients with Gliomas after Awake Craniotomy. Neuro-Oncology 16(Suppl 5): v134

Correa, D.; Satagopan, J.; Baser, R.; Cheung, K.; DeAngelis, L.; Orlow, I. 2014: Nc-03 * Polymorphisms in the Comt, Bdnf and Dtnbp1 Genes and Cognitive Functions in Patients with Brain Tumors. Neuro-Oncology 16(Suppl 5): v134

Flechl, B.; Sax, C.; Ackerl, M.; Hainfellner, J.A.; Widhalm, G.; Dieckmann, K.; Wohrer, A.; Preusser, M.; Marosi, C. 2014: Nc-04 * the Course of Qol and Neurocognition in Newly Diagnosed Patients with Gbm. Neuro-Oncology 16(Suppl 5): v134

Hall, W.A.; Pugh, S.L.; Wefel, J.S.; Armstrong, T.S.; Gilbert, M.R.; Brachman, D.G.; Werner-Wasik, M.; Wendland, M.; Brown, P.D.; Chao, S.T.; Roof, K.; Robins, H.I.; Curran, W.J.; Mehta, M. 2014: Nc-05 * Association of Neurocognitive and Patient Reported Outcomes with the Presence of Residual Disease following Surgical Resection in Glioblastoma (Gbm). Neuro-Oncology 16(Suppl 5): v135

Hervey-Jumper, S.; Li, J.; Lau, D.; Molinaro, A.; Perry, D.; Meng, L.; Berger, M. 2014: Nc-06 * Awake Craniotomy to Maximize Glioma Resection: Methods and Technical Nuances. Neuro-Oncology 16(Suppl 5): v135

Jancalek, R.; Pospisil, P.; Bulik, M.; Dobiaskova, M.; Kazda, T.; Slampa, P. 2014: Nc-07 * Correlation of Mr Spectroscopy Image of Hippocampus Region and Impairment of Neurocognitive Functions in Patients after Whole Brain Radiotherapy - Preliminary Data. Neuro-Oncology 16(Suppl 5): v135

Kilian, A.; Parvex, K.; Monsalves, E.; Larjani, S.; Klironomos, G.; Zadeh, G. 2014: Nc-08 * Predictors of Survival after Second Surgery for Recurrent Glioblastoma Multiforme Tumours. Neuro-Oncology 16(Suppl 5): v135-v136

Kitabayashi, T.; Nakada, M.; Furuta, T.; Miyashita, K.; Kinoshita, M.; Tanaka, S.; Hayashi, Y. 2014: Nc-09 * the Impact of Supratotal Resection for Glioblastoma. Neuro-Oncology 16(Suppl 5): v136

Abe, T.; Momii, Y.; Morisaki, I.; Sasaki, M.; Watanabe, J.; Kamida, T.; Kashino, G.; Matsumoto, S.; Hayashi, K.; Mori, H.; Nakayama, K.; Beppu, T.; Ogasawara, K.; Terasaki, K.; Iwata, R. 2014: Ni-01 * Gene Profiles In High Uptake Area On Positron Emission Tomography With A Hypoxic Cell Tracer, 18F-Frp170. Neuro-Oncology 16(Suppl 5): v138

Calligaris, D.; Loginov, D.; Machaidze, R.; Alberta, J.A.; Stiles, C.D.; Love, J.C.; Agar, N.Y.R. 2014: Ni-10 * a Mass Spectrometry Imaging Platform to Study Drug-Susceptibility of Brain Tumors. Neuro-Oncology 16(Suppl 5): v140

Carapella, C.; Chiaravalloti, A.; Villani, V.; Vidiri, A.; Piludu, F.; Terrenato, I.; Fabi, A.; Schillaci, O.; Pace, A.; Floris, R. 2014: Ni-11 * The Potential Role Of 18F-Fdopa Pet Imaging In The Evaluation Of Low-Grade Gliomas. Neuro-Oncology 16(Suppl 5): v140

Chen, Z.; Tie, Y.; O'Donnell, L.; Rigolo, L.; Mehrtash, A.; Olubiyi, O.; Norton, I.; Pasternak, O.; Rathi, Y.; Golby, A. 2014: Ni-13 * Resolving the Challenges of Peritumoral Edema in Tracing Arcuate Fasciculus for Surgical Planning using Two-Tensor Unscented Kalman Filter Tractography. Neuro-Oncology 16(Suppl 5): v140

Cohen, A.; Pechman, K.; Schmainda, K. 2014: Ni-14 * the Diffusion Weighted Imaging Derived Inflection B-Value as a Potential Marker for Brain Tumor Heterogeneity. Neuro-Oncology 16(Suppl 5): v140

Dolati, P.; Gokoglu, A.; Golby, A.; Al-Mefty, O. 2014: Ni-17 * Multimodal Navigated Skull Base Tumor Resection using Image-Based Vascular and Cranial Nerve Segmentation: A Prospective Validation Study. Neuro-Oncology 16(Suppl 5): v141

Dolati, P.; Raber, M.; Golby, A.; Laws, E. 2014: Ni-18 * Multimodal Navigation in Endoscopic Trans-Sphenoidal Resection of Pituitary Tumors using Image-Based Vascular and Cranial Nerve Segmentation: A Prospective Validation Study. Neuro-Oncology 16(Suppl 5): v141

Ellingson, B.; Chang, W.; Harris, R.; Mody, R.; Lai, A.; Nghiemphu, P.; Cloughesy, T.; Pope, W. 2014: Ni-20 * Adc Histogram Analysis following Radiotherapy Predicts Response to Adjuvant Temozolomide in Newly Diagnosed Gbm. Neuro-Oncology 16(Suppl 5): v142

Waldman, A.; Upadhyay, N.; Adams, A.; Peterson, D.; Roncaroli, F. 2014: Ni-02 * Elevated Myoinositol in Diffuse Astrocytoma; a Marker of Anaplastic Phenotype, and not Attributable to Microglial Infiltration. Neuro-Oncology 16(Suppl 5): v138

Ellingson, B.; Kim, G.; Woodworth, D.; Pope, W.; Nghiemphu, P.; Lai, A.; Cloughesy, T. 2014: Ni-21 * Contrast Enhanced T1 Subtraction Maps Improve Detection of Residual Tumor following Resection, Reduces Measurement Variability, and Predicts Survival after Anti-Angiogenic Therapy in Glioblastoma. Neuro-Oncology 16(Suppl 5): v142

Ellingson, B.; Pope, W.; Nghiemphu, P.; Lai, A.; Cloughesy, T. 2014: Ni-22 * Non-Enhancing Tumor Response using Quantitative T2 Maps Predicts Survival in Glioblastoma Treated with Bevacizumab. Neuro-Oncology 16(Suppl 5): v142-v143

Emblem, K.; Pinho, M.; Chandra, V.; Gerstner, E.; Stufflebeam, S.; Sorenson, G.; Harris, G.; Freedman, R.; Sohl, J.; Younger, J.; Krop, I.; Winer, E.; Lin, N. 2014: Ni-23 * Brain Breast Metastases Respond to Anti-Angiogenic Therapy by Modes of Vascular Normalization. Neuro-Oncology 16(Suppl 5): v143

Eschbacher, J.; Georges, J.; Zehri, A.; Mooney, M.; Carlson, E.; Nichols, J.; Farhat, K.; Anderson, T.; Preul, M.; Jensen, K.; Nakaji, P. 2014: Ni-24 * Improving Biobanked Specimen Quality: Label-Free Microscopic Assessment of Human Brain Tumor Biopsies Prior to Biobanking. Neuro-Oncology 16(Suppl 5): v143

Fouke, S.; LaMontagne, P.; Fontana, E.; Marcus, D.; Benzinger, T.; Rich, K.; Abraham, C.; Milchenko, M.; Robinson, C. 2014: Ni-25 * Physiologic Imaging in Patients with Brain Metastases; Heterogeneity Based upon Primary Tumor Subtype. Neuro-Oncology 16(Suppl 5): v143

Franceschi, E.; Agati, R.; Finocchiaro, G.; Zagonel, V.; Fabi, A.; Reni, M.; Caserta, C.; Maiello, E.; Carteni, G.; Clavarezza, M.; Rosti, G.; Eoli, M.; Lombardi, G.; Bacci, A.; Monteforte, M. 2014: Ni-26 * Comparative Analysis Of The Rano And Macdonad'S Criteria In Recurrent Glioblastoma Treated In The Randomized Phase Ii Trial Avareg With Bevacizumab Or Fotemustine. Neuro-Oncology 16(Suppl 5): v143-v144

Fujimoto, K.; Arakawa, Y.; Murata, D.; Fukui, N.; Kunieda, T.; Takagi, Y.; Miyamoto, S. 2014: Ni-28 * Analysis of Bevacizumab Response to Distinguish between Tumor Recurrence and Cerebral Radiation Necrosis. Neuro-Oncology 16(Suppl 5): v144

Galldiks, N.; Dunkl, V.; Stoffels, G.; Hutterer, M.; Rapp, M.; Kebir, S.; Goldbrunner, R.; Ruge, M.I.; Schmidt, M.; Langen, K.-J. 2014: Ni-29 * Diagnosis of Pseudoprogression in Patients with Glioblastoma using Amino Acid Pet. Neuro-Oncology 16(Suppl 5): v144

Habets, E.; Hendriks, E.; Taphoorn, M.; Barkhof, F.; Vandertop, P.; Hamer, P.d.W.; Klein, M. 2014: Ni-31 * using Tumor Localization Maps to Identify Brain Locations Involved in Cognitive Functioning in Glioma Patients before Therapy. Neuro-Oncology 16(Suppl 5): v144-v145

Al-Gizawiy, M.; Prah, M.; Mueller, W.; LaViolette, P.; Schmainda, K. 2014: Ni-03 * Dsc-Mri Measures Of rCbv Predict Tumor Characteristics Beyond Standard Histopathology. Neuro-Oncology 16(Suppl 5): v138

Hariri, O.R.; Farr, S.; Gupta, R.; Bieber, A.J.; Corsino, C.; Miulli, D.; Siddiqi, J. 2014: Ni-33 * Third Ventricular Glioblastoma Multiforme: Case Report and Literature Review. Neuro-Oncology 16(Suppl 5): v145

Hendriks, E.J.; Habets, E.J.; Klein, M.; Barkhof, F.; Vandertop, W.P.; Taphoorn, M.J.; Hamer, P.C.d.W. 2014: Ni-34 * Brain Locations Involved in Cognitive Alterations after Resective Brain Surgery Identified by Resection Probability Maps. Neuro-Oncology 16(Suppl 5): v145

Huang, C.-Y.; Wu, H.-W.; Wang, H.-Y.J.; Chen, P.-Y.; Wei, K.-C. 2014: Ni-35 * Establishment of Brain Tumor Phospholipid Imaging Profiling by Maldi Mass Spectrometry - a Mouse Model. Neuro-Oncology 16(Suppl 5): v145

Huang, R.; Rahman, R.; Pope, W.; Ellingson, B.; Ballman, K.; Felton, S.; Anderson, S.K.; Nayak, L.; Lee, E.; Abrey, L.; Galanis, E.; Reardon, D.; Cloughesy, T.; Wen, P. 2014: Ni-36 * Validation of Rano Criteria: Contribution of T2/Flair Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab. Neuro-Oncology 16(Suppl 5): v145-v146

Hutterer, M.; Krenn, Y.; Kunz, A.; McCoy, M.; Egger, B.; Schroder, M.; Wendl, C.; Marienhagen, J.; Fritsch, B.; Urbach, H.; Meyer, P.T.; Galldiks, N.; Langen, K.-J.; Hau, P.; Trinka, E. 2014: Ni-37 * Increased Cerebral Amino Acid Uptake During And After Epileptic Disorders Mimics Brain Tumor In 18F-Fet Pet. Neuro-Oncology 16(Suppl 5): v146

Itakura, H.; Achrol, A.; Loya, J.; Mitchell, L.; Azad, T.; Echegaray, S.; Yeom, K.; Napel, S.; Harsh, G.; Gevaert, O. 2014: Ni-38 * Glioblastoma Subtypes Defined by Quantitative Imaging Map to different Canonical Signaling Pathways. Neuro-Oncology 16(Suppl 5): v146

Jackson, S.; Lodge, M.; Piotrowski, A.; Wahl, R.; Grossman, S. 2014: Ni-39 * Initial Evaluation Of An Adenosine Receptor Agonist'S Ability To Transiently Disrupt The Blood Brain Barrier (Bbb) In Patients With In Normal Brains. Neuro-Oncology 16(Suppl 5): v146

Jalbert, L.; Phillips, J.; Molinaro, A.; Chang, S.; Nelson, S. 2014: Ni-40 * Mr Imaging and Spectroscopy Provides Insight into Malignant Transformation and Idh-Mutation Status in Diffuse Low-Grade Glioma. Neuro-Oncology 16(Suppl 5): v146-v147

Jansen, N.L.; Suchorska, B.; Wenter, V.; Schmid-Tannwald, C.; Niyazi, M.; Bartenstein, P.; Kreth, F.-W.; Fougere, C.L.; Tonn, J.-C. 2014: Ni-41 * Prognostic Significance Of Dynamic Analysis Of 18Fet-Pet In Newly Diagnosed High Grade Glioma. Neuro-Oncology 16(Suppl 5): v147

Amer, A.; Zinn, P.; Colen, R. 2014: Ni-04 * Immediate Post Operative Volume of Abnormal Flair Signal Predicts Patient Survival in Glioblastoma Patients. Neuro-Oncology 16(Suppl 5): v138

Jeong, J.-W.; Lee, J.; Kamson, D.; Robinette, N.; Barger, G.; Mittal, S.; Juhasz, C. 2014: Ni-42 * Altered Structural Connectivity in Widely Distributed Bilateral Hemispheric Networks of Patients with Glioblastoma. Neuro-Oncology 16(Suppl 5): v147

Juliano, J.; Rockne, R.; Hawkins-Daarud, A.; Jackson, P.; Jacobs, J.; Kokkinos, E.; Rosenberg, A.; Crisman, J.; Peters, C.; Sharfman, D.; Johnston, S.; Sondag, M.; Badhe, S.; Lester, M.; Gallagher, T. 2014: Ni-43 * Growth Kinetics of Contrast Enhancing Gliomas Associate Invasive Growth with Seizure Presentation. Neuro-Oncology 16(Suppl 5): v147

Kambhampati, M.; Yadavilli, S.; McNeeley, K.M.; Pai, S.B.; Yu, Q.; Bellamkonda, R.; Fernandes, R.; Packer, R.J.; Nazarian, J. 2014: Ni-44 * Liposomal Nanoparticles for Targeting and Imaging of Pediatric Brain Tumors. Neuro-Oncology 16(Suppl 5): v147-v148

Kamson, D.; Mittal, S.; Kupsky, W.; Muzik, O.; Robinette, N.; Michelhaugh, S.; Juhasz, C. 2014: Ni-45 * Kinetic Analysis of Tryptophan Pet can Estimate Histologic Grade and Proliferative Activity in Meningiomas. Neuro-Oncology 16(Suppl 5): v148

Kandula, S.; Cordova, J.S.; Schreibmann, E.; Crocker, I.; Holder, C.; Shim, H.; Shu, H.-K. 2014: Ni-46 * the Impact of Integrating Volumetric Mr Spectroscopic Imaging in Radiation Treatment Planning for Glioblastoma. Neuro-Oncology 16(Suppl 5): v148

Khouri, J.; Taylor, L. 2014: Ni-47 * Gliomatosis Meningi and Gliomatosis Cerebri: Kissing Cousins? Case Report and Review of the Literature. Neuro-Oncology 16(Suppl 5): v148

Kinoshita, M.; Arita, H.; Kagawa, N.; Watanabe, Y.; Hatazawa, J.; Hashimoto, N.; Yoshimine, T. 2014: Ni-48 * Comparison Of Dti And 11C-Methionine Pet Focusing On Their Predictive Values Of Tumor Cell Density In Gliomas. Neuro-Oncology 16(Suppl 5): v148-v149

LaMontagne, P.; Milchencko, M.; Velez, M.; Abraham, C.; Marcus, D.; Robinson, C.; Fouke, S. 2014: Ni-50 * Segmentation of Metastatic Lesions in Large-Scale Registries: Comparison of Expert Manual Segmentation Vs. Semi-Automated Methods. Neuro-Oncology 16(Suppl 5): v149

Lary, A.; Alzahrani, A.; Alahmari, A.; Alshardan, M. 2014: Ni-51 * Stereotactic Robot-Guided Biopsies of Brain Lesions: Experience with 4 Cases. Neuro-Oncology 16(Suppl 5): v149

Amer, A.; Zinn, P.; Colen, R. 2014: Ni-05 * Immediate Post-Resection Pericavitarian Dwi Hyperintensity in Glioblastoma Patients is Predictive of Patient Outcome. Neuro-Oncology 16(Suppl 5): v138-v139

Lau, J.C.; Khan, A.; Peters, T.; Parrent, A.; Megyesi, J. 2014: Ni-52 * Towards Improved Integration of Advanced Imaging Techniques into the Neurosurgical Operating Suite: A Canadian Experience. Neuro-Oncology 16(Suppl 5): v149

Lee, M.; Walsh, K.; Rey-Dios, R.; Anderson, M. 2014: Ni-53 * Progressive Multifocal Leukoencephalopathy Mimicking high Grade Glioma in an Immunocompetent Patient: A Case Report. Neuro-Oncology 16(Suppl 5): v149-v150

Leu, K.; Enzmann, D.; Woodworth, D.; Teixeira, S.; Lai, A.; Nghiemphu, P.; Pope, W.; Cloughesy, T.; Ellingson, B. 2014: Ni-54 * Hypervascular Volume Estimated by Comparison to a Large-Scale Cerebral Blood Volume (Cbv) Radiographic Atlas Predicts Survival in Recurrent Glioblastoma Treated with Bevacizumab. Neuro-Oncology 16(Suppl 5): v150

Leu, K.; Tran, A.; Pope, W.; Lai, A.; Nghiemphu, P.; Harris, R.; Woodworth, D.; Cloughesy, T.; Ellingson, B. 2014: Ni-55 * Parametric Maps of Contrast Agent Diffusion using a Novel Diffusion-Perfusion Model Applied to Dce-Mri can Differentiate Non-Enhancing Tumor from Edema in Human Glioblastoma. Neuro-Oncology 16(Suppl 5): v150

Lundemann, M.; Costa, J.; Law, I.; Engelholm, S.A. 2014: Ni-56 * Fet-Pet Adds Predictive Value to Localization of Treatment Failure in high Grade Gliomas. Neuro-Oncology 16(Suppl 5): v150

Magge, R.; Perez, J.A.; Young, R.; Kaley, T.; Pentsova, E.; DeAngelis, L.; Diamond, E.; Mellinghoff, I.; Peck, K.; Anderson, B.; Gorman, G.; Mclean, S.; Karmali, R.; Omuro, A. 2014: Ni-57 * Dynamic Contrast-Enhanced Magnetic Resonance Perfusion Weighted Imaging (Dce-Mri) and Diffusion Weighted Imaging (Dwi) for Pharmacodynamic Evaluation of Carboxyamidotriazole Orotate (Cto) and Temozolomide in Malignant Glioma. Neuro-Oncology 16(Suppl 5): v150-v151

Mickevicius, N.; Carle, A.; Santarriaga-Escamilla, S.; Bluemel, T.; Connelly, J.; Rand, S.; Mueller, W.; Schmainda, K.; LaViolette, P. 2014: Ni-58 * Location of Glioblastoma Intersectiing White Matter Tracts Predict Patient Prognosis and Response to Bevacizumab Prior to Therapy. Neuro-Oncology 16(Suppl 5): v151

Morrison, M.; Golestanirad, L.; Schweizer, T.; Graham, S.; Das, S. 2014: Ni-59 * Tablet Technology for Improved Preoperative Speech Mapping using Functional Mri in Patients with Low-Grade Glioma. Neuro-Oncology 16(Suppl 5): v151

Nagane, M.; Kobayashi, K.; Saito, K.; Shiokawa, Y. 2014: Ni-60 * Recurrent Patterns of Bevacizumab Monotherapy for Recurrent Primary Glioblastoma and Perspectives on Bevacizumab-Based Therapies. Neuro-Oncology 16(Suppl 5): v151

Nelson, S.; Li, Y.; Prados, M.; Butowski, N.; Clarke, J.; Chang, S. 2014: Ni-61 * Volumetric H-1 Mr Metabolic Imaging for Definition of Lesion Burden and Prediction of Outcome for Patients with Newly Diagnosed Gbm. Neuro-Oncology 16(Suppl 5): v151-v152

Arakawa, Y.; Nakamoto, Y.; Okada, T.; Takeuchi, Y.; Minamiguchi, S.; Kunieda, T.; Takagi, Y.; Miyamoto, S. 2014: Ni-06 * Molecular Imaging Of Pineal Parenchymal Tumor By (68)Ga-Dotatoc-Pet/C. Neuro-Oncology 16(Suppl 5): v139

Nowosielski, M.; Kremser, C.; Schocke, M.; Gizewski, E.; Iglseder, S.; Muigg, A.; Freyschlag, C.; Stockhammer, G.; Hutterer, M. 2014: Ni-62 * Dce-Mri Discriminates between Responder and Non-Responder in Progressive high Grade Glioma Patients Undergoing Anti-Angiogenic Treatment. Neuro-Oncology 16(Suppl 5): v152

Ohla, V.; Kasper, E.; Doostkam, S.; Volk, B.; Ostertag, C. 2014: Ni-63 * Gliomatosis Cerebri: Diagnosis, Management and Outcomes in the Largest Series from a Single European Institution. Neuro-Oncology 16(Suppl 5): v152

Pellatt, B.; Mickevicius, N.; Cochran, E.; LaViolette, P. 2014: Ni-64 * 3D-Printed Mri-Based Custom Brain Molds For Minimizing Tissue Distortion And Precisely Slicing Tissue For Co-Registration With Clinically Acquired Mri In Glioma Patients. Neuro-Oncology 16(Suppl 5): v152

Prah, M.; Al-Gizawiy, M.; Mueller, W.; Hoffmann, R.; Schmainda, K. 2014: Ni-65 * Differentiating Radiation effect and Necrosis from Glioblastoma with Dynamic Susceptibility Contrast (Dsc) Mri. Neuro-Oncology 16(Suppl 5): v152

Raval, A.; Schulder, M.; Kingsley, P. 2014: Ni-66 * Color Coded Maps of White Matter Tracts: No Need for Tractography. Neuro-Oncology 16(Suppl 5): v153

Ryu, W.H.A.; Dronyk, J.; Kelly, J.J. 2014: Ni-67 * the Role of Flair Volume as a Prognosticating Factor in Patients with Glioblastoma. Neuro-Oncology 16(Suppl 5): v153

Schwarzenberg, J.; Czernin, J.; Cloughesy, T.; Lai, A.; Phelps, M.; Chen, W. 2014: Ni-68 * 18F-Fdopa Pet In Treated Low-Grade Gliomas With Non-Enhancing T2 Changes On Mri Is Prognostic Of Tumor Progression And Overall Survival. Neuro-Oncology 16(Suppl 5): v153

Sher, A.; Montagnese, J.; Rogers, L.; Abboud, S.; Wolansky, L. 2014: Ni-69 * Utility Of 18F-Fdg Pet/Mr In Differentiation Of Recurrent High-Grade Glioma From Delayed Radiation Tissue Injury: Comparison Of Pet/Ct To Pet/Mr. Neuro-Oncology 16(Suppl 5): v153

Smith-Cohn, M.; Chabot, J.; Schulder, M. 2014: Ni-70 * Stereotactic Biopsy with and without Intraoperative Mri. Neuro-Oncology 16(Suppl 5): v153-v154

Smrcka, M.; Jancalek, R.; Bulik, M.; Kazda, T.; Pospisil, P.; Slampa, P. 2014: Ni-71 * Developing Role of Advanced Mri Techniques for Diagnosis of High-Grade Glioma Relapse after Complex Oncology Treatment. Neuro-Oncology 16(Suppl 5): v154

Badve, C.; Yu, A.; Ma, D.; Jiang, Y.; Deshmane, A.; Gulani, V.; Sunshine, J.; Sloan, A.; Griswold, M. 2014: Ni-07 * Magnetic Resonance Fingerprinting of Brain Tumors: Initial Clinical Results. Neuro-Oncology 16(Suppl 5): v139

Suchorska, B.; Jansen, N.L.; Sosnova, M.; Janssen, H.; Grabowski, M.; Kreth, F.-W.; Vogelbaum, M.A.; Tonn, J.-C. 2014: Ni-72 * Correlation Of Volumetrical Analyses Derived From 18Fet-Pet And Mri With Outcome In Glioblastoma Patients. Neuro-Oncology 16(Suppl 5): v154

Tamura, K.; Inaji, M.; Nariai, T.; Tamaki, M.; Hirai, S.; Saigusa, K.; Tanaka, Y.; Maehara, T. 2014: Ni-73 * Monitoring Of Biological Response To Bevacizumab In Malignant Glioma Patients Based On L-[methyl-11C] Methionine-Positron Emission Tomography. Neuro-Oncology 16(Suppl 5): v154

Thomas, A.; Perez, J.A.; Peck, K.; Schneider, T.; Lyo, J.; Young, R.; Kaley, T. 2014: Ni-74 * Dynamic Contrast Enhanced (Dce) T1 Mri Perfusion Differentiates Pseudoprogression from Recurrent Glioblastoma. Neuro-Oncology 16(Suppl 5): v154-v155

Tiwari, P.; Prasanna, P.; Rogers, L.; Wolansky, L.; Cohen, M.; Madabhushi, A. 2014: Ni-76 * Computer Extracted Oriented Texture Features on T1-Gadolinium Mri for Distinguishing Radiation Necrosis from Recurrent Brain Tumors. Neuro-Oncology 16(Suppl 5): v155

Tong, J.; Liu, H.; Zhang, L.; Liu, Y.; Yuan, J.; Zhang, X. 2014: Ni-77 * Surgical Treatments for Large and Giant Meningiomas: Experiences with 35 Consecutive Patients. Neuro-Oncology 16(Suppl 5): v155

Uckermann, O.; Galli, R.; Geiger, K.; Koch, E.; Schackert, G.; Steiner, G.; Kirsch, M. 2014: Ni-78 * Label-Free Multiphoton Microscopy: A Novel Tool for the Imaging of Brain Tumors. Neuro-Oncology 16(Suppl 5): v155-v156

Vaziri, S.; Lafontaine, M.; Olson, B.; Crane, J.C.; Chang, S.; Lupo, J.; Nelson, S.J. 2014: Ni-79 * Rapid Assessment of Lesion Volumes for Patients with Glioma using the Smartbrush Software Package. Neuro-Oncology 16(Suppl 5): v156

Wajnsztajn, F.; Mirchandani, N.; Kowalska, A. 2014: Ni-80 * Case Report: Treatment Response in Leptomeningeal Carcinomatosis from Gliomatosis Cerebri Treated with Bevacizumab (Avastin). Neuro-Oncology 16(Suppl 5): v156

Wassal, E.; Thomas, G.; Zinn, P.; Colen, R. 2014: Ni-81 * Diffusion Mr Imaging Genomic Features Identifies Genomic Targets Involved in Invasion and Poor Prognosis. Neuro-Oncology 16(Suppl 5): v156

Blasiak, B.; Barnes, S.; Abulrob, A.; Obenaus, A.; Tomanek, B. 2014: Ni-08 * Optimization of Molecular Mr Imaging of Glioma. Neuro-Oncology 16(Suppl 5): v139

Wassal, E.; Zinn, P.; Colen, R. 2014: Ni-82 * Diffusion and Conventional Mr Imaging Genomic Biomarker Signature for Egfr Mutation Identification in Glioblastoma. Neuro-Oncology 16(Suppl 5): v156-v157

Wassal, E.; Zinn, P.; Colen, R. 2014: Ni-83 * Diffusion and Conventional Mr Imaging Genomic Biomarker Signature Predicts Idh-1 Mutation in Glioblastoma Patients. Neuro-Oncology 16(Suppl 5): v157

Yang, D.; Narang, S.; Rao, G.; Martinez, J.; Rao, A. 2014: Ni-84 * Molecular Characteristics Underlying the Radiologically-Defined Volumetric Composition of Glioblastoma. Neuro-Oncology 16(Suppl 5): v157

Zach, L.; Last, D.; Guez, D.; Daniels, D.; Grober, Y.; Nissim, O.; Hoffmann, C.; Nass, D.; Talianski, A.; Spiegelmann, R.; Salomon, S.; Kanner, A.; Blumenthal, D.; Bukshtein, F.; Yalon, M. 2014: Ni-85 * Delayed Contrast Mri for Differentiating Tumor/Non-Tumor Tissues in Brain Tumor Patients - Histological Validation and Comparison with Dsc/Dce. Neuro-Oncology 16(Suppl 5): v157

Zavarella, S.M.; Gandhi, S.V.; Nardi, D.; Schaffer, S.; Schulder, M. 2014: Ni-86 * Combined Awake Brain Mapping and Low-Field Intraoperative Mri for Brain Tumor Resection. Neuro-Oncology 16(Suppl 5): v157-v158

Bruning-Richardson, A.; Roberts, N.; Crellin, D.; Treanor, D.; Short, S. 2014: Ni-09 * high Resolution Three-Dimensional Histological Reconstruction of Glioma Spheroids and Application in Research. Neuro-Oncology 16(Suppl 5): v139-v140

Abuali, I.; Strowd, R.; Ye, X.; Grossman, S. 2014: Nt-01 * Utility of Temozolomide in the Management of Anaplastic Astrocytoma: A Comparison of Survival in the Era Prior to and following Temozolomide. Neuro-Oncology 16(Suppl 5): v159

Dhruv, H.; Mathews, I.; Chow, D.; Yin, H.; Berens, M.; Tran, N. 2014: Nt-10 * Identification of Aurintricarboxylic Acid (Ata) as an Inhibitor of Tweak-Fn14 Signaling in Glioblastoma cells. Neuro-Oncology 16(Suppl 5): v161

Ilkhanizadeh, S.; Miroshnikova, Y.; Frantz, A.; James, D.; Berger, M.; McKnight, T.; Weaver, V.; Weiss, W.; Persson, A. 2014: Nt-11 * Targeting Interstitial Fluid Pressure to Reduce Tumor Growth and Increase Drug Uptake in Brain Tumors. Neuro-Oncology 16(Suppl 5): v161

Jaime-Ramirez, A.; Bolyard, C.; Meisen, W.; Dmitrieva, N.; Banasavadi-Siddegowda, Y.; Kaur, B. 2014: Nt-12 * Impact of Humanized Chondroitinase Abc on Ov Therapy for Intracranial Tumors. Neuro-Oncology 16(Suppl 5): v161

Eliyas, J.K.; Bailes, J. 2014: Nt-14 * Early Experience with Trans-Sulcal Parafascicular Exoscopic Resection of Supratentorial Brain Tumors. Neuro-Oncology 16(Suppl 5): v161

Lal, S.; Lawrence, S.; Raffel, C. 2014: Nt-17 * Treatment of Diffuse Intrinsic Pontine Glioma (Dipg) with an Oncolytic Measles Virus in Combination with Inhibitors of the Pi3-Kinase Pathway. Neuro-Oncology 16(Suppl 5): v162

Lang, F.F.; Conrad, C.; Gomez-Manzano, C.; Tufaro, F.; Sawaya, R.; Weinberg, J.; Prabhu, S.; Fuller, G.; Aldape, K.; Fueyo, J. 2014: Nt-18 * Phase I Clinical Trial of Oncolytic Virus Delta-24-Rgd (Dnx-2401) with Biological Endpoints: Implications for Viro-Immunotherapy. Neuro-Oncology 16(Suppl 5): v162

Madani, D.; Nixdorf, S.; McDonald, K. 2014: Nt-20 * Targeting Cdk4 and 6 in the Classical Subtype of Glioblastoma. Neuro-Oncology 16(Suppl 5): v163

Manning, M.; Wiant, D.; Sintay, B.; Stern, J. 2014: Nt-21 * Preliminary Clinical Outcomes following Rapid Delivery Radiosurgery for Multiple Brain Metastases. Neuro-Oncology 16(Suppl 5): v163

Alkins, R.; Burgess, A.; Francia, G.; Kerbel, R.; Wels, W.; Hynynen, K. 2014: Nt-02 * Early Treatment of Her2-Amplified Brain Tumours with Targeted Nk-92 cells and Focused Ultrasound Improves Survival. Neuro-Oncology 16(Suppl 5): v159

Matsutani, T.; Hirono, S.; Shinozaki, N.; Iwadate, Y.; Saeki, N. 2014: Nt-22 * Pav Treatment without Immediate Radiotherapy for Anaplastic Oligodendroglial Tumor with 1p/19q Co-Deletion. Neuro-Oncology 16(Suppl 5): v163

Kerklaan, B.M.; Jager, A.; Aftimos, P.; Dieras, V.; Altintas, S.; Anders, C.; Arnedos, M.; Gelderblom, H.; Soetekouw, P.; Gladdines, W.; Gaillard, P.; de Sousa, C.; Awada, A.; Schellens, J.; van Linde, M. 2014: Nt-23 * Phase 1/2A Study Of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) In Breast Cancer Patients With Brain Metastases (Bcbm) Or Recurrent High Grade Gliomas (Hgg). Neuro-Oncology 16(Suppl 5): v163

Mulholland, P.; Shaw, H. 2014: Nt-24 * Ipilimumab and Bevacizumab in Glioblastoma. Neuro-Oncology 16(Suppl 5): v163-v164

Muragaki, Y.; Nitta, M.; Okumura, T.; Tabei, Y.; Maruyama, T.; Kaneko, S.; Suzuki, I. 2014: Nt-25 * Early Japanese Experience With NovoTtf-100A System For Recurrent Gbm. Neuro-Oncology 16(Suppl 5): v164

New, P.; Powell, S. 2014: Nt-26 * Pathology of Cases of Imaging Progression in Patients Diagnosed with Glioblastoma Who Have Been Treated with the Novocure - Ttf Device in the Ef-14 Trial. Neuro-Oncology 16(Suppl 5): v164

Nonaka, M.; Okita, Y.; Kanemura, Y.; Goto, H.; Kamei, T.; Iwata, R.; Takeda, J.; Oshige, H.; Yoshimura, K.; Asai, A. 2014: Nt-27 * Surgical Resection of Thalamic Malignant Glioma. Neuro-Oncology 16(Suppl 5): v164

Ramachandran, C.; Quirin, K.-W.; Escalon, E.; Melnick, S. 2014: Nt-28 * Neuroprotective effects of Bacopa Monnieri and Rosmarinus Officinalis Supercritical Co2 Extracts. Neuro-Oncology 16(Suppl 5): v164

Roberts, C.; Chagoya, G.; Nanni, C.; Kwatra, M. 2014: Nt-29 * Upregulation Of Beta-Catenin In Patient-Derived Glioblastoma Xenografts Expressing EgfrvIii. Neuro-Oncology 16(Suppl 5): v164-v165

Schulder, M.; Black, K.; Mehta, A.; Gamble, A. 2014: Nt-30 * Complications of Laser Interstitial Thermal Therapy in Patients with Brain Tumors. Neuro-Oncology 16(Suppl 5): v165